The Sequence of the Human Genome

Decoding of the DNA that constitutes the human genome has been widely anticipated for the contribution it will make toward understanding human evolution, the causation of disease, and the interplay between the environment and heredity in defining the human condition. A project with the goal of determining the complete nucleotide sequence of the human genome was first formally proposed in 1985 (1). In subsequent years, the idea met with mixed reactions in the scientific community (2). However, in 1990, the Human Genome Project (HGP) was officially initiated in the United States under the direction of the National Institutes of Health and the U.S. Department of Energy with a 15-year, $3 billion plan for completing the genome sequence. In 1998 we announced our intention to build a unique genome-sequencing facility, to determine the sequence of the human genome over a 3-year period. Here we report the penultimate milestone along the path toward that goal, a nearly complete sequence of the euchromatic portion of the human genome. The sequencing was performed by a whole-genome random shotgun method with subsequent assembly of the sequenced segments.

The modern history of DNA sequencing began in 1977, when Sanger reported his method for determining the order of nucleotides of DNA using chain-terminating nucleotide analogs (3). In the same year, the first human gene was isolated and sequenced (4). In 1986, Hood and co-workers (5) described an improvement in the Sanger sequencing method that included attaching fluorescent dyes to the nucleotides, which permitted them to be sequentially read by a computer. The first automated DNA sequencer, developed by Applied Biosystems in California in 1987, was shown to be successful when the sequences of two genes were obtained with this new technology (6). From early sequencing of human genomic regions (7), it became clear that CDNA sequences (which are reverse-transcribed from RNA) would be essential to annotate and validate gene predictions in the human genome. These studies were the basis in part for the development of the expressed sequence tag (EST) method of gene identification (8), which is a random selection, very high throughput sequencing approach to characterize cDNA libraries. The EST method led to the rapid discovery and mapping of human genes (9). The increasing numbers of human EST sequences necessitated the development of new computer algorithms to analyze large amounts of sequence data, and in 1993 at The Institute for Genomic Research (TIGR), an algorithm was developed that permitted assembly and analysis of hundreds of thousands of ESTs. This algorithm permitted characterization and annotation of human genes on the basis of the 30,000 EST assemblies (10).

The complete 49-kbp bacteriophage lambda genome sequence was determined by a shotgun restriction digest method in 1982 (11). When considering methods for sequencing the smallpox virus genome in 1991 (12), a whole-genome shotgun sequencing method was discussed and subsequently rejected owing to the lack of appropriate software tools for genome assembly. However, in 1994, when a microbial genome-sequencing project was contemplated at TIGR, a whole-genome shotgun sequencing approach was considered possible with the TIGR EST assembly algorithm. In 1995, the 1.8-Mbp \textit{Haemophilus influenzae} genome was completed by a whole-genome shotgun sequencing method (13). The experience with several subsequent genome-sequencing efforts established the broad applicability of this approach (14, 15). A key feature of the sequencing approach used for these megabase-size and larger genomes was the use of paired-end sequences (also called mate pairs), derived from subclone libraries with distinct insert sizes and cloning characteristics. Paired-end sequences are sequences 500 to 600 bp in length from both ends of double-stranded DNA clones of prescribed lengths. The success of using end sequences from long segments (18 to 20 kbp) of DNA cloned into bacteriophage lambda in assembly of the microbial genomes led to the suggestion (16) of an approach to simulta-
neously map and sequence the human genome by means of end sequences from 150-kbp bacterial artificial chromosomes (BACs) (17, 18). The end sequences spanned by known distances provide long-range continuity across the genome. A modification of the BAC end-sequencing (BES) method was applied successfully to complete chromosome 2 from the Arabidopsis thaliana genome (19).

In 1997, Weber and Myers (20) proposed whole-genome shotgun sequencing of the human genome. Their proposal was not well received (21). However, by early 1998, as less than 5% of the genome had been sequenced, it was clear that the rate of progress in human genome sequencing worldwide was very slow (22), and the prospects for finishing the genome by the 2005 goal were uncertain.

In early 1998, PE Biosystems (now Applied Biosystems) developed an automated, high-throughput capillary DNA sequencer, subsequently called the ABI PRISM 3700 DNA Analyzer. Discussions between PE Biosystems and TIGR scientists resulted in a plan to undertake the sequencing of the human genome with the 3700 DNA Analyzer and the whole-genome shotgun sequencing techniques developed at TIGR (23). Many of the principles of operation of a genome-sequencing facility were established in the TIGR facility (24). However, the facility envisioned for Celera would have a capacity roughly 50 times that of TIGR, and thus new developments were required for sample preparation and tracking and for whole-genome assembly. Some argued that the required 150-fold scale-up from the H. influenzae genome to the human genome with its complex repeat sequences was not feasible (25). The Drosophila melanogaster genome was thus chosen as a test case for whole-genome assembly on a large and complex eukaryotic genome. In collaboration with Gerald Rubin and the Berkeley Drosophila Genome Project, the nucleotide sequence of the 120-Mbp euchromatic portion of the Drosophila genome was determined over a 1-year period (26–28). The Drosophila genome-sequencing effort resulted in two key findings: (i) that the assembly algorithms could generate chromosome assemblies with highly accurate order and orientation with substantially less than 10-fold coverage, and (ii) that undertaking multiple interim assemblies in place of one comprehensive final assembly was not of value.

These findings, together with the dramatic changes in the public genome effort subsequent to the formation of Celera (29), led to a modified whole-genome shotgun sequencing approach to the human genome. We initially proposed to do 10-fold sequence coverage of the genome over a 3-year period and to make interim assembled sequence data available quarterly. The modifications included a plan to perform random shotgun sequencing to ~5-fold coverage and to use the unordered and unoriented BAC sequence fragments and subassemblies published in GenBank by the publicly funded genome effort (30) to accelerate the project. We also abandoned the quarterly announcements in the absence of interim assemblies to report.

Although this strategy provided a reasonable result very early that was consistent with a whole-genome shotgun assembly with eightfold coverage, the human genome sequence is not as finished as the Drosophila genome was with an effective 13-fold coverage. However, it became clear that even with this reduced coverage strategy, Celera could generate an accurately ordered and oriented scaffold sequence of the human genome in less than 1 year. Human genome sequencing was initiated 8 September 1999 and completed 17 June 2000. The first assembly was completed 25 June 2000, and the assembly reported here was completed 1 October 2000. Here we describe the whole-genome random shotgun sequencing effort applied to the human genome. We developed two different assembly approaches for assembling the ~3 billion bp that make up the 23 pairs of chromosomes of the Homo sapiens genome. Any GenBank-derived data were shreded to remove potential bias to the final sequence from chimeric clones, foreign DNA contamination, or misassembled contigs. Insofar as a correctly and accurately assembled genome sequence with faithful order and orientation of contigs is essential for an accurate analysis of the human genetic code, we have devoted a considerable portion of this manuscript to the documentation of the quality of our reconstruction of the genome. We also describe our preliminary analysis of the human genetic code on the basis of computational methods. Figure 1 (see fold-out chart associated with this issue; files for each chromosome can be found in Web fig. 1 on Science Online at www.sciencemag.org/cgi/content/full/291/5507/1304/DC1) provides a graphical overview of the genome and the features encoded in it. The detailed manual curation and interpretation of the genome are just beginning.

To aid the reader in locating specific analytical sections, we have divided the paper into seven broad sections. A summary of the major results appears at the beginning of each section.

1 Sources of DNA and Sequencing Methods
2 Genome Assembly Strategy and Characterization
3 Gene Prediction and Annotation
4 Genome Structure
5 Genome Evolution
6 A Genome-Wide Examination of Sequence Variations
7 An Overview of the Predicted Protein-Coding Genes in the Human Genome
8 Conclusions

The Human Genome

Summary. This section discusses the rationale and ethical rules governing donor selection to ensure ethnic and gender diversity along with the methodologies for DNA extraction and library construction. The plasmid library construction is the first critical step in shotgun sequencing. If the DNA libraries are not uniform in size, nonchimeric, and do not randomly represent the genome, then the subsequent steps cannot accurately reconstruct the genome sequence. We used automated high-throughput DNA sequencing and the computational infrastructure to enable efficient tracking of enormous amounts of sequence information (27.3 million sequence reads; 14.9 billion bp of sequence). Sequencing and tracking from both ends of plasmid clones from 2-, 10-, and 50-kbp libraries were essential to the computational reconstruction of the genome. Our evidence indicates that the accurate pairing rate of end sequences was greater than 98%.

Various policies of the United States and the World Medical Association, specifically the Declaration of Helsinki, offer recommendations for conducting experiments with human subjects. We convened an Institutional Review Board (IRB) (31) that helped us establish the protocol for obtaining and using human DNA and the informed consent process used to enroll research volunteers for the DNA-sequencing studies reported here. We adopted several steps and procedures to protect the privacy rights and confidentiality of the research subjects (donors). These included a two-stage consent process, a secure random alphanumeric coding system for specimens and records, circumscribed contact with the subjects by researchers, and options for off-site contact of donors. In addition, Celera applied for and received a Certificate of Confidentiality from the Department of Health and Human Services. This Certificate authorized Celera to protect the privacy of the individuals who volunteered to be donors as provided in Section 301(d) of the Public Health Service Act 42 U.S.C. 241(d).

Celera and the IRB believed that the initial version of a completed human genome should be a composite derived from multiple donors of diverse ethnic backgrounds. Prospective donors were asked, on a voluntary basis, to self-designate an ethnographic category (e.g., African-American, Chinese, Hispanic, Caucasian, etc.). We enrolled 21 donors (32).

Three basic items of information from each donor were recorded and linked by confidential code to the donated sample: age, sex, and self-designated ethnographic group. From females, ~130 ml of whole, heparinized blood was collected. From males, ~130 ml of whole, heparinized blood was
collected, as well as five specimens of semen, collected over a 6-week period. Permanent lymphoblastoid cell lines were created by Epstein-Barr virus immortalization. DNA from five subjects was selected for genomic DNA sequencing: two males and three females—one African-American, one Asian-Chinese, one Hispanic-Mexican, and two Caucasians (see Web fig. 2 on Science Online at www.sciencemag.org/cgi/content/291/5507/1304/DC1). The decision of whose DNA to sequence was based on a complex mix of factors, including the goal of achieving diversity as well as technical issues such as the quality of the DNA libraries and availability of immortalized cell lines.

1.1 Library construction and sequencing

Central to the whole-genome shotgun sequencing process is preparation of high-quality plasmid libraries in a variety of insert sizes so that pairs of sequence reads (mates) are obtained, one read from both ends of each plasmid insert. High-quality libraries have an equal representation of all parts of the genome, a small number of clones without inserts, and no contamination from such sources as the mitochondrial genome and Escherichia coli genomic DNA. DNA from each donor was used to construct plasmid libraries in one or more of three size classes: 2 kbp, 10 kbp, and 50 kbp (Table 1) (33).

In designing the DNA-sequencing process, we focused on developing a simple system that could be implemented in a robust and reproducible manner and monitored effectively (Fig. 2) (34).

Current sequencing protocols are based on the dideoxy sequencing method (35), which typically yields only 500 to 750 bp of sequence per reaction. This limitation on read length has made monumental gains in throughput a prerequisite for the analysis of large eukaryotic genomes. We accomplished this at the Celera facility, which occupies about 30,000 square feet of laboratory space and produces sequence data continuously at a rate of 175,000 total reads per day. The DNA-sequencing facility is supported by a high-performance computational facility (36).

The process for DNA sequencing was modular by design and automated. Intermodule sample backlogs allowed four principal modules to operate independently: (i) library transformation, plating, and colony picking; (ii) DNA template preparation; (iii) dideoxy sequencing reaction set-up and purification; and (iv) sequence determination with the ABI PRISM 3700 DNA Analyzer. Because the inputs and outputs of each module have been carefully matched and sample backlogs are continuously managed, sequencing has proceeded without a single day’s interruption since the initiation of the Drosophila project in May 1999. The ABI 3700 is a fully automated capillary array sequencer and as such can be operated with a minimal amount of hands-on time, currently estimated at about 15 min per day. The capillary system also facilitates correct associations of sequencing traces with samples through the elimination of manual sample loading and lane-tracking errors associated with slab gels. About 65 production staff were hired and trained, and were rotated on a regular basis through the four production modules. A central laboratory information management system (LIMS) tracked all sample plates by unique bar code identifiers. The facility was supported by a quality control team that performed raw material and in-process testing and a quality assurance group with responsibilities including document control, validation, and auditing of the facility. Critical to the success of the scale-up was the validation of all software and instrumentation before implementation, and production-scale testing of any process changes.

1.2 Trace processing

An automated trace-processing pipeline has been developed to process each sequence file (37). After quality and vector trimming, the average trimmed sequence length was 543 bp, and the sequencing accuracy was exponentially distributed with a mean of 99.5% and with less than 1 in 1000 reads being less than 98% accurate (26). Each trimmed sequence was screened for matches to contaminants including sequences of vector alone, E. coli genomic DNA, and human mitochondrial DNA. The entire read for any sequence with a significant match to a contaminant was discarded. A total of 713 reads matched E. coli genomic DNA and 2114 reads matched the human mitochondrial genome.

1.3 Quality assessment and control

The importance of the base-pair level accuracy of the sequence data increases as the size and repetitive nature of the genome to be sequenced increases. Each sequence read must be placed uniquely in the genome.

Table 1. Celera-generated data input into assembly.

<table>
<thead>
<tr>
<th>Individual</th>
<th>2 kbp</th>
<th>10 kbp</th>
<th>50 kbp</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of sequencing reads</td>
<td>2 kbp</td>
<td>10 kbp</td>
<td>50 kbp</td>
<td>Total</td>
</tr>
<tr>
<td>A</td>
<td>1,173,757</td>
<td>7,467,755</td>
<td>66,930</td>
<td>19,271,442</td>
</tr>
<tr>
<td>B</td>
<td>853,819</td>
<td>881,290</td>
<td>0</td>
<td>1,735,109</td>
</tr>
<tr>
<td>C</td>
<td>952,523</td>
<td>1,046,815</td>
<td>0</td>
<td>1,999,338</td>
</tr>
<tr>
<td>D</td>
<td>1,498,607</td>
<td>1,498,607</td>
<td>0</td>
<td>1,998,607</td>
</tr>
<tr>
<td>F</td>
<td>13,543,099</td>
<td>10,894,467</td>
<td>2,834,287</td>
<td>27,271,853</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fold sequence coverage (2.9Gb genome)</th>
<th>2 kbp</th>
<th>10 kbp</th>
<th>50 kbp</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>0</td>
<td>0</td>
<td>0.52</td>
<td>0.52</td>
</tr>
<tr>
<td>B</td>
<td>2.20</td>
<td>1.40</td>
<td>0.01</td>
<td>3.61</td>
</tr>
<tr>
<td>C</td>
<td>0.16</td>
<td>1.17</td>
<td>0</td>
<td>0.32</td>
</tr>
<tr>
<td>D</td>
<td>0.18</td>
<td>0.20</td>
<td>0</td>
<td>0.37</td>
</tr>
<tr>
<td>F</td>
<td>0</td>
<td>0.28</td>
<td>0</td>
<td>0.28</td>
</tr>
<tr>
<td>Total</td>
<td>2.54</td>
<td>2.04</td>
<td>0.53</td>
<td>5.11</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fold clone coverage</th>
<th>2 kbp</th>
<th>10 kbp</th>
<th>50 kbp</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>0</td>
<td>0</td>
<td>18.39</td>
<td>18.39</td>
</tr>
<tr>
<td>B</td>
<td>2.96</td>
<td>11.26</td>
<td>0.44</td>
<td>14.67</td>
</tr>
<tr>
<td>C</td>
<td>0.22</td>
<td>1.33</td>
<td>0</td>
<td>1.54</td>
</tr>
<tr>
<td>D</td>
<td>0.24</td>
<td>1.58</td>
<td>0</td>
<td>1.82</td>
</tr>
<tr>
<td>F</td>
<td>0</td>
<td>2.26</td>
<td>0</td>
<td>2.26</td>
</tr>
<tr>
<td>Total</td>
<td>3.42</td>
<td>16.43</td>
<td>18.84</td>
<td>38.68</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Insert size* (mean)</th>
<th>2 kbp</th>
<th>10 kbp</th>
<th>50 kbp</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average</td>
<td>1,951 bp</td>
<td>10,800 bp</td>
<td>50,715 bp</td>
<td></td>
</tr>
<tr>
<td>Insert size* (SD)</td>
<td>6.10%</td>
<td>8.10%</td>
<td>14.90%</td>
<td></td>
</tr>
<tr>
<td>% Mates†</td>
<td>74.50</td>
<td>80.80</td>
<td>75.60</td>
<td></td>
</tr>
</tbody>
</table>

*Insert size and SD are calculated from assembly of mates on contigs. †% Mates is based on laboratory tracking of sequencing runs.
nomine, and even a modest error rate can reduce the effectiveness of assembly. In addition, maintaining the validity of mate-pair information is absolutely critical for the algorithms described below. Procedural controls were established for maintaining the validity of sequence mate-pairs as sequencing reactions proceeded through the process, including strict rules built into the LIMS. The accuracy of sequence data produced by the Celera process was validated in the course of the *Drosophila* genome project (26). By collecting data for the entire genome in a single facility, we were able to ensure uniform quality standards and the cost advantages associated with automation, an economy of scale, and process consistency.

2 Genome Assembly Strategy and Characterization

**Summary.** We describe in this section the two approaches that we used to assemble the genome. One method involves the computational combination of all sequence reads with shredded data from GenBank to generate an independent, nonbiased view of the genome. The second approach involves clustering all of the fragments to a region or chromosome on the basis of mapping information. The clustered data were then shredded and subjected to computational assembly. Both approaches provided essentially the same reconstruction of assembled DNA sequence with proper order and orientation. The second method provided slightly greater sequence coverage (fewer gaps) and was the principal sequence used for the analysis phase. In addition, we document the completeness and correctness of this assembly process.

**Potential Entry Points**

- Human Samples [Medical Affairs]
- Tissue Samples [DNA Resources]
- DNA/RNA (External) [DNA Resources]
- Libraries [DNA Resources]
- Fluorescently Labeled DNA [Pre-Sequencing Lab]
- Trace Files [UNIX] [Sequencing Lab]
- External Fragments [Content Systems - EDA]
- External & Trimmed Fragments [Content Systems]
- Proto I/O Files [Content Systems]

**Process Management**

- DNA/RNA Extraction [DNA Resources]
- Library Construction [DNA Resources]
- Pre-Sequencing [Pre-Sequencing Lab]
- Sequencing [Sequencing Lab]
- Post-Sequencing [Content Systems]
- External Data Processing [Content Systems]
- Pre-Assembly [Content Systems]
- Proto I/O File Generation [Content Systems]
- Assembly [Informatics Research]

**Potential Exit Points**

- DNA/RNA [DNA Resources]
- Libraries [DNA Resources]
- Fluorescently Labeled DNA [Pre-Sequencing Lab]
- Trace Files [NT] [Sequencing Lab]
- Trimmed Fragments [Content Systems]
- Proto I/O Files [Content Systems]

**Fig. 2.** Flow diagram for sequencing pipeline. Samples are received, selected, and processed in compliance with standard operating procedures, with a focus on quality within and across departments. Each process has defined inputs and outputs with the capability to exchange samples and data with both internal and external entities according to defined quality guidelines. Manufacturing pipeline processes, products, quality control measures, and responsible parties are indicated and are described further in the text.
and provide a comparison to the public genome sequence, which was reconstructed largely by an independent BAC-by-BAC approach. Our assemblies effectively covered the euchromatic regions of the human chromosomes. More than 90% of the genome was in scaffold assemblies of 100,000 bp or greater, and 25% of the genome was in scaffolds of 10 million bp or larger.

Shotgun sequence assembly is a classic example of an inverse problem: given a set of reads randomly sampled from a target sequence, reconstruct the order and the position of those reads in the target. Genome assembly algorithms developed for *Drosophila* have now been extended to assemble the ~25-fold larger human genome. Celera assemblies consist of a set of contigs that are ordered and oriented into scaffolds that are then mapped to chromosomal locations by using known markers. The contigs consist of a collection of overlapping sequence reads that provide a consensus reconstruction for a contiguous interval of the genome. Mate pairs are a central component of the assembly strategy. They are used to produce scaffolds in which the size of gaps between consecutive contigs is known with reasonable precision. This is accomplished by observing that a pair of reads, one of which is in one contig, and the other of which is in another, implies an orientation and distance between the two contigs (Fig. 3). Finally, our assemblies did not incorporate all reads into the final set of reported scaffolds. This set of unincorporated reads is termed “chaff,” and typically consisted of reads from within highly repetitive regions, data from other organisms introduced through various routes as well as reads that were not assembled. In the past 2 years the PFP has focused on a product of lower quality and completeness, but on a faster time-course, by concentrating on the production of Phase 1 data from a 3× to 4× light-shotgun of each BAC clone.

We screened the bactig sequences for contaminants by using the BLAST algorithm against three data sets: (i) vector sequences in Univec core (38), filtered for a 25-bp match at 98% sequence identity at the ends of the sequence and a 30-bp match internal to the sequence; (ii) the nonhuman portion of the High Throughput Genomic (HTG) Sequences division of GenBank (39), filtered at 200 bp at 98%; and (iii) the nonredundant nucleotide sequences from GenBank without primate and human virus entries, filtered at 200 bp at 98%. Whenever 25 bp or more of vector was found within 50 bp of the end of a contig, the tip up to the matching vector was excised. Under these criteria we removed 2.6 Mbp of possible contaminant and vector from the Phase 3 data, 61.0 Mbp from the Phase 1 and 2 data, and 16.1 Mbp from the Phase 0 data (Table 2). This left us with a total of 4363.7 Mbp of PFP sequence data 20% finished, 75% rough-draft (Phase 1 and 2), and 5% single sequencing reads (Phase 0). An additional 104,018 BAC end-sequence mate pairs were also downloaded and included in the data sets for both assembly processes (18).

### 2.2 Assembly strategies

Two different approaches to assembly were pursued. The first was a whole-genome assembly process that used Celera data and the PFP data in the form of additional synthetic shotgun data, and the second was a compartmentalized assembly process that first partitioned the Celera and PFP data into sets localized to large chromosomal segments and then performed ab initio shotgun assembly on each set. Figure 4 gives a schematic of the overall process flow.

For the whole-genome assembly, the PFP data was first disassembled or “shredded” into a synthetic shotgun data set of 550-bp reads that form a perfect 2× covering of the bactigs. This resulted in 16.05 million “faux” reads that were sufficient to cover the genome 2.96× because of redundancy in the BAC data set, without incorporating the biases inherent in the PFP assembly process. The combined data set of 43.32 million reads (8×), and all associated mate-pair information, were then subjected to our whole-genome assembly algorithm to produce a reconstruction of the genome. Neither the location of a BAC in the genome nor its assembly of bactigs was used in this process. Bactigs were shredded into reads because we found strong evidence that 2.13% of them were misassembled (40). Furthermore, BAC location

![Fig. 3. Anatomy of whole-genome assembly. Overlapping shredded bactig fragments (red lines) and internally derived reads from five different individuals (black lines) are combined to produce a contig and a consensus sequence (green line). Contigs are connected into scaffolds (red) by using mate pair information. Scaffolds are then mapped to the genome (grey line) with STS (blue star) physical map information.](http://science.sciencemag.org/)
information was ignored because some BACs were not correctly placed on the PFP physical map and because we found strong evidence that at least 2.2% of the BACs contained sequence data that were not part of the given BAC (41), possibly as a result of sample-tracking errors (see below). In short, we performed a true, ab initio whole-genome assembly in which we took the expedient of deriving additional sequence coverage, but not mate pairs, assembled bactigs, or genome locality, from some externally generated data.

In the compartmentalized shotgun assembly (CSA), Celera and PFP data were partitioned into the largest possible chromosomal segments or “components” that could be determined with confidence, and then shotgun assembly was applied to each partitioned subset wherein the bactig data were again shredded into faux reads to ensure an independent ab initio assembly of the component. By subsets the data in this way, the overall computational effort was reduced and the effect of interchromosomal duplications was ameliorated. This also resulted in a reconstruction of the genome that was relatively independent of the whole-genome assembly results so that the two assemblies could be compared for consistency. The quality of the partitioning into components was crucial so that different genome regions were not mixed together. We constructed components from (i) the largest scaffolds of the sequence from each BAC and (ii) assembled scaffolds of data unique to Celera’s data set. The BAC assemblies were obtained by a combining assembler that used the bactigs and the 5 × Celera data mapped to those bactigs as input. This effort was undertaken as an interstep solely because the more accurate and complete the scaffold for a given sequence stretch, the more accurately one can tile those scaffolds into contiguous components on the basis of sequence overlap and mate-pair information. We further visually inspected and curated the scaffold tiling of the components to further increase its accuracy. For the final CSA assembly, all but the partitioning was ignored, and an independent, ab initio reconstruction of the sequence in each component was obtained by applying our whole-genome assembly algorithm to the partitioned, relevant Celera data and the shredded, faux reads of the partitioned, relevant bactig data.

### 2.3 Whole-genome assembly

The algorithms used for whole-genome assembly (WGA) of the human genome were enhancements to those used to produce the sequence of the *Drosophila* genome reported in detail in (28).

The WGA assembler consists of a pipeline composed of five principal stages: Screener, Overlaplar, Unitigger, Scaffold, and Resolve Resolver, respectively. The Screener finds and marks all microsatellite repeats with less than a 6-bp element, and screens out all known interspersed repeat elements, including Alu, Line, and ribosomal DNA. Marked regions get searched for overlaps, whereas screened regions do not get searched, but can be part of an overlap that involves unscreened matching segments.

---

**Table 2. GenBank data input into assembly.**

<table>
<thead>
<tr>
<th>Center</th>
<th>Statistics</th>
<th>Completion phase sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Whitehead Institute/ MIT Center for Genome Research, USA</td>
<td>Number of accession records</td>
<td>2,825</td>
</tr>
<tr>
<td></td>
<td>Number of contigs</td>
<td>243,786</td>
</tr>
<tr>
<td></td>
<td>Total base pairs</td>
<td>194,490,158</td>
</tr>
<tr>
<td></td>
<td>Total vector masked (bp)</td>
<td>1,553,597</td>
</tr>
<tr>
<td></td>
<td>Total contaminant masked (bp)</td>
<td>13,654,482</td>
</tr>
<tr>
<td></td>
<td>Average contig length (bp)</td>
<td>798</td>
</tr>
<tr>
<td>Washington University, USA</td>
<td>Number of accession records</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Number of contigs</td>
<td>2,127</td>
</tr>
<tr>
<td></td>
<td>Total base pairs</td>
<td>1,195,732</td>
</tr>
<tr>
<td></td>
<td>Total vector masked (bp)</td>
<td>21,604</td>
</tr>
<tr>
<td></td>
<td>Total contaminant masked (bp)</td>
<td>22,469</td>
</tr>
<tr>
<td></td>
<td>Average contig length (bp)</td>
<td>562</td>
</tr>
<tr>
<td>Baylor College of Medicine, USA</td>
<td>Number of accession records</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>Number of contigs</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total base pairs</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total vector masked (bp)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total contaminant masked (bp)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Average contig length (bp)</td>
<td>0</td>
</tr>
<tr>
<td>Production Sequencing Facility, DOE Joint Genome Institute, USA</td>
<td>Number of accession records</td>
<td>7,052</td>
</tr>
<tr>
<td></td>
<td>Number of contigs</td>
<td>2,127</td>
</tr>
<tr>
<td></td>
<td>Total base pairs</td>
<td>8,680,214</td>
</tr>
<tr>
<td></td>
<td>Total vector masked (bp)</td>
<td>22,644</td>
</tr>
<tr>
<td></td>
<td>Total contaminant masked (bp)</td>
<td>22,469</td>
</tr>
<tr>
<td></td>
<td>Average contig length (bp)</td>
<td>562</td>
</tr>
<tr>
<td>The Institute of Physical and Chemical Research (RIKEN), Japan</td>
<td>Number of accession records</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Number of contigs</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total base pairs</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total vector masked (bp)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total contaminant masked (bp)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Average contig length (bp)</td>
<td>0</td>
</tr>
<tr>
<td>Sanger Centre, UK</td>
<td>Number of accession records</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Number of contigs</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total base pairs</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total vector masked (bp)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Total contaminant masked (bp)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Average contig length (bp)</td>
<td>0</td>
</tr>
<tr>
<td>Others*</td>
<td>Number of accession records</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Number of contigs</td>
<td>5,978</td>
</tr>
<tr>
<td></td>
<td>Total base pairs</td>
<td>5,564,879</td>
</tr>
<tr>
<td></td>
<td>Total vector masked (bp)</td>
<td>57,448</td>
</tr>
<tr>
<td></td>
<td>Total contaminant masked (bp)</td>
<td>575,366</td>
</tr>
<tr>
<td></td>
<td>Average contig length (bp)</td>
<td>931</td>
</tr>
<tr>
<td>All centers combined†</td>
<td>Number of accession records</td>
<td>3,021</td>
</tr>
<tr>
<td></td>
<td>Number of contigs</td>
<td>258,943</td>
</tr>
<tr>
<td></td>
<td>Total base pairs</td>
<td>209,930,983</td>
</tr>
<tr>
<td></td>
<td>Total vector masked (bp)</td>
<td>1,655,293</td>
</tr>
<tr>
<td></td>
<td>Total contaminant masked (bp)</td>
<td>14,918,135</td>
</tr>
<tr>
<td></td>
<td>Average contig length (bp)</td>
<td>811</td>
</tr>
</tbody>
</table>

*Other centers contributing at least 0.1% of the sequence include: Chinese National Human Genome Center; Genomanaalyse Gesellschaft fuer Biotechnologische Forschung mbH; Genome Therapeutics Corporation; GenOSCOPE; Chinese Academy of Sciences; Institute of Molecular Biotechnology; Keio University School of Medicine; Lawrence Livermore National Laboratory; Cold Spring Harbor Laboratory; Los Alamos National Laboratory; Max-Planck Institut fuer Molekulare, Genetik; Japan Science and Technology Corporation; Stanford University; Cellen, The Institute for Genomic Research; The Institute of Physical and Chemical Research, Gene Bank; The University of Oklahoma; University of Texas Southwestern Medical Center, University of Washington. †The 4.405,700,825 bases contributed by all centers were shredded into faux reads resulting in 2.96× coverage of the genome.
The Overlapper compares every read against every other read in search of complete end-to-end overlaps of at least 40 bp and with no more than 6% differences in the match. Because all data are scrupulously vector-trimmed, the Overlapper can insist on complete overlap matches. Computing the set of all overlaps took roughly 10,000 CPU hours with a suite of four-processor Alpha SMPs with 4 gigabytes of RAM. This took 4 to 5 days in elapsed time with 40 such machines operating in parallel.

Every overlap computed above is statistically a 1-in-10^17 event and thus not a coincidental event. What makes assembly combinatorially difficult is that while many overlaps are actually sampled from overlapping regions of the genome, and thus imply that the sequence reads should be assembled together, even more overlaps are actually from two distinct copies of a low-copy repeated element not screened above, thus constituting an error if put together. We call the former "true overlaps" and the latter "repeat-induced overlaps." The assembler must avoid choosing repeat-induced overlaps, especially early in the process.

We achieve this objective in the Unitigger. We first find all assemblies of reads that appear to be uncontested with respect to all other reads. We call the contigs formed from these subassemblies unitigs (for uniquely assembled contigs). Formally, these unitigs are the uncontested interval subgraphs of the graph of all overlaps (42). Unfortunately, although empirically many of these assemblies are correct (and thus involve only true overlaps), some are in fact collections of reads from several copies of a repetitive element that have been overcollapsed into a single subassembly. However, the overcollapsed unitigs are easily identified because their average coverage depth is too high to be consistent with the overall level of sequence coverage. We developed a simple statistical discriminator that gives the logarithm of the odds ratio that a unitig is composed of unique DNA or of a repeat consisting of two or more copies. The discriminator, set to a sufficiently stringent threshold, identifies a subset of the unitigs that we are certain are correct. In addition, a second, less stringent threshold identifies a subset of remaining unitigs very likely to be correctly assembled, of which we select those that will consistently scaffold (see below), and thus are again almost certain to be correct. We call the union of these two sets U-unitigs. Empirically, we found from a 6x simulated shotgun of human chromosome 22 that we get U-unitigs covering 98% of the stretches of unique DNA that are >2 kbp long. We are further able to identify the boundary of the start of a repetitive element at the ends of a U-unitig and leverage this so that U-unitigs span more than 93% of all singly interspersed Alu elements and other 100-to 400-bp repetitive segments.

The result of running the Unitigger was thus a set of correctly assembled subcontigs covering an estimated 73.6% of the human genome. The Scaffolder then proceeded to use mate-pair information to link these together into scaffolds. When there are two or more mate pairs that imply that a given pair of U-unitigs are at a certain distance and orientation with respect to each other, the probability of this being wrong is again roughly 1 in 10^10, assuming that mate pairs are false less than 2% of the time. Thus, one can with high confidence link together all U-unitigs that are linked by at least two 2- or 10-kbp mate pairs producing intermediate-sized scaffolds that are then recursively linked together by confirming 50-kbp mate pairs and BAC end sequences. This process yielded scaffolds that are on the order of megabase pairs in size with gaps between their contigs that generally correspond to repetitive elements and occasionally to small sequencing gaps. These scaffolds reconstruct the majority of the unique sequence within a genome.

For the Drosophila assembly, we engaged in a three-stage repeat resolution strategy where each stage was progressively more aggressive and thus more likely to make a mistake. For the human assembly, we continued to use the first “Rocks” substage where all unitigs with a good, but not definitive, discriminator score are placed in a scaffold gap. This was done with the condition that two or more mate pairs with one of their reads already in the scaffold unambiguously place the unitig in the given gap. We estimate the probability of inserting a unitig into an incorrect gap with this strategy to be less than 10^-17 based on a probabilistic analysis.

We revised the ensuing “Stones” substage of the human assembly, making it more like the mechanism suggested in our earlier work (43). For each gap, every read R that is placed in the gap by virtue of its mated pair M being in a contig of the scaffold and implying R’s placement is collected. Celera’s mate-pairing information is correct more than 99% of the time. Thus, almost every, but not all, of the reads in the set belong in the gap, and when a read does not belong it rarely agrees with the remainder of the reads. Therefore, we simply assemble this set of reads within the gap, eliminating any reads that conflict with the assembly. This operation proved much more reliable than the one it replaced for the Drosophila assembly; in the assembly of a simulated shotgun data set of human chromo-

Fig. 4. Architecture of Celera’s two-pronged assembly strategy. Each oval denotes a computation process performing the function indicated by its label, with the labels on arcs between ovals describing the nature of the objects produced and/or consumed by a process. This figure summarizes the discussion in the text that defines the terms and phrases used.
some 22, all stones were placed correctly.

The final method of resolving gaps is to fill them with assembled BAC data that cover the gap. We call this external gap "walking." We did not include the very aggressive "Pebbles" substage described in our *Drosophila* work, which made enough mistakes so as to produce repeat reconstructions for long interspersed elements whose quality was only 99.62% correct. We decided that for the human genome it was philosophically better not to introduce a step that was certain to produce less than 99.99% accuracy. The cost was a somewhat larger number of gaps of somewhat larger size.

At the final stage of the assembly process, and also at several intermediate points, a consensus sequence of every contig is produced. Our algorithm is driven by the principle of maximum parsimony, with quality-value–weighted measures for evaluating each base. The net effect is a Bayesian estimate of the correct base to report at each position. Consensus generation uses Celera data whenever it is present. In the event that no Celera data cover a given region, the BAC data sequence is used.

A key element of achieving a WGA of the human genome was to parallelize the Overlapper and the central consensus sequence–constructing subroutines. In addition, memory was a real issue—a straightforward application of the software we had built for *Drosophila* would have required a computer with a 600-gigabyte RAM. By making the Overlapper and Unitigger incremental, we were able to achieve the same computation with a maximum of instantaneous usage of 28 gigabytes of RAM. Moreover, the incremental nature of the first three stages allowed us to continually update the state of this part of the computation as data were delivered and then perform a 7-day run to complete Scaffolding and Repeat Resolution whenever desired. For our assembly operations, the total compute infrastructure consists of 10 four-processor SMPs with 4 gigabytes of memory per cluster (Compaq's ES40, Regatta) and a 16-processor NUMA machine with 64 gigabytes of memory (Compaq's GS160, Wildfire). The total compute for a run of the assembler was roughly 20,000 CPU hours.

The assembly of Celera's data, together with the shredded bactig data, produced a set of scaffolds totaling 2.848 Gbp in span and consisting of 2.586 Gbp of sequence. The chaff, or set of reads not incorporated in the assembly, numbered 11.27 million (26%), which is consistent with our experience for *Drosophila*. More than 84% of the genome was covered by scaffolds >100 kbp long, and these averaged 91% sequence and 9% gaps with a total of 2.297 Gbp of sequence. There were a total of 93,857 gaps among the 1637 scaffolds >100 kbp. The average scaffold size was 1.5 Mbp, the average contig size was 24.06 kbp, and the average gap size was 2.43 kbp, where the distribution of each was essentially exponential. More than 50% of all gaps were less than 500 bp long, >62% of all gaps were less than 1 kbp long, and no gap was >100 kbp long. Similarly, more than 65% of the sequence is in contigs >30 kbp, more than 31% is in contigs >100 kbp, and the largest contig was 1.22 Mbp long. Table 3 gives detailed summary statistics for the structure of this assembly with a direct comparison to the compartmentalized shotgun assembly.

### 2.4 Compartmentalized shotgun assembly

In addition to the WGA approach, we pursued a localized assembly approach that was intended to subdivide the genome into segments, each of which could be shotgun assembled individually. We expected that this would help in resolution of large interchromosomal duplications and improve the statistics for calculating U-unitigs. The compartmentalized assembly process involved clustering Celera reads and bactigs into large, multiple megabase regions of the genome, and then running the WGA assembler on the Celera data and shredded, faux reads obtained from the bactig data.

The first phase of the CSA strategy was to separate Celera reads into those that matched the BAC contigs for a particular PFP BAC entry, and those that did not match any public data. Such matches must be guaranteed to

---

**Table 3. Scaffold statistics for whole-genome and compartmentalized shotgun assemblies.**

<table>
<thead>
<tr>
<th>Scaffold size</th>
<th>All</th>
<th>&gt;30 bp</th>
<th>&gt;100 bp</th>
<th>&gt;500 bp</th>
<th>&gt;1000 bp</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Compartimentalized shotgun assembly</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of bp in scaffolds</td>
<td>2,905,568,203</td>
<td>2,748,892,430</td>
<td>2,700,489,906</td>
<td>2,489,357,260</td>
<td>2,248,689,128</td>
</tr>
<tr>
<td>(including intrascaffold gaps)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of bp in contigs</td>
<td>2,653,979,733</td>
<td>2,524,251,302</td>
<td>2,491,538,372</td>
<td>2,320,648,201</td>
<td>2,106,521,902</td>
</tr>
<tr>
<td>No. of scaffolds</td>
<td>53,591</td>
<td>2,845</td>
<td>1,935</td>
<td>1,060</td>
<td>721</td>
</tr>
<tr>
<td>No. of contigs</td>
<td>170,033</td>
<td>112,207</td>
<td>107,199</td>
<td>93,138</td>
<td>82,009</td>
</tr>
<tr>
<td>No. of gaps</td>
<td>116,442</td>
<td>109,362</td>
<td>105,264</td>
<td>92,078</td>
<td>75,731</td>
</tr>
<tr>
<td>No. of gaps ≤1 kbp</td>
<td>72,091</td>
<td>69,175</td>
<td>67,289</td>
<td>59,915</td>
<td>53,354</td>
</tr>
<tr>
<td>Average scaffold size (bp)</td>
<td>54,217</td>
<td>966,219</td>
<td>1,395,602</td>
<td>2,348,450</td>
<td>3,118,848</td>
</tr>
<tr>
<td>Average contig size (bp)</td>
<td>15,609</td>
<td>22,496</td>
<td>23,242</td>
<td>24,916</td>
<td>25,686</td>
</tr>
<tr>
<td>Average intrascaffold gap size (bp)</td>
<td>2,161</td>
<td>2,054</td>
<td>1,985</td>
<td>1,832</td>
<td>1,749</td>
</tr>
<tr>
<td>Largest contig (bp)</td>
<td>1,988,321</td>
<td>1,988,321</td>
<td>1,988,321</td>
<td>1,988,321</td>
<td>1,988,321</td>
</tr>
<tr>
<td>% of total contigs</td>
<td>100</td>
<td>95</td>
<td>94</td>
<td>87</td>
<td>79</td>
</tr>
<tr>
<td><strong>Whole-genome assembly</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of bp in scaffolds</td>
<td>2,847,890,390</td>
<td>2,574,792,618</td>
<td>2,525,334,447</td>
<td>2,328,535,466</td>
<td>2,140,943,032</td>
</tr>
<tr>
<td>(including intrascaffold gaps)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of bp in contigs</td>
<td>2,586,634,108</td>
<td>2,334,343,339</td>
<td>2,297,678,935</td>
<td>2,143,002,184</td>
<td>1,983,305,432</td>
</tr>
<tr>
<td>No. of scaffolds</td>
<td>119,968</td>
<td>2,507</td>
<td>1,637</td>
<td>518</td>
<td>18</td>
</tr>
<tr>
<td>No. of contigs</td>
<td>221,036</td>
<td>99,189</td>
<td>95,494</td>
<td>84,641</td>
<td>76,285</td>
</tr>
<tr>
<td>No. of gaps</td>
<td>102,068</td>
<td>96,682</td>
<td>93,857</td>
<td>83,823</td>
<td>75,731</td>
</tr>
<tr>
<td>No. of gaps ≤1 kbp</td>
<td>65,356</td>
<td>60,343</td>
<td>59,156</td>
<td>54,079</td>
<td>49,592</td>
</tr>
<tr>
<td>Average scaffold size (bp)</td>
<td>23,938</td>
<td>1,027,041</td>
<td>1,542,660</td>
<td>2,846,620</td>
<td>3,864,518</td>
</tr>
<tr>
<td>Average contig size (bp)</td>
<td>11,702</td>
<td>23,534</td>
<td>24,061</td>
<td>25,319</td>
<td>25,999</td>
</tr>
<tr>
<td>Average intrascaffold gap size (bp)</td>
<td>2,560</td>
<td>2,487</td>
<td>2,426</td>
<td>2,213</td>
<td>2,082</td>
</tr>
<tr>
<td>Largest contig (bp)</td>
<td>1,224,073</td>
<td>1,224,073</td>
<td>1,224,073</td>
<td>1,224,073</td>
<td>1,224,073</td>
</tr>
<tr>
<td>% of total contigs</td>
<td>100</td>
<td>90</td>
<td>89</td>
<td>83</td>
<td>77</td>
</tr>
</tbody>
</table>
properly place a Celera read, so all reads were first masked against a library of common repetitive elements, and only matches of at least 40 bp to unmasked portions of the read constituted a hit. Of Celera's 27.27 million reads, 20.76 million matched a bactig and another 0.62 million reads, which did not have any matches, were nonetheless identified as belonging in the region of the bactig's BAC because their mate matched the bactig. Of the remaining reads, 2.92 million were completely screened out and so could not be matched, but the other 2.97 million reads had unmasked sequence totaling 1.189 Gbp that were not found in the GenBank data set. Because the Celera data are 5.11× redundant, we estimate that 240 Mbp of unique Celera sequence is not in the GenBank data set.

In the next step of the CSA process, a combining assembler took the relevant 5× Celera reads and bactigs for a BAC entry, and produced an assembly of the combined data for that locale. These high-quality sequence reconstructions were a transient result whose utility was simply to provide more reliable information for the purposes of their tiling into sets of overlapping and adjacent scaffold sequences in the next step. In outline, the combining assembler first examines the set of matching Celera reads to determine if there are excessive pileups indicative of unscreened repetitive elements. Wherever these occur, reads in the repeat region whose mates have not been mapped to consistent positions are removed. Then all sets of mate pairs that consistently imply the same relative position of two bactigs are bundled into a link and weighted according to the number of mates in the bundle. A “greedy” strategy then attempts to order the bactigs by selecting bundles of mate-pairs in order of their weight. A selected mate-pair bundle can tie together two formative scaffolds. It is incorporated to form a single scaffold only if it is consistent with the majority of links between contigs of the scaffold. Once scaffolding is complete, gaps are filled by the “Stones” strategy described above for the WGA assembler.

The GenBank data for the Phase 1 and 2 BACs consisted of an average of 19.8 bactigs per BAC of average size 8099 bp. Application of the combining assembler resulted in individual Celera BAC assemblies being put together into an average of 1.83 scaffolds (median of 1 scaffold) consisting of an average of 8.57 contigs of average size 18,973 bp. In addition to defining order and orientation of the sequence fragments, there were 57% fewer gaps in the combined result. For Phase 0 data, the average GenBank entry consisted of 91.52 reads of average length 784 bp. Application of the combining assembler resulted in an average of 54.8 scaffolds consisting of an average of 58.1 contigs of average size 873 bp. Basically, some small amount of assembly took place, but not enough Celera data were matched to truly assemble the 0.5× to 1× data set represented by the typical Phase 0 BACs. The combining assembler was also applied to the Phase 3 BACs for SNP identification, confirmation of assembly, and localization of the Celera reads. The phase 0 data suggest that a combined whole-genome shotgun data set and 1× light-shotgun of BACs will not yield good assembly of BAC regions; at least 3× light-shotgun of each BAC is needed.

The 5.89 million Celera fragments not matching the GenBank data were assembled with our whole-genome assembler. The assembly resulted in a set of scaffolds totaling 442 Mbp in span and consisting of 326 Mbp of sequence. More than 20% of the scaffolds were >5 kbp long, and these averaged 63% sequence and 27% gaps with a total of 302 Mbp of sequence. All scaffolds >5 kbp were forwarded along with all scaffolds produced by the combining assembler to the subsequent tiling phase.

At this stage, we typically had one or two scaffolds for every BAC region constituting at least 95% of the relevant sequence, and a collection of disjoint Celera-unique scaffolds. The next step in developing the genome components was to determine the order and overlap tiling of these BAC and Celera-unique scaffolds across the genome. For this, we used Celera’s 50-kbp mate-pairs information, and BAC-end pairs (18) and sequence tagged site (STS) markers (44) to provide long-range guidance and chromosome separation. Given the relatively manageable number of scaffolds, we chose not to produce this tiling in a fully automated manner, but to compute an initial tiling with a good heuristic and then use human curators to resolve discrepancies or missed join opportunities. To this end, we developed a graphical user interface that displayed the graph of tiling overlaps and the evidence for each. A human curator could then explore the implication of mapped STS data, dot-plots of sequence overlap, and a visual display of the mate-pair evidence supporting a given choice. The result of this process was a collection of “components,” where each component was a tiled set of BAC and Celera-unique scaffolds that had been curator-approved. The process resulted in 3845 components with an estimated span of 2.922 Gbp.

In order to generate the final CSA, we assembled each component with the WGA algorithm. As was done in the WGA process, the bactig data were shredded into a synthetic 2× shotgun data set in order to give the assembler the freedom to independently assemble the data. By using faux reads rather than bactigs, the assembly algorithm could correct errors in the assembly of bactigs and remove chimeric content in a PPF data entry.

Chimeric or contaminating sequence (from another part of the genome) would not be incorporated into the reassembly of the component because it did not belong there. In effect, the previous steps in the CSA process served only to bring together Celera fragments and PPF data relevant to a large contiguous segment of the genome, wherein we applied the assembler used for WGA to produce an ab initio assembly of the region.

WGA assembly of the components resulted in a set of scaffolds totaling 2.906 Gbp in span and consisting of 2.654 Gbp of sequence. The chaff, or set of reads not incorporated into the assembly, numbered 6.17 million, or 22%. More than 90.0% of the genome was covered by scaffolds spanning >100 kbp long, and these averaged 92.2% sequence and 7.8% gaps with a total of 2.492 Gbp of sequence. There were a total of 105,264 gaps among the 107,199 contigs that belong to the 1940 scaffolds spanning >100 kbp. The average scaffold size was 1.4 Mbp, the average contig size was 23.24 kbp, and the average gap size was 2.0 kbp where each distribution of sizes was exponential. As such, averages tend to be underrepresentative of the majority of the data. Figure 5 shows a histogram of the bases in scaffolds of various size ranges. Consider also that more than 49% of all gaps were <500 bp long, more than 62% of all gaps were <1 kbp, and all gaps are <100 kbp long. Similarly, more than 73% of the sequence is in contigs >30 kbp, more than 49% is in contigs >100 kbp, and the largest contig was 1.99 Mbp long. Table 3 provides summary statistics for the structure of this assembly with a direct comparison to the WGA assembly.

2.5 Comparison of the WGA and CSA scaffolds

Having obtained two assemblies of the human genome via independent computational processes (WGA and CSA), we compared scaffolds from the two assemblies as another means of investigating their completeness, consistency, and contiguity. From each assembly, a set of reference scaffolds containing at least 1000 fragments (Celera sequencing reads or bactig shreds) was obtained; this amounted to 2218 WGA scaffolds and 1717 CSA scaffolds, for a total of 2.087 Gbp and 2.474 Gbp. The sequence of each reference scaffold was compared to the sequence of all scaffolds from the other assembly with which it shared at least 20 fragments or at least 20% of the fragments of the smaller scaffold. For each such comparison, all matches of at least 200 bp with at most 2% mismatch were tabulated.

From this tabulation, we estimated the amount of unique sequence in each assembly in two ways. The first was to determine the number of bases of each assembly that were
not covered by a matching segment in the other assembly. Some 82.5 Mbp of the WGA (3.95%) was not covered by the CSA, whereas 204.5 Mbp (8.26%) of the CSA was not covered by the WGA. This estimate did not require any consistency of the assemblies or any uniqueness of the matching segments. Thus, another analysis was conducted in which matches of less than 1 kbp between a pair of scaffolds were excluded unless they were confirmed by other matches having a consistent order and orientation. This gives some measure of consistent coverage: 1.982 Gbp (95.00%) of the WGA is covered by the CSA, and 2.169 Gbp (87.69%) of the CSA is covered by the WGA by this more stringent measure.

The comparison of WGA to CSA also permitted evaluation of scaffolds for structural inconsistencies. We looked for instances in which a large section of a scaffold from one assembly matched only one scaffold from the other assembly, but failed to match over the full length of the overlap implied by the matching segments. An initial set of candidates was identified automatically, and then each candidate was inspected by hand. From this process, we identified 31 instances in which the assemblies appear to disagree in a nonlocal fashion. These cases are being further evaluated to determine which assembly is in error and why.

In addition, we evaluated local inconsistencies of order or orientation. The following results exclude cases in which one contig in one assembly corresponds to more than one overlapping contig in the other assembly (as long as the order and orientation of the latter agrees with the positions they match in the former). Most of these small rearrangements involved segments on the order of hundreds of base pairs and rarely >1 kbp. We found a total of 295 kbp (0.012%) in the CSA assemblies that were locally inconsistent with the WGA assemblies, whereas 2.108 Mbp (0.11%) in the WGA assembly were inconsistent with the CSA assembly.

The CSA assembly was a few percentage points better in terms of coverage and slightly more consistent than the WGA, because it was in effect performing a few thousand shotgun assemblies of megabase-sized problems, whereas the WGA is performing a shotgun assembly of a gigabase-sized problem. When one considers the increase of two-and-a-half orders of magnitude in problem size, the information loss between the two is remarkably small. Because CSA was logistically easier to deliver and the better of the two results available at the time when downstream analyses needed to be begun, all subsequent analysis was performed on this assembly.

2.6 Mapping scaffolds to the genome

The final step in assembling the genome was to order and orient the scaffolds on the chromosomes. We first grouped scaffolds together on the basis of their order in the components from CSA. These grouped scaffolds were reordered by examining residual mate-pairing data between the scaffolds. We next mapped the scaffold groups onto the chromosome using physical mapping data. This step depends on having reliable high-resolution map information such that each scaffold will overlap multiple markers. There are two genome-wide types of map information available: high-density STS maps and fingerprint maps of BAC clones developed at Washington University (45). Among the genome-wide STS maps, GeneMap99 (GM99) has the most markers and therefore was most useful for mapping scaffolds. The two different mapping approaches are complementary to one another. The fingerprint maps should have better local order because they were built by comparison of overlapping BAC clones. On the other hand, GM99 should have a more reliable long-range order, because the framework markers were derived from well-validated genetic maps. Both types of maps were used as a reference for human curation of the components that were the input to the regional assembly, but they did not determine the order of sequences produced by the assembler.

In order to determine the effectiveness of the fingerprint maps and GM99 for mapping scaffolds, we first examined the reliability of these maps by comparison with large scaffolds. Only 1% of the STS markers on the 10 largest scaffolds (those >9 Mbp) were mapped on a different chromosome on GM99. Two percent of the STS markers disagreed in position by more than five framework bins. However, for the fingerprint maps, a 2% chromosome discrepancy was observed, and on average 23.8% of BAC locations in the scaffold sequence disagreed with fingerprint map placement by more than five BACs. When further examining the source of discrepancy, it was found that most of the discrepancy came from 4 of the 10 scaffolds, indicating this there is variation in the quality of either the map or the scaffolds. All four scaffolds were assembled, as well as the other six, as judged by clone coverage analysis, and showed the same low discrepancy rate to GM99, and thus we concluded that the fingerprint map global order in these cases was not reliable. Smaller scaffolds had a higher discordance rate with GM99 (4.21% of STSs were discordant by more than five framework bins), but a lower discordance rate with the fingerprint maps (11% of BACs disagreed with fingerprint maps by more than five BACs). This observation agrees with the clone coverage analysis (46) that Celera scaffold construction was better supported by long-range mate pairs in larger scaffolds than in small scaffolds.

We created two orderings of Celera scaffolds on the basis of the markers (BAC or STS) on these maps. Where the order of scaffolds agreed between GM99 and the WashU BAC map, we had a high degree of confidence that that order was correct; these scaffolds were termed “anchor scaffolds.” Only scaffolds with a low overall discrepancy rate with both maps were considered anchor scaffolds. Scaffolds in GM99 bins were allowed to permute in their order to match WashU ordering, provided they did not violate their framework orders. Orientation of individual scaffolds was determined by the presence of multiple mapped markers with consistent order. Scaffolds with only one marker have insufficient information to assign orientation. We found 70.1% of the genome in anchored scaffolds, more than 99% of which are also oriented (Table 4). Because GM99 is of lower resolution than the WashU map, a number of scaffolds without STS matches could be ordered relative to the anchored scaffolds because they included sequence from the same or adjacent BACs on the WashU map. On the other hand, because of occasional WashU global ordering discrepancies, a number of scaffolds determined to be “unmappable” on the WashU map could be ordered relative to the anchored scaffolds.
with GM99. These scaffolds were termed “ordered scaffolds.” We found that 13.9% of the assembly could be ordered by these additional methods, and thus 84.0% of the genome was ordered unambiguously.

Next, all scaffolds that could be placed, but not ordered, between anchors were assigned to the interval between the anchored scaffolds and were deemed to be “bounded” between them. For example, small scaffolds having STS hits from the same Gene-Map bin or hitting the same BAC cannot be ordered relative to each other, but can be assigned a placement boundary relative to other anchored or ordered scaffolds. The remaining scaffolds either had no localization information, conflicting information, or could only be assigned to a generic chromosome location. Using the above approaches, ~98% of the genome was anchored, ordered, or bounded.

Finally, we assigned a location for each scaffold placed on the chromosome by spreading out the scaffolds per chromosome. We assumed that the remaining unmapped scaffolds, constituting 2% of the genome, were distributed evenly across the genome. By dividing the sum of unmapped scaffold lengths with the sum of the number of mapped scaffolds, we arrived at an estimate of interscaffold gap of 1483 bp. This gap was used to separate all the scaffolds on each chromosome and to assign an offset in the chromosome.

During the scaffold-mapping effort, we encountered many problems that resulted in additional quality assessment and validation analysis. At least 978 (3% of 33,173) BACs were believed to have sequence data from more than one location in the genome (47). This is consistent with the bactig chimerism analysis reported above in the Assembly Strategies section. These BACs could not be assigned to unique positions within the CSA assembly and thus could not be used for ordering scaffolds. Likewise, it was not always possible to assign STSs to unique locations in the assembly because of genome duplications, repetitive elements, and pseudogenes.

Because of the time required for an exhaustive search for a perfect overlap, CSA generated 21,607 intrascaffold gaps where the mate-pair data suggested that the contigs should overlap, but no overlap was found. These gaps were defined as a fixed 50 bp in length and make up 18.6% of the total 116,442 gaps in the CSA assembly.

We chose not to use the order of exons implied in cDNA or EST data as a way of ordering scaffolds. The rationale for not using this data was that doing so would have biased certain regions of the assembly by rearranging scaffolds to fit the transcript data and made validation of both the assembly and gene definition processes more difficult.

### Table 4. Summary of scaffold mapping

<table>
<thead>
<tr>
<th>Scaffold category</th>
<th>Number</th>
<th>Length (bp)</th>
<th>% Total length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anchored</td>
<td>1,526</td>
<td>1,860,676,676</td>
<td>70</td>
</tr>
<tr>
<td>Oriented</td>
<td>1,246</td>
<td>1,852,088,645</td>
<td>70</td>
</tr>
<tr>
<td>Unoriented</td>
<td>280</td>
<td>8,588,031</td>
<td>0.3</td>
</tr>
<tr>
<td>Ordered</td>
<td>2,001</td>
<td>369,235,857</td>
<td>14</td>
</tr>
<tr>
<td>Oriented</td>
<td>839</td>
<td>329,633,166</td>
<td>12</td>
</tr>
<tr>
<td>Unoriented</td>
<td>1,162</td>
<td>39,602,691</td>
<td>2</td>
</tr>
<tr>
<td>Bounded</td>
<td>38,241</td>
<td>368,753,463</td>
<td>14</td>
</tr>
<tr>
<td>Oriented</td>
<td>7,453</td>
<td>274,536,424</td>
<td>10</td>
</tr>
<tr>
<td>Unoriented</td>
<td>30,788</td>
<td>94,217,039</td>
<td>4</td>
</tr>
<tr>
<td>Unmapped</td>
<td>11,823</td>
<td>55,313,737</td>
<td>2</td>
</tr>
<tr>
<td>Known chromosome</td>
<td>281</td>
<td>2,505,844</td>
<td>0.1</td>
</tr>
<tr>
<td>Unknown chromosome</td>
<td>11,542</td>
<td>52,807,893</td>
<td>2</td>
</tr>
</tbody>
</table>
assembly against other finished sequence for determining sequencing accuracy at the nucleotide level, although this has been done for identifying polymorphisms as described in Section 6. The accuracy of the consensus sequence is at least 99.96% on the basis of a statistical estimate derived from the quality values of the underlying reads.

The structural consistency of the assembly can be measured by mate-pair analysis. In a correct assembly, every mated pair of sequencing reads should be located on the consensus sequence with the correct separation and orientation between the pairs. A pair is termed “valid” when the reads are in the correct orientation and the distance between them is within the mean - 2 standard deviations of the distribution of insert sizes of the library from which the pair was sampled. A pair is termed “misoriented” when the reads are not correctly oriented, and termed “mis-separated” when the distance between the reads is not in the correct range but the reads are correctly oriented. The mean ± the standard deviation of each library used by the assembler was determined as described above. To validate these, we examined all reads mapped to the finished sequence of chromosome 21 (48) and determined how many incorrect mate pairs there were as a result of laboratory tracking errors and chimerism (two different segments of the genome cloned into the same plasmid), and how tight the distribution of insert sizes was for those that were correct (Table 5). The standard deviations for all Celera libraries were quite small, less than 15% of the insert length, with the exception of a few 50-kbp libraries. The 2- and 10-kbp libraries contained less than 2% invalid mate pairs, whereas the 50-kbp libraries were somewhat higher (~10%). Thus, although the mate-pair information was not perfect, its accuracy was such that measuring valid, misoriented, and mis-separated pairs with respect to a given assembly was deemed to be a reliable instrument for validation purposes, especially when several mate pairs confirm or deny an ordering.

The clone coverage of the genome was 39×, meaning that any given base pair was, on average, contained in 39 clones or, equivalently, spanned by 39 mate-paired reads. Areas of low clone coverage or areas with a high proportion of invalid mate pairs would indicate potential assembly problems. We computed the coverage of each base in the assembly by valid mate pairs (Table 6). In summary, for scaffolds >30 kbp in length, less than 1% of the Celera assembly was in regions of less than 3× clone coverage. Thus, more than 99% of the assembly, including order and orientation, is strongly supported by this measure alone.

We examined the locations and number of all misoriented and misseparated mates. In addition to doing this analysis on the CSA assembly (as of 1 October 2000), we also performed a study of the PFP assembly as of 5 September 2000 (30, 55b). In this latter case, Celera mate pairs had to be mapped to the PFP assembly. To avoid mapping errors due to high-fidelity repeats, the only pairs mapped were those for which both reads matched at only one location with less than 6% differences. A threshold was set such that sets of five or more simultaneously invalid mate pairs indicated a potential breakpoint, where the construction of the two assemblies differed. The graphic comparison of the CSA chromosome 21 assembly with the published sequence (Fig. 6A) serves as a validation of this methodology. Blue tick marks in the panels indicate breakpoints. There were a similar (small) number of breakpoints on both chromosome sequences. The exception was 12 sets of scaffolds in the Celera assembly (a total of 3% of the chromosome length in 212 single-contig scaffolds) that were mapped to the wrong positions because they were too small to be mapped reliably. Figures 6 and 7 and Table 6 illustrate the mate-pair differences and breakpoints between the two assemblies. There was a higher percentage of misoriented and misseparated mate pairs in the large-insert libraries (50 kbp and BAC ends) than in the small-insert libraries in both assemblies (Table 6). The large-insert libraries are more likely to identify discrepancies simply because they span a larger segment of the genome. The graphic comparison between the two assemblies for chromosome 8 (Fig. 6, B and C) shows that there are many

---

**Table 5. Mate-pair validation.** Celera fragment sequences were mapped to the published sequence of chromosome 21. Each mate pair uniquely mapped was evaluated for correct orientation and placement (number of mate pairs tested). If the two mates had incorrect relative orientation or placement, they were considered invalid (number of invalid mate pairs).

<table>
<thead>
<tr>
<th>Library type</th>
<th>Library no.</th>
<th>Mean insert size (bp)</th>
<th>SD (bp)</th>
<th>SD/mean (%)</th>
<th>No. of mate pairs tested</th>
<th>No. of invalid mate pairs</th>
<th>% invalid</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 kbp</td>
<td>1</td>
<td>2,081</td>
<td>106</td>
<td>5.1</td>
<td>3,642</td>
<td>38</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>1,913</td>
<td>152</td>
<td>7.9</td>
<td>28,029</td>
<td>413</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>2,166</td>
<td>175</td>
<td>8.1</td>
<td>4,405</td>
<td>57</td>
<td>1.3</td>
</tr>
<tr>
<td>10 kbp</td>
<td>4</td>
<td>11,385</td>
<td>851</td>
<td>7.5</td>
<td>4,319</td>
<td>80</td>
<td>1.9</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>14,523</td>
<td>1,875</td>
<td>12.9</td>
<td>7,355</td>
<td>156</td>
<td>2.1</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>9,635</td>
<td>1,035</td>
<td>10.7</td>
<td>5,573</td>
<td>109</td>
<td>2.0</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>10,223</td>
<td>928</td>
<td>9.1</td>
<td>34,079</td>
<td>399</td>
<td>1.2</td>
</tr>
<tr>
<td>50 kbp</td>
<td>8</td>
<td>64,888</td>
<td>2,747</td>
<td>4.2</td>
<td>16</td>
<td>1</td>
<td>6.3</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>53,410</td>
<td>5,834</td>
<td>10.9</td>
<td>914</td>
<td>170</td>
<td>18.6</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>52,034</td>
<td>7,312</td>
<td>14.1</td>
<td>5,871</td>
<td>569</td>
<td>9.7</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>52,282</td>
<td>7,454</td>
<td>14.3</td>
<td>2,629</td>
<td>213</td>
<td>8.1</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>46,616</td>
<td>7,378</td>
<td>15.8</td>
<td>2,153</td>
<td>215</td>
<td>10.0</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>55,788</td>
<td>10,099</td>
<td>18.1</td>
<td>2,244</td>
<td>249</td>
<td>11.1</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>39,894</td>
<td>5,019</td>
<td>12.6</td>
<td>199</td>
<td>7</td>
<td>3.5</td>
</tr>
<tr>
<td>BES</td>
<td>15</td>
<td>48,931</td>
<td>9,813</td>
<td>20.1</td>
<td>144</td>
<td>10</td>
<td>6.9</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>48,130</td>
<td>4,232</td>
<td>8.8</td>
<td>195</td>
<td>14</td>
<td>7.2</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>106,027</td>
<td>27,778</td>
<td>26.2</td>
<td>330</td>
<td>16</td>
<td>4.8</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>160,575</td>
<td>54,973</td>
<td>34.2</td>
<td>155</td>
<td>8</td>
<td>5.2</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>164,155</td>
<td>19,453</td>
<td>11.9</td>
<td>642</td>
<td>44</td>
<td>6.9</td>
</tr>
<tr>
<td>Sum</td>
<td></td>
<td>102,894</td>
<td>2,768</td>
<td>(mean = 2.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---
more breakpoints for the PFP assembly than for the Celera assembly. Figure 7 shows the breakpoint map (blue tick marks) for both assemblies of each chromosome in a side-by-side fashion. The order and orientation of Celera’s assembly shows substantially fewer breakpoints except on the two finished chromosomes. Figure 7 also depicts large gaps (>10 kbp) in both assemblies as red tick marks. In the CSA assembly, the size of all gaps have been estimated on the basis of the mate-pair data. Breakpoints can be caused by structural polymorphisms, because the two assemblies were derived from different human genomes. They also reflect the unfinished nature of both genome assemblies.

3 Gene Prediction and Annotation

Summary. To enumerate the gene inventory, we developed an integrated, evidence-based approach named Otto. The evidence used to increase the likelihood of identifying genes includes regions conserved between the mouse and human genomes, similarity to ESTs or other mRNA-derived data, or similarity to other proteins. A comparison of Otto (combined Otto-RefSeq and Otto homology) with Genscan, a standard gene-prediction algorithm, showed greater sensitivity (0.78 versus 0.50) and specificity (0.93 versus 0.63) of Otto in the ability to define gene structure. Otto-predicted genes were complemented with a set of genes from three gene-prediction programs that exhibited weaker, but still significant, evidence that they may be expressed. Conservative criteria, requiring at least two lines of evidence, were used to define a set of 26,383 genes with good confidence that were used for more detailed analysis presented in the subsequent sections.

Extensive manual curation to establish precise characterization of gene structure will be necessary to improve the results from this initial computational approach.

3.1 Automated gene annotation

A gene is a locus of cotranscribed exons. A single gene may give rise to multiple transcripts, and thus multiple distinct proteins with multiple functions, by means of alternative splicing and alternative transcription initiation and termination sites. Our cells are able to discern within the billions of base pairs of the genomic DNA the signals for initiating transcription and for splicing together exons separated by a few or hundreds of thousands of base pairs. The first step in characterizing the genome is to define the structure of each gene and each transcription unit.

The number of protein-coding genes in mammals has been controversial from the outset. Initial estimates based on reassociation data placed it between 30,000 to 40,000, whereas later estimates from the brain were >100,000 (56). More recent data from both the corporate and public sectors, based on extrapolations from EST, CpG island, and transcript density–based extrapolations, have not reduced this variance. The highest recent number of 142,634 genes emanates from a report from Incyte Pharmaceuticals, and is based on a combination of EST data and the association of ESTs with CpG islands (57). In stark contrast are three quite different, and much lower estimates: one of ~35,000 genes derived with genome-wide EST data and sampling procedures in conjunction with chromosome 22 data (58); another of 28,000 to 34,000 genes derived with a comparative methodologies involving sequence conservation between humans and the puffer fish Tetraodon nigroviridis (59); and a figure of 35,000 genes, which was derived simply by extrapolating from the density of 770 known and predicted genes in the 67 Mbp of chromosomes 21 and 22, to the approximately 10 kbp euchromatic genome.

The problem of computational identification of transcriptional units in genomic DNA sequence can be divided into two phases. The first is to partition the sequence into segments that are likely to correspond to individual genes. This is not trivial and is a weakness of most de novo gene-finding algorithms. It is also critical to determining the number of genes in the human gene inventory. The second challenge is to construct a gene model that reflects the probable structure of the transcript(s) encoded in the region. This can be done with reasonable accuracy when a full-length cDNA has been sequenced or a highly homologous protein sequence is known. De novo gene prediction, although less accurate, is the only way to find genes that are not represented by homologous proteins or ESTs. The following section describes the methods we have developed to address these problems for the prediction of protein-coding genes.

We have developed a rule-based expert system, called Otto, to identify and characterize genes in the human genome (60). Otto attempts to simulate in software the process that a human annotator uses to identify a gene and refine its structure. In the process of annotating a region of the genome, a human curator examines the evidence provided by the computational pipeline (described below) and examines how various types of evidence relate to one another. A curator puts different levels of confidence in different types of evidence and looks for certain patterns of evidence to support gene annotation. For example, a curator may examine homology to a number of ESTs and evaluate whether or not they can be connected into a longer, virtual mRNA. The curator would also evaluate the strength of the similarity and the contiguity of the match, in essence asking whether any ESTs cross splice-junctions and whether the edges of putative exons have consensus splice sites. This kind of manual annotation process was used to annotate the Drosophila genome.

The Otto system can promote observed evidence to a gene annotation in one of two ways. First, if the evidence includes a high-quality match to the sequence of a known gene [here defined as a human gene represented in a curated subset of the RefSeq database (61)], then Otto can promote this to a gene annotation. In the second method, Otto evaluates a broad spectrum of evidence and determines if this evidence is adequate to support promotion to a gene annotation. These processes are described below.

Initially, gene boundaries are predicted on the basis of examination of sets of overlapping protein and EST matches generated by a computational pipeline (62). This pipeline searches the scaffold sequences against protein, EST, and genome-sequence databases to define regions of sequence similarity and runs three de novo gene-prediction programs. To identify likely gene boundaries, regions of the genome were partitioned by Otto on the basis of sequence matches identified by BLAST. Each of the database sequences matched in the region under analysis was compared by an algorithm that takes into account both coordinates of the matching sequence, as well as the sequence type (e.g., protein, EST, and so forth). The results were used to group the matches into bins of related sequences that may define a gene and identify

Table 6. Genome-wide mate pair analysis of compartmentalized shotgun (CSA) and PFP assemblies.†

<table>
<thead>
<tr>
<th>Genome library</th>
<th>CSA % valid</th>
<th>CSA % mis-oriented</th>
<th>CSA % mis-separated†</th>
<th>PFP % valid</th>
<th>PFP % mis-oriented</th>
<th>PFP % mis-separated†</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 kbp</td>
<td>98.5</td>
<td>0.6</td>
<td>1.0</td>
<td>95.7</td>
<td>2.0</td>
<td>2.3</td>
</tr>
<tr>
<td>10 kbp</td>
<td>96.7</td>
<td>1.0</td>
<td>2.3</td>
<td>81.9</td>
<td>9.6</td>
<td>8.6</td>
</tr>
<tr>
<td>50 kbp</td>
<td>93.9</td>
<td>4.5</td>
<td>1.5</td>
<td>64.2</td>
<td>22.3</td>
<td>13.5</td>
</tr>
<tr>
<td>BES</td>
<td>94.1</td>
<td>2.1</td>
<td>3.8</td>
<td>62.0</td>
<td>19.3</td>
<td>18.8</td>
</tr>
<tr>
<td>Mean</td>
<td>97.4</td>
<td>1.0</td>
<td>1.6</td>
<td>87.3</td>
<td>6.8</td>
<td>5.9</td>
</tr>
</tbody>
</table>

†Mates are misseparated if their distance is >3 SD from the mean library size.
gene boundaries. During this process, multiple hits to the same region were collapsed to a coherent set of data by tracking the coverage of a region. For example, if a group of bases was represented by multiple overlapping ESTs, the union of these regions matched by the set of ESTs on the scaffold was marked as being supported by EST evidence. This resulted in a series of “gene bins,” each of which was believed to contain a single gene. One weakness of this initial implementation of the algorithm was in predicting gene boundaries in regions of tandemly duplicated genes. Gene clusters frequently resulted in homologous neighboring genes being joined together, resulting in an annotation that artificially concatenated these gene models.

Next, known genes (those with exact matches of a full-length cDNA sequence to the genome) were identified, and the region corresponding to the cDNA was annotated as a predicted transcript. A subset of the curated human gene set RefSeq from the National Center for Biotechnology Information (NCBI) was included as a data set searched in the computational pipeline. If a RefSeq transcript matched the genome assembly for at least 50% of its length at >92% identity, then the SIM4 alignment of the RefSeq transcript to the region of the genome under analysis was promoted to the status of an Otto annotation. Because the genome sequence has gaps and sequence errors such as frameshifts, it was not always possible to predict a transcript that agrees precisely with the experimentally determined cDNA sequence. A total of 6538 genes in our inventory were identified and transcripts predicted in this way.

Regions that have a substantial amount of sequence similarity, but do not match known genes, were analyzed by that part of the Otto system that uses the sequence similarity information to predict a transcript. Here, Otto

---

**Fig. 6.** Comparison of the CSA and the PFP assembly. (A) All of chromosome 21, (B) all of chromosome 8, and (C) a 1-Mb region of chromosome 8 representing a single Celera scaffold. To generate the figure, Celera fragment sequences were mapped onto each assembly. The PFP assembly is indicated in the upper third of each panel; the Celera assembly is indicated in the lower third. In the center of the panel, green lines show Celera sequences that are in the same order and orientation in both assemblies and form the longest consistently ordered run of sequences. Yellow lines indicate sequence blocks that are in the same orientation, but out of order. Red lines indicate sequence blocks that are not in the same orientation. For clarity, in the latter two cases, lines are only drawn between segments of matching sequence that are at least 50 kbp long. The top and bottom thirds of each panel show the extent of Celera mate-pair violations (red, misoriented; yellow, incorrect distance between the mates) for each assembly grouped by library size. (Mate pairs that are within the correct distance, as expected from the mean library insert size, are omitted from the figure for clarity.) Predicted breakpoints, corresponding to stacks of violated mate pairs of the same type, are shown as blue ticks on each assembly axis. Runs of more than 10,000 Ns are shown as cyan bars. Plots of all 24 chromosomes can be seen in Web fig. 3 on *Science* Online at www.sciencemag.org/cgi/content/full/291/5507/1304/DC1.
evaluates evidence generated by the computational pipeline, corresponding to conservation between mouse and human genomic DNA, similarity to human transcripts (ESTs and cDNAs), similarity to rodent transcripts (ESTs and cDNAs), and similarity of the translation of human genomic DNA to known proteins to predict potential genes in the human genome. The sequence from the region of genomic DNA contained in a gene bin was extracted, and the subsequences supported by any homology evidence were marked (plus 100

Fig. 7. Schematic view of the distribution of breakpoints and large gaps on all chromosomes. For each chromosome, the upper pair of lines represent the PFP assembly, and the lower pair of lines represent Celera's assembly. Blue tick marks represent breakpoints, whereas red tick marks represent a gap of larger than 10,000 bp. The number of breakpoints per chromosome is indicated in black, and the chromosome numbers in red.
bases flanking these regions). The other bases in the region, those not covered by any homology evidence, were replaced by N’s. This sequence segment, with high confidence regions represented by the consensus genomic sequence and the remainder represented by N’s, was then evaluated by Genscan to see if a consistent gene model could be generated. This procedure simplified the gene-prediction task by first establishing the boundary for the gene (not a strength of most gene-finding algorithms), and by eliminating regions with no supporting evidence. If Genscan returned a plausible gene model, it was further evaluated before being promoted to an “Otto” annotation. The final Genscan predictions were often quite different from the prediction that Genscan returned on the same region of native genomic sequence. A weakness of using Genscan to refine the gene model is the loss of valid, small exons from the final annotation.

The next step in defining gene structures based on sequence similarity was to compare each predicted transcript with the homology-based evidence that was used in previous steps to evaluate the depth of evidence for each exon in the prediction. Internal exons were considered to be supported if they were covered by homology evidence to within ±10 bases of their edges. For first and last exons, the internal edge was required to be within 10 bases, but the external edge was allowed greater latitude to allow for 5’ and 3’ untranslated regions (UTRs). To be retained, a prediction for a multi-exon gene must have evidence such that the total number of “hits,” as defined above, divided by the number of exons in the prediction must be >0.66 or must correspond to a RefSeq sequence. A single-exon gene must be covered by at least three supporting hits (±10 bases on each side), and these must cover the complete predicted open reading frame. For a single-exon gene, we also required that the Genscan prediction include both a start and a stop codon. Gene models that did not meet these criteria were disregarded, and those that passed were promoted to Otto predictions. Homology-based Otto predictions do not contain 3’ and 5’ untranslatable sequence. Although three de novo gene-finding programs [GRAIL, Genscan, and FgenesH (63)] were run as part of the computational analysis, the results of these programs were not directly used in making the Otto predictions. Otto predicted 11,226 additional genes by means of sequence similarity.

3.2 Otto validation

To validate the Otto homology-based process and the method that Otto uses to define the structures of known genes, we compared transcripts predicted by Otto with their corresponding (and presumably correct) transcript from a set of 4512 RefSeq transcripts for which there was a unique SIM4 alignment (Table 7). In order to evaluate the relative performance of Otto and Genscan, we made three comparisons. The first involved a determination of the accuracy of gene models predicted by Otto with only homology data other than the corresponding RefSeq sequence (Otto homology in Table 7). We measured the sensitivity (correctly predicted bases divided by the total length of the cDNA) and specificity (correctly predicted bases divided by the sum of the correctly and incorrectly predicted bases). Second, we examined the sensitivity and specificity of the Otto predictions that were made solely with the RefSeq sequence, which is the process that Otto uses to annotate known genes (Otto-RefSeq). And third, we determined the accuracy of the Genscan predictions corresponding to these RefSeq sequences. As expected, the alignment method (Otto-RefSeq) was the most accurate, and Otto-homology performed better than Genscan by both criteria. Thus, 6.1% of true RefSeq nucleotides were not represented in the Otto-RefSeq annotations and 2.7% of the nucleotides in the Otto-RefSeq transcripts were not contained in the original RefSeq transcripts. The discrepancies could come from legitimate differences between the Celera assembly and the RefSeq transcript due to polymorphisms, incomplete or incorrect data in the Celera assembly, errors introduced by Sim4 during the alignment process, or the presence of alternatively spliced forms in the data set used for the comparisons.

Because Otto uses an evidence-based approach to reconstruct genes, the absence of experimental evidence for intervening exons may inadvertently result in a set of exons that cannot be spliced together to give rise to a transcript. In such cases, Otto may “split genes” when in fact all the evidence should be combined into a single transcript. We also examined the tendency of these methods to incorrectly split gene predictions. These trends are shown in Fig. 8. Both RefSeq and homology-based predictions by Otto split known genes into fewer segments than Genscan alone.

Table 7. Sensitivity and specificity of Otto and Genscan. Sensitivity and specificity were calculated by first aligning the prediction to the published RefSeq transcript, tallying the number (N) of uniquely aligned RefSeq bases. Sensitivity is the ratio of N to the length of the published RefSeq transcript. Specificity is the ratio of N to the length of the prediction. All differences are significant (Tukey HSD; P < 0.001).

<table>
<thead>
<tr>
<th>Method</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Otto (RefSeq only)*</td>
<td>0.939</td>
<td>0.973</td>
</tr>
<tr>
<td>Otto (homology)</td>
<td>0.604</td>
<td>0.884</td>
</tr>
<tr>
<td>Genscan</td>
<td>0.501</td>
<td>0.633</td>
</tr>
</tbody>
</table>

*Refers to those annotations produced by Otto using only the Sim4-polished RefSeq alignment rather than an evidence-based Genscan prediction. 1 Refers to those annotations produced by supplying all available evidence to Genscan.

3.3 Gene number

Recognizing that the Otto system is quite conservative, we used a different gene-prediction strategy in regions where the homology evidence was less strong. Here the results of de novo gene predictions were used. For these genes, we insisted that a predicted transcript have at least two of the following types of evidence to be included in the gene set for further analysis: protein, human EST, rodent EST, or mouse genome fragment matches. This final class of predicted genes is a subset of the predictions made by the three gene-finding programs that were used in the computational pipeline. For these, there was not sufficient sequence similarity information for Otto to attempt to predict a gene structure. The three de novo gene-finding programs resulted in about 155,695 predictions, of which ~76,410 were nonredundant (nonoverlapping with one another). Of these, 57,935 did not overlap known genes or predictions made by Otto. Only 21,350 of the gene predictions that did not overlap Otto predictions were partially supported by at least one type of sequence similarity evidence, and 8619 were partially supported by two types of evidence (Table 8).

The sum of this number (21,350) and the number of Otto annotations (17,764), 39,114, is near the upper limit for the human gene complement. As seen in Table 8, if the requirement for other supporting evidence is made more stringent, this number drops rapidly so that demanding two types of evidence reduces the total gene number to 26,383 and demanding three types reduces it to ~23,000. Requiring that a prediction be supported by all four categories of evidence is too stringent because it would eliminate genes that encode novel proteins (members of currently undescribed protein families). No correction for pseudogenes has been made at this point in the analysis.

In a further attempt to identify genes that were not found by the autoannotation process or any of the de novo gene finders, we examined regions outside of gene predictions that were similar to the EST sequence, and where the EST matched the genomic sequence across a splice junction. After correcting for potential 3’ UTRs of predicted genes, about 2500 such regions remained. Addition of a requirement for at least one of the following evidence types—homology to mouse genomic sequence fragments, rodent ESTs, or cDNAs—or similarity to a known protein reduced this number to 1010. Adding this to the numbers from the previous paragraph would give us estimates of about 40,000, 27,000, and 24,000 potential genes in the human genome, depending on the stringency of evidence considered. Table 8 illustrates the number of genes and presents the degree of
confidence based on the supporting evidence. Transcripts encoded by a set of 26,383 genes were assembled for further analysis. This set includes the 6538 genes predicted by Otto on the basis of matches to known genes, 11,226 transcripts predicted by Otto based on homology evidence, and 8619 from the subset of transcripts from de novo gene-prediction programs that have two types of supporting evidence. The 26,383 genes are illustrated along chromosome diagrams in Fig. 1. These are a very preliminary set of annotations and are subject to all the limitations of an automated process. Considerable refinement is still necessary to improve the accuracy of these transcript predictions. All the predictions and descriptions of genes and the associated evidence that we present are the product of completely computational processes, not expert curation. We have attempted to enumerate the genes in the human genome in such a way that we have different levels of confidence based on the amount of supporting evidence: known genes, genes with good protein or EST homology evidence, and de novo gene predictions confirmed by modest homology evidence.

3.4 Features of human gene transcripts

We estimate the average span for a “typical” gene in the human DNA sequence to be about 27,894 bases. This is based on the average span covered by RefSeq transcripts, used because it represents our highest confidence set.

The set of transcripts promoted to gene annotations varies in a number of ways. As can be seen from Table 8 and Fig. 9, transcripts predicted by Otto tend to be longer, having on average about 7.8 exons, whereas those promoted from gene-prediction programs average about 3.7 exons. The largest number of exons that we have identified in a transcript is 234 in the titin mRNA. Table 8 compares the amounts of evidence that support the Otto and other predicted transcripts. For example, one can see that a typical Otto transcript has 6.99 of its 7.81 exons supported by protein homology evidence. As would be expected, the Otto transcripts generally have more support than do transcripts predicted by the de novo methods.

4 Genome Structure

Summary. This section describes several of the noncoding attributes of the assembled genome sequence and their correlations with the predicted gene set. These include an analysis of G+C content and gene density in the context of cytogenetic maps of the genome, an enumerative analysis of CpG islands, and a brief description of the genome-wide repetitive elements.

---

**Table 8. Numbers of exons and transcripts supported by various types of evidence for Otto and de novo gene prediction methods. Highlighted cells indicate the gene sets analyzed in this paper (boldface, set of genes selected for protein analysis; italic, total set of accepted de novo predictions).**

<table>
<thead>
<tr>
<th>Type of evidence</th>
<th>Total</th>
<th>Mouse</th>
<th>Rodent</th>
<th>Protein</th>
<th>Human</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Otto</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of transcripts</td>
<td>17,969</td>
<td>17,065</td>
<td>14,881</td>
<td>15,477</td>
<td>16,374</td>
</tr>
<tr>
<td>Number of exons</td>
<td>141,218</td>
<td>111,174</td>
<td>89,569</td>
<td>108,431</td>
<td>118,869</td>
</tr>
<tr>
<td><strong>De novo</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of transcripts</td>
<td>58,032</td>
<td>14,463</td>
<td>5,094</td>
<td>8,043</td>
<td>9,220</td>
</tr>
<tr>
<td>Number of exons</td>
<td>319,935</td>
<td>48,594</td>
<td>19,344</td>
<td>26,264</td>
<td>40,104</td>
</tr>
<tr>
<td><strong>No. of exons per transcript</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Otto</td>
<td>7.84</td>
<td>5.77</td>
<td>6.01</td>
<td>6.99</td>
<td>7.24</td>
</tr>
<tr>
<td>De novo</td>
<td>5.53</td>
<td>3.71</td>
<td>3.80</td>
<td>3.27</td>
<td>3.42</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of lines of evidence</th>
<th>≥1</th>
<th>≥2</th>
<th>≥3</th>
<th>≥4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Otto (homology)</strong></td>
<td>17,968</td>
<td>17,501</td>
<td>15,877</td>
<td>12,451</td>
</tr>
<tr>
<td><strong>Otto (RefSeq only)</strong></td>
<td>140,710</td>
<td>127,955</td>
<td>99,574</td>
<td>59,804</td>
</tr>
<tr>
<td><strong>Genscan</strong></td>
<td>21,350</td>
<td>8,619</td>
<td>4,947</td>
<td>1,904</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>79,148</td>
<td>31,130</td>
<td>17,508</td>
<td>6,520</td>
</tr>
</tbody>
</table>

---

4.1 Cytogenetic maps

Perhaps the most obvious, and certainly the most visible, element of the structure of the genome is the banding pattern produced by Giemsa stain. Chromosomal banding studies have revealed that about 17% to 20% of the human chromosome complement consists of C-bands, or constitutive heterochromatin (64). Much of this heterochromatin is highly polymorphic and consists of different families of alpha satellite DNAs with various higher order repeat structures (65). Many chromosomes have complex inter- and intrachromosomal duplications present in pericentromeric regions (66). About 5% of the sequence reads were identified as alpha satellite sequences; these were not included in the assembly.
Examination of pericentromeric regions is ongoing.

The remaining ~80% of the genome, the euchromatic component, is divisible into G-, R-, and T-bands (67). These cytogenetic bands have been presumed to differ in their nucleotide composition and gene density, although we have been unable to determine precise band boundaries at the molecular level. T-bands are the most G+C-rich, and G-bands are G+C-poor (68). Bernardi has also offered a description of the euchromatin at the molecular level as long stretches of DNA of differing base composition, termed isochromosomes (denoted L, H1, H2, and H3), which are >300 kbp in length (69). Bernardi defined the L (light) isochromosomes as G+C-poor (<43%), whereas the H (heavy) isochromosomes fall into three G+C-rich classes representing 24, 8, and 5% of the genome. Gene concentration has been claimed to be very low in the L isochromosomes and 20-fold more enriched in the H2 and H3 isochromosomes (70). By examining contiguous 50-kbp windows of G+C content across the assembly, we found that regions of G+C content >48% (H3 isochromosomes) averaged 273.9 kbp in length, those with G+C content between 43 and 48% (H1/H2 isochromosomes) averaged 202.8 kbp in length, and the average span of regions with <43% (L isochromosomes) was 1078.6 kbp. The correlation between G+C content and gene density was also examined in 50-kbp windows along the assembled sequence (Table 9 and Figs. 10 and 11). We found that the density of genes was greater in regions of high G+C than in regions of low G+C content, as expected. However, the correlation between G+C content and gene density was not as skewed as previously predicted (69). A higher proportion of genes were located in the G+C-poor regions than had been expected.

Chromosomes 17, 19, and 22, which have a disproportionate number of H3-containing bands, had the highest gene density (Table 10). Conversely, of the chromosomes that we found to have the lowest gene density, X, 4, 18, 13, and Y, also have the fewest H3 bands. Chromosome 15, which also has few H3 bands, did not have a particularly low gene density in our analysis. In addition, chromosome 8, which we found to have a low gene density, does not appear to be unusual in its H3 banding.

How valid is Ohno’s postulate (71) that mammalian genomes consist of oases of genes in otherwise essentially empty deserts? It appears that the human genome does indeed contain deserts, or large, gene-poor regions. If we define a desert as a region >500 kbp without a gene, then we see that 605 Mbp, or about 20% of the genome, is in deserts. These are not uniformly distributed over the various chromosomes. Gene-rich chromosomes 17, 19, and 22 have only about 12% of their collective 171 Mbp in deserts, whereas gene-poor chromosomes 4, 13, 18, and X have 27.5% of their 492 Mbp in deserts (Table 11). The apparent lack of predicted genes in these regions does not necessarily imply that they are devoid of biological function.

### 4.2 Linkage map

Linkage maps provide the basis for genetic analysis and are widely used in the study of the inheritance of traits and in the positional cloning of genes. The distance metric, centimorgans (cM), is based on the recombination rate between homologous chromosomes during meiosis. In general, the rate of recombination in females is greater than that in males, and this degree of map expansion is not uniform across the genome (72). One of the opportunities enabled by a nearly complete genome sequence is to produce the ultimate physical map, and to fully analyze its correspondence with two other maps that have been widely used in genome and genetic analysis: the linkage map and the cytogenetic map. This would close the loop between the mapping and sequencing phases of the genome project.

We mapped the location of the markers that constitute the Genethon linkage map to the genome. The rate of recombination, expressed as cM per Mbp, was calculated for 3-Mbp windows as shown in Table 12. Higher rates of recombination in the telomeric region of the chromosomes have been previously documented (73). From this mapping result, there is a difference of 4.99 between lowest rates and highest rates and the largest difference of 4.4 between males and females (4.99 to 0.47 on chromosome 16). This indicates that the variability in recombination rates among regions of the genome exceeds the differences in recombination rates between males and females. The human genome has recombination hotspots, where recombination rates vary fivefold or more over a space of 1 kbp, so the picture one gets of the magnitude of variability in recombination rate will depend on the size of the window.

---

**Table 9. Characteristics of G+C in isochores.**

<table>
<thead>
<tr>
<th>Isochore</th>
<th>G+C (%)</th>
<th>Fraction of genome</th>
<th>Fraction of genes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Predicted*</td>
<td>Observed</td>
<td>Predicted*</td>
</tr>
<tr>
<td>H3</td>
<td>&gt;48</td>
<td>5</td>
<td>9.5</td>
</tr>
<tr>
<td>H1/H2</td>
<td>43-48</td>
<td>25</td>
<td>21.2</td>
</tr>
<tr>
<td>L</td>
<td>&lt;43</td>
<td>67</td>
<td>69.2</td>
</tr>
</tbody>
</table>

*The predictions were based on Bernardi’s definitions (70) of the isochore structure of the human genome.

---

**Fig. 9.** Comparison of the number of exons per transcript between the 17,968 Otto transcripts and 21,350 de novo transcript predictions with at least one line of evidence that do not overlap with an Otto prediction. Both sets have the highest number of transcripts in the two-exon category, but the de novo gene predictions are skewed much more toward smaller transcripts. In the Otto set, 19.7% of the transcripts have one or two exons, and 5.7% have more than 20. In the de novo set, 49.3% of the transcripts have one or two exons, and 0.2% have more than 20.
examined. Unfortunately, too few meiotic crossovers have occurred in Centre d’Etude du Polymorphism Humain (CEPH) and other reference families to provide a resolution any finer than about 3 Mbp. The next challenge will be to determine a sequence basis of recombination at the chromosomal level. An accurate predictor for the rate for variation in recombination rates between any pair of markers would be extremely useful in designing markers to narrow a region of linkage, such as in positional cloning projects.

4.3 Correlation between CpG islands and genes

CpG islands are stretches of unmethylated DNA with a higher frequency of CpG dinucleotides when compared with the entire genome (74). CpG islands are believed to preferentially occur at the transcriptional start of genes, and it has been observed that most housekeeping genes have CpG islands at the 5’ end of the transcript (75, 76). In addition, experimental evidence indicates that CpG island methylation is correlated with gene inactivation (77) and has been shown to be important during gene imprinting (78) and tissue-specific gene expression (79).

Experimental methods have been used that resulted in an estimate of 30,000 to 45,000 CpG islands in the human genome (74, 80) and an estimate of 499 CpG islands on human chromosome 22 (81). Larsen et al. (76) and Gardiner-Garden and Frommer (75) used a computational method to identify CpG islands and defined them as regions of DNA of >200 bp that have a G+C content of >50% and a ratio of observed versus expected frequency of CG dinucleotide \( \approx 0.6 \).

It is difficult to make a direct comparison of experimental definitions of CpG islands with computational definitions because computational methods do not consider the methylation state of cytosine and experimental methods do not directly select regions of high G+C content. However, we can determine the correlation of CpG island with gene starts, given a set of annotated genomic transcripts and the whole genome sequence. We have analyzed the publicly available annotation of chromosome 22, as well as using the entire human genome in our assembly and the computationally annotated genes. A variation of the CpG island computation was compared with Larsen et al. (76). The main differences are that we use a sliding window of 200 bp, consecutive windows are merged only if they overlap, and we recompute the CpG value upon merging, thus rejecting any potential island if it scores less than the threshold.

To compute various CpG statistics, we used two different thresholds of CG dinucleotide likelihood ratio. Besides using the original threshold of 0.6 (method 1), we used a higher threshold of CG dinucleotide likelihood ratio of 0.8 (method 2), which results in the number of CpG islands on chromosome 22 close to the number of annotated genes on this chromosome. The main results are summarized in Table 13. CpG islands computed with method 1 predicted only 2.6% of the CSA sequence as CpG, but 40% of the gene starts (start codons) are contained inside a CpG island. This is comparable to ratios reported by others (82). The last two rows of the table show the observed and expected average distance, respectively, of the closest CpG island from the first exon. The observed average closest CpG islands are smaller than the corresponding expected distances, confirming an association between CpG island and the first exon.

We also looked at the distribution of CpG island nucleotides among various sequence classes such as intergenic regions, introns, exons, and first exons. We computed the likelihood score for each sequence class as the ratio of the observed fraction of CpG island nucleotides in that sequence class and the expected fraction of CpG island nucleotides in that sequence class. The result of applying method 1 on CSA were scores of 0.89 for intergenic region, 1.2 for intron, 5.86 for exon, and 13.2 for first exon. The same trend was also found for chromosome 22 and after the application of a higher threshold (method 2) on both data sets. In sum, genome-wide analysis has extended earlier analysis and suggests a strong correlation between CpG islands and first coding exons.

4.4 Genome-wide repetitive elements

The proportion of the genome covered by various classes of repetitive DNA is presented in Table 14. We observed about 35% of the genome in these repeat classes, very similar to values reported previously (83). Repetitive sequence may be underrepresented in the Celera assembly as a result of incomplete repeat resolution, as discussed above. About 8% of the scaffold length is in gaps, and we expect that much of this is repetitive sequence. Chromosome 19 has the highest repeat density (57%), as well as the highest gene density (Table 10). Of interest, among the different classes of repeat elements, we observe a clear association of Alu elements and gene density, which was not observed between LINEs and gene density.

5 Genome Evolution

Summary. The dynamic nature of genome evolution can be captured at several levels. These include gene duplications mediated by RNA intermediates (retrotransposition) and segmental genomic duplications. In this section, we document the genome-wide occurrence of retrotransposition events generating functional (intronless paralogs) or inactive genes (pseudogenes). Genes involved in translational processes and nuclear regulation account for nearly 50% of all intronless paralogs and processed pseudogenes detected in our survey. We have also cataloged the extent of segmental genomic duplication and provide evidence for 1077 duplicated blocks covering 3522 distinct genes.
Fig. 11. Genome structural features.
5.1 Retrotransposition in the human genome

Retrotransposition of processed mRNA transcripts into the genome results in functional genes, called intronless paralogs, or inactivated genes (pseudogenes). A paralog refers to a gene that appears in more than one copy in a given organism as a result of a duplication event. The existence of both intron-containing and intronless forms of genes encoding functionally similar or identical proteins has been previously described (84, 85). Cataloging these evolutionary events on the genomic landscape is of value in understanding the functional consequences of such gene-duplication events in cellular biology. Identification of conserved intronless paralogs in the mouse or other mammalian genomes should provide the basis for capturing the evolutionary chronology of these transposition events and provide insights into gene loss and accretion in the mammalian radiation.

A set of proteins corresponding to all 901
### Table 10. Features of the chromosomes. De novo/any refers to the union of de novo predictions that do not overlap Otto predictions and have at least one other type of supporting evidence; de novo/2x refers to the union of de novo predictions that do not overlap Otto predictions and have at least two types of evidence. Deserts are regions of sequence with no annotated genes.

<table>
<thead>
<tr>
<th>Chr.</th>
<th>Size (Mbp)</th>
<th>No. of scaffolds</th>
<th>Largest scaffold (Mbp)</th>
<th>No. of scaffolds &gt;500 kbp</th>
<th>Sequence coverage (CS assembly)</th>
<th>% of total sequence in scaffolds &gt;500 kbp</th>
<th>% repeat</th>
<th>% GC</th>
<th>No. of CpG islands</th>
<th>Gene prediction*</th>
<th>Gene density (genes/Mbp)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Base composition</td>
<td>Gene prediction*</td>
<td>Gene density (genes/Mbp)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Otto</td>
<td>De novo/any</td>
<td>De novo/2x</td>
<td>Total (Otto + de novo/any)</td>
<td>Total (Otto + de novo/any)</td>
<td>Sequence in deserts &gt;500 Mbp</td>
<td>Sequence in deserts &gt;1 Mbp</td>
</tr>
<tr>
<td>1</td>
<td>220</td>
<td>2,549</td>
<td>11</td>
<td>82</td>
<td>192</td>
<td>88</td>
<td>37</td>
<td>42</td>
<td>2,335</td>
<td>1,743</td>
<td>1,710</td>
</tr>
<tr>
<td>2</td>
<td>240</td>
<td>3,263</td>
<td>13</td>
<td>78</td>
<td>217</td>
<td>91</td>
<td>36</td>
<td>40</td>
<td>1,703</td>
<td>1,183</td>
<td>1,771</td>
</tr>
<tr>
<td>3</td>
<td>200</td>
<td>3,532</td>
<td>7</td>
<td>78</td>
<td>173</td>
<td>87</td>
<td>37</td>
<td>40</td>
<td>1,271</td>
<td>1,013</td>
<td>1,414</td>
</tr>
<tr>
<td>4</td>
<td>186</td>
<td>2,180</td>
<td>10</td>
<td>70</td>
<td>169</td>
<td>91</td>
<td>37</td>
<td>38</td>
<td>1,081</td>
<td>696</td>
<td>1,165</td>
</tr>
<tr>
<td>5</td>
<td>182</td>
<td>2,331</td>
<td>11</td>
<td>63</td>
<td>163</td>
<td>89</td>
<td>37</td>
<td>40</td>
<td>1,302</td>
<td>892</td>
<td>1,244</td>
</tr>
<tr>
<td>6</td>
<td>172</td>
<td>1,713</td>
<td>13</td>
<td>58</td>
<td>160</td>
<td>93</td>
<td>37</td>
<td>40</td>
<td>1,384</td>
<td>943</td>
<td>1,314</td>
</tr>
<tr>
<td>7</td>
<td>146</td>
<td>1,326</td>
<td>14</td>
<td>53</td>
<td>130</td>
<td>89</td>
<td>38</td>
<td>40</td>
<td>1,406</td>
<td>759</td>
<td>1,072</td>
</tr>
<tr>
<td>8</td>
<td>146</td>
<td>1,772</td>
<td>11</td>
<td>54</td>
<td>135</td>
<td>92</td>
<td>36</td>
<td>40</td>
<td>948</td>
<td>583</td>
<td>977</td>
</tr>
<tr>
<td>9</td>
<td>113</td>
<td>1,616</td>
<td>8</td>
<td>40</td>
<td>101</td>
<td>89</td>
<td>38</td>
<td>41</td>
<td>1,315</td>
<td>689</td>
<td>848</td>
</tr>
<tr>
<td>10</td>
<td>130</td>
<td>2,005</td>
<td>9</td>
<td>55</td>
<td>116</td>
<td>89</td>
<td>36</td>
<td>42</td>
<td>1,087</td>
<td>685</td>
<td>968</td>
</tr>
<tr>
<td>11</td>
<td>132</td>
<td>2,814</td>
<td>9</td>
<td>44</td>
<td>116</td>
<td>88</td>
<td>39</td>
<td>42</td>
<td>1,461</td>
<td>1,051</td>
<td>1,134</td>
</tr>
<tr>
<td>12</td>
<td>134</td>
<td>2,614</td>
<td>8</td>
<td>51</td>
<td>117</td>
<td>87</td>
<td>38</td>
<td>41</td>
<td>1,131</td>
<td>925</td>
<td>936</td>
</tr>
<tr>
<td>13</td>
<td>99</td>
<td>1,038</td>
<td>13</td>
<td>34</td>
<td>91</td>
<td>91</td>
<td>36</td>
<td>38</td>
<td>644</td>
<td>341</td>
<td>691</td>
</tr>
<tr>
<td>14</td>
<td>87</td>
<td>576</td>
<td>11</td>
<td>16</td>
<td>83</td>
<td>95</td>
<td>40</td>
<td>41</td>
<td>913</td>
<td>583</td>
<td>700</td>
</tr>
<tr>
<td>15</td>
<td>80</td>
<td>1,747</td>
<td>8</td>
<td>31</td>
<td>70</td>
<td>87</td>
<td>37</td>
<td>42</td>
<td>722</td>
<td>558</td>
<td>640</td>
</tr>
<tr>
<td>16</td>
<td>75</td>
<td>1,520</td>
<td>8</td>
<td>27</td>
<td>62</td>
<td>82</td>
<td>40</td>
<td>44</td>
<td>1,533</td>
<td>748</td>
<td>673</td>
</tr>
<tr>
<td>17</td>
<td>78</td>
<td>1,683</td>
<td>6</td>
<td>40</td>
<td>61</td>
<td>78</td>
<td>39</td>
<td>45</td>
<td>1,489</td>
<td>897</td>
<td>648</td>
</tr>
<tr>
<td>18</td>
<td>79</td>
<td>1,333</td>
<td>13</td>
<td>18</td>
<td>72</td>
<td>92</td>
<td>36</td>
<td>40</td>
<td>510</td>
<td>283</td>
<td>543</td>
</tr>
<tr>
<td>19</td>
<td>58</td>
<td>2,282</td>
<td>3</td>
<td>31</td>
<td>38</td>
<td>67</td>
<td>57</td>
<td>49</td>
<td>2,804</td>
<td>1,141</td>
<td>534</td>
</tr>
<tr>
<td>20</td>
<td>61</td>
<td>580</td>
<td>14</td>
<td>17</td>
<td>58</td>
<td>94</td>
<td>41</td>
<td>44</td>
<td>997</td>
<td>517</td>
<td>469</td>
</tr>
<tr>
<td>21</td>
<td>33</td>
<td>358</td>
<td>10</td>
<td>6</td>
<td>32</td>
<td>96</td>
<td>38</td>
<td>41</td>
<td>519</td>
<td>184</td>
<td>265</td>
</tr>
<tr>
<td>22</td>
<td>36</td>
<td>333</td>
<td>11</td>
<td>12</td>
<td>32</td>
<td>88</td>
<td>44</td>
<td>48</td>
<td>1,173</td>
<td>494</td>
<td>341</td>
</tr>
<tr>
<td>X</td>
<td>128</td>
<td>1,346</td>
<td>4</td>
<td>91</td>
<td>93</td>
<td>73</td>
<td>46</td>
<td>39</td>
<td>726</td>
<td>605</td>
<td>860</td>
</tr>
<tr>
<td>Y</td>
<td>19</td>
<td>638</td>
<td>2</td>
<td>12</td>
<td>10</td>
<td>65</td>
<td>50</td>
<td>39</td>
<td>65</td>
<td>55</td>
<td>155</td>
</tr>
<tr>
<td>U*</td>
<td>75</td>
<td>11,542</td>
<td>1</td>
<td>479</td>
<td>196</td>
<td>278</td>
<td>132</td>
<td>24</td>
<td>328</td>
<td>479</td>
<td>278</td>
</tr>
<tr>
<td>Total</td>
<td>2907</td>
<td>53,591</td>
<td>1059</td>
<td>2,490</td>
<td>28,519</td>
<td>17,764</td>
<td>21,350</td>
<td>8,619</td>
<td>39,114</td>
<td>26,383</td>
<td>606</td>
</tr>
<tr>
<td>Avg.</td>
<td>116</td>
<td>2,144</td>
<td>9</td>
<td>44</td>
<td>104</td>
<td>87</td>
<td>40</td>
<td>41</td>
<td>1,160</td>
<td>714</td>
<td>812</td>
</tr>
</tbody>
</table>

*Chromosomal assignment unknown.
Otto-predicted, single-exon genes were subjected to BLAST analysis against the proteins encoded by the remaining multixen predicted transcripts. Using homology criteria of 70% sequence identity over 90% of the length, we identified 298 instances of single-to multi-exon correspondence. Of these 298 sequences, 97 were represented in the GenBank data set of experimentally validated full-length genes at the stringency specified and were verified by manual inspection.

We believe that these 97 cases may represent intronless paralogs (see Web table 1 on Science Online at www.sciencemag.org/cgi/content/full/291/5507/1304/DC1) of known genes. Most of these are flanked by direct repeat sequences, although the precise nature of these repeats remains to be determined. All of the cases for which we have high confidence contain polyadenylated [poly(A)] tails characteristic of retrotransposition.

Recent publications describing the phenomenon of functional intronless paralogs speculate that retrotransposition may serve as a mechanism used to escape X-chromosomal inactivation (84, 86). We do not find a bias toward X chromosome origination of these retrotransposed genes; rather, the results show a random chromosome distribution of both the intron-containing and corresponding intronless paralogs. We also have found several cases of retrotransposition from a single source chromosome to multiple target chromosomes. Interesting examples include the retrotransposition of a five-exon—containing ribosomal protein L21 gene on chromosome 13 onto chromosomes 1, 3, 4, 7, 10, and 14, respectively. The size of the source genes can also show variability. The largest example is the 31-exon dicyglycerol kinase zeta gene on chromosome 11 that has an intronless paralog on chromosome 13. Regardless of route, retrotransposition with subsequent gene changes in coding or noncoding regions that lead to different functions or expression patterns, represents a key route to providing an enhanced functional repertoire in mammals (87).

Our preliminary set of retrotransposed intronless paralogs contains a clear overrepresentation of genes involved in translational processes (40% ribosomal proteins and 10% translation elongation factors) and nuclear regulation (HMG nonhistone proteins, 4%), as well as metabolic and regulatory enzymes. EST matches specific to a subset of intronless paralogs suggest expression of these intronless paralogs. Differences in the upstream regulatory sequences between the source genes and their intronless paralogs could account for differences in tissue-specific gene expression. Defining which, if any, of these processed genes are functionally expressed and translated will require further elucidation and experimental validation.

Table 11. Genome overview.

<table>
<thead>
<tr>
<th></th>
<th>Size of the genome (including gaps)</th>
<th>Size of the genome (excluding gaps)</th>
<th>Longest contig</th>
<th>Longest scaffold</th>
<th>Percent of A+T in the genome</th>
<th>Percent of G+C in the genome</th>
<th>Percent of undetermined bases in the genome</th>
<th>Most GC-rich 50 kb</th>
<th>Least GC-rich 50 kb</th>
<th>Percent of genome classified as repeats</th>
<th>Number of annotated genes</th>
<th>Percent of annotated genes with unknown function</th>
<th>Number of genes (hypothetical and annotated)</th>
<th>Percent of hypothetical and annotated genes with unknown function</th>
<th>Gene with the most exons</th>
<th>Average gene size</th>
<th>Most gene-rich chromosome</th>
<th>Least gene-rich chromosomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>2.91 Gbp</td>
<td>2.66 Gbp</td>
<td>1.99 Mb</td>
<td>14.4 Mb</td>
<td>54</td>
<td>38</td>
<td>9</td>
<td>Chr. 2 (66%)</td>
<td>Chr. X (25%)</td>
<td>35</td>
<td>26.383</td>
<td>42</td>
<td>39,114</td>
<td>59</td>
<td>Titin (234 exons)</td>
<td>27 kbp</td>
<td>13 genes/Mb</td>
<td>5 genes/Mb</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1327</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 12. Rate of recombination per physical distance (cM/Mb) across the genome. Genethon markers were placed on CSA-mapped assemblies, and then relative physical distances and rates were calculated in 3-Mb windows for each chromosome. NA, not applicable.

<table>
<thead>
<tr>
<th>Chrom.</th>
<th>Male</th>
<th>Sex-average</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2.60</td>
<td>1.12 0.23</td>
<td>1.42 0.52</td>
</tr>
<tr>
<td>2</td>
<td>2.23</td>
<td>0.78 0.33</td>
<td>1.14 0.42</td>
</tr>
<tr>
<td>3</td>
<td>2.55</td>
<td>0.86 0.23</td>
<td>1.07 0.42</td>
</tr>
<tr>
<td>4</td>
<td>1.66</td>
<td>0.67 0.15</td>
<td>1.06 0.60</td>
</tr>
<tr>
<td>5</td>
<td>1.00</td>
<td>1.07 0.18</td>
<td>1.08 0.42</td>
</tr>
<tr>
<td>6</td>
<td>1.97</td>
<td>0.71 0.28</td>
<td>1.17 0.37</td>
</tr>
<tr>
<td>7</td>
<td>2.34</td>
<td>1.16 0.48</td>
<td>1.76 0.17</td>
</tr>
<tr>
<td>8</td>
<td>1.83</td>
<td>0.73 0.14</td>
<td>1.05 0.46</td>
</tr>
<tr>
<td>9</td>
<td>2.01</td>
<td>0.99 0.53</td>
<td>1.32 0.77</td>
</tr>
<tr>
<td>10</td>
<td>3.73</td>
<td>1.03 0.22</td>
<td>1.29 0.66</td>
</tr>
<tr>
<td>11</td>
<td>1.43</td>
<td>0.72 0.31</td>
<td>1.09 0.47</td>
</tr>
<tr>
<td>12</td>
<td>4.12</td>
<td>0.76 0.26</td>
<td>1.35 0.16</td>
</tr>
<tr>
<td>13</td>
<td>1.60</td>
<td>0.75 0.01</td>
<td>1.87 0.17</td>
</tr>
<tr>
<td>14</td>
<td>3.15</td>
<td>0.98 0.18</td>
<td>2.65 0.62</td>
</tr>
<tr>
<td>15</td>
<td>2.28</td>
<td>0.94 0.34</td>
<td>1.22 0.42</td>
</tr>
<tr>
<td>16</td>
<td>1.83</td>
<td>1.00 0.47</td>
<td>1.55 0.63</td>
</tr>
<tr>
<td>17</td>
<td>3.87</td>
<td>0.87 0.00</td>
<td>1.35 0.54</td>
</tr>
<tr>
<td>18</td>
<td>3.12</td>
<td>1.37 0.86</td>
<td>1.66 0.43</td>
</tr>
<tr>
<td>19</td>
<td>3.02</td>
<td>0.97 0.10</td>
<td>1.41 0.49</td>
</tr>
<tr>
<td>20</td>
<td>3.64</td>
<td>0.89 0.00</td>
<td>1.50 0.83</td>
</tr>
<tr>
<td>21</td>
<td>3.23</td>
<td>1.26 0.69</td>
<td>1.62 1.08</td>
</tr>
<tr>
<td>22</td>
<td>1.25</td>
<td>1.10 0.84</td>
<td>1.41 1.08</td>
</tr>
<tr>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Genome</td>
<td>4.12</td>
<td>0.88 0.00</td>
<td>1.22 0.17</td>
</tr>
</tbody>
</table>

The Human Genome

5.2 Pseudogenes

A pseudogene is a nonfunctional copy that is very similar to a normal gene but that has been altered slightly so that it is not expressed. We developed a method for the preliminary analysis of processed pseudogenes in the human genome as a starting point in elucidating the ongoing evolutionary forces.
that account for gene inactivation. The general structural characteristics of these processed pseudogenes include the complete lack of intervening sequences found in the functional counterparts, a poly(A) tract at the 3’ end, and direct repeats flanking the pseudogene sequence. Processed pseudogenes occur as a result of retrotransposition, whereas unprocessed pseudogenes arise from segmental genome duplication.

We searched the complete set of Otto-predicted transcripts against the genomic sequence by means of BLAST. Genomic regions corresponding to all Otto-predicted transcripts were excluded from this analysis. We identified 2909 regions matching with greater than 70% identity over at least 70% of the length of the transcripts that likely represent processed pseudogenes. This number is probably an underestimate because specific methods to search for pseudogenes were not used.

We looked for correlations between structural elements and the propensity for retrotransposition in the human genome. GC content and transcript length were compared between the genes with processed pseudogenes (1177 source genes) versus the remainder of the predicted gene set. Transcripts that give rise to processed pseudogenes have shorter average transcript length (1027 bp versus 1594 bp for the Otto set) as compared with genes for which no pseudogene was detected. The overall GC content did not show any significant difference, contrary to a recent report (88). There is a clear trend in gene families that are present as processed pseudogenes. These include ribosomal proteins (67%), lamin receptors (10%), translation elongation factor alpha (5%), and HMG–non-histone proteins (2%). The increased occurrence of retrotransposition (both intronless paralogs and processed pseudogenes) among genes involved in translation and nuclear regulation may reflect an increased transcriptional activity of these genes.

5.3 Gene duplication in the human genome

Building on a previously published procedure (27), we developed a graph-theoretic algorithm, called Lek, for grouping the predicted human protein set into protein families (89).

<table>
<thead>
<tr>
<th>Chromosome 22</th>
<th>Whole genome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CpG islands detected</td>
<td>5,211</td>
</tr>
<tr>
<td>Average length of island (bp)</td>
<td>390</td>
</tr>
<tr>
<td>Percent of sequence predicted as CpG</td>
<td>5.9</td>
</tr>
<tr>
<td>Percent of first exons that overlap a CpG island</td>
<td>44</td>
</tr>
<tr>
<td>Percent of first exon with first position of exon contained inside a CpG island</td>
<td>37</td>
</tr>
<tr>
<td>Average distance between first exon and closest CpG island (bp)</td>
<td>1,013</td>
</tr>
<tr>
<td>Expected distance between first exon and closest CpG island (bp)</td>
<td>3,262</td>
</tr>
</tbody>
</table>

Table 14. Characteristics of CpG islands identified in chromosome 22 (34-Mbp sequence length) and the whole genome (2.9-Gbp sequence length) by means of two different methods. Method 1 uses a CG likelihood ratio of ≥0.6. Method 2 uses a CG likelihood ratio of ≥0.8.

The complete clusters that result from the Lek clustering provide one basis for comparing the role of whole-genome or chromosomal duplication in protein family expansion as opposed to other means, such as tandem duplication. Because each complete cluster represents a closed and certain island of homology, and because Lek is capable of simultaneously clustering protein complements of several organisms, the number of proteins contributed by each organism to a complete cluster can be predicted with confidence depending on the quality of the annotation of each genome. The variance of each organism’s contribution to each cluster can then be calculated, allowing an assessment of the relative importance of large-scale duplication versus smaller-scale, organism-specific expansion and contraction of protein families, presumably as a result of natural selection operating on individual protein families within an organism. As can be seen in Fig. 12, the large variance in the relative numbers of human as compared with D. melanogaster and Caenorhabditis elegans proteins in complete clusters may be explained by multiple events of relative expansions in gene families in each of the three animal genomes. Such expansions would give rise to the distribution that shows a peak at 1:1 in the ratio for human-worm or human-fly clusters with the slope spread covering both human and fly/worm predominance, as we observed (Fig. 12). Furthermore, there are nearly as many clusters where worm and fly proteins predominate despite the larger numbers of proteins in the human. At face value, this analysis suggests that natural selection acting on individual protein families has been a major force driving the expansion of at least some elements of the human protein set. However, in our analysis, the difference between an ancient whole-genome duplication followed by loss, versus piecemeal duplication, cannot be easily distinguished. In order to differentiate these scenarios, more extended analyses were performed.

5.4 Large-scale duplications

Using two independent methods, we searched for large-scale duplications in the human genome. First, we describe a protein family–based method that identified highly conserved blocks of duplication. We then describe our comprehensive method for identifying all interchromosomal block duplications. The latter method identified a large number of duplicated chromosomal segments covering parts of all 24 chromosomes.

The first of the methods is based on the idea of searching for blocks of highly conserved homologous proteins that occur in more than one location on the genome. For this comparison, two genes were considered equivalent if their protein products were de-
termed to be in the same family and the same complete Lek cluster (essentially paralogous genes) (89). Initially, each chromosome was represented as a string of genes ordered by the start codons for predicted genes along the chromosome. We considered the two strands as a single string, because local inversions are relatively common events relative to large-scale duplications. Each gene was indexed according to the protein family and Lek complete cluster (89). All pairs of indexed gene strings were then aligned in both the forward and reverse directions with the Smith-Waterman algorithm (90). A match between two proteins of the same Lek complete cluster was given a score of 10 and a mismatch of -4 and -1, with gap open and extend penalties of -4 and -1. With these parameters, 19 conserved interchromosomal blocks of duplication were observed, all of which were also detected and expanded by the comprehensive method described below. The detection of only a relatively small number of block duplications was a consequence of using an intrinsically conservative method grounded in the conservative constraints of the complete Lek clusters.

In the second, more comprehensive approach, we aligned all chromosomes directly with one another using an algorithm based on the MUMmer system (91). This alignment method uses a suffix tree data structure and a linear-time algorithm to align long sequences very rapidly; for example, two chromosomes of 100 Mb can be aligned in less than 20 min (on a Compaq Alpha computer) with 4 gigabytes of memory. This procedure was used recently to identify numerous large-scale segmental duplications among the five chromosomes of A. thaliana (92); in that organism, the method revealed that 60% of the genome (66 Mb) is covered by 24 very large duplicated segments. For Arabidopsis, a DNA-based alignment was sufficient to reveal the segmental duplications between chromosomes; in the human genome, DNA alignments at the whole-chromosome level are insufficiently sensitive. Therefore, a modified procedure was developed and applied, as follows. First, all 26,588 proteins (9,675,713 million amino acids) were concatenated end-to-end in order as they occur along each of the 24 chromosomes, irrespective of strand location. The concatenated protein set was then aligned against each chromosome in 24 panels in which only duplications mapped to the indexed chromosome are displayed. The figure makes it clear that the duplications are ubiquitous in the genome. One feature that it displays is many relatively small chromosomal stretches, which contain three genes, 137 contain four genes, and 781 contain five or more genes.

To illustrate the extent of the detected duplications, Fig. 13 shows all 1077 block duplications indexed to each chromosome in 24 panels in which only duplications mapped to the blocks explain the excess of gene pairs to distinct genes. In the shuffled data, by contrast, only 370 gene pairs were found, giving a false-positive estimate of 3.6%. The most likely explanation for the 1077 block duplications is ancient segmental duplications. In many cases, the order of the proteins has been shuffled, although proximity is preserved. Out of the 1077 blocks, 159 contain only three genes, 137 contain four genes, and 781 contain five or more genes.

An additional large duplication, between chromosomes 18 and 20, serves as a good example to illustrate some of the features common to many of the other observed large duplications (Fig. 13, inset). This duplication contains 64 detected ordered intrachromosomal pairs of homologous genes. After discounting a 40-Mb stretch of chromosome 18 free of matches to chromosome 20, which is likely to represent a large insert (between the gene assignments “Krup rel” and “collagen rel” on chromosome 18 in Fig. 13), the full duplication segment covers 36 Mb on chromosome 18 and 28 Mb on chromosome 20.
The Human Genome

By this measure, the duplication segment spans nearly half of each chromosome’s net length. The most likely scenario is that the whole span of this region was duplicated as a single very large block, followed by shuffling owing to smaller scale rearrangements. As such, at least four subsequent rearrangements would need to be invoked to explain the relative insertions and inversions seen in the duplicated segment interval. The 64 protein pairs in this alignment occur among 217 protein assignments on chromosome 18, and among 322 protein assignments on chromosome 20, for a density of involved proteins of 20 to 30%. This is consistent with an ancient large-scale duplication followed by subsequent gene loss on one or both chromosomes. Loss of just one member of a gene pair subsequent to the duplication would result in a failure to score a gene pair in the block; less than 50% gene loss on the chromosomes would lead to the duplication density observed here. As an independent verification of the significance of the alignments detected, it can be seen that a substantial number of the pairs of aligning proteins in this duplication, including some of those annotated (Fig. 13), are those populating small Lek complete clusters (see above). This indicates that they are members of very small families of paralogs; their relative scarcity within the genome validates the uniqueness and robust nature of their alignments.

Two additional qualitative features were observed among many of the large-scale duplications. First, several proteins with disease associations, with OMIM (Online Mendelian Inheritance in Man) assignments, are members of duplicated segments (see web table 2 on Science Online at www.sciencemag.org/cgi/content/full/291/5507/1304/DC1). We have also observed a few instances where paralogs on both duplicated segments are associated with similar disease conditions. Notable among these genes are proteins involved in hemostasis (coagulation factors) that are associated with bleeding disorders, transcriptional regulators like the homeobox proteins associated with developmental disorders, and potassium channels associated with cardiovascular conduction abnormalities. For each of these disease genes, closer study of the paralogous genes in the duplicated segment may reveal new insights into disease causation, with further investigation needed to determine whether they might be involved in the same or similar genetic diseases. Second, although there is a conserved number of proteins and coding exons predicted for specific large duplicated spans within the chromosome 18 to 20 alignment, the genomic DNA of chromosome 18 in these specific spans is in some cases more than 10-fold longer than the corresponding chromosome 20 DNA. This selective accretion of noncoding DNA (or conversely, loss of noncoding DNA) on one of a pair of duplicated chromosome regions was observed in many compared regions. Hypotheses to explain which mechanisms foster these processes must be tested.

Evaluation of the alignment results gives some perspective on dating of the duplications. As noted above, large-scale ancient segmental duplication in fact best explains many of the blocks detected by this genome-wide analysis. The regions of human chromosomes involved in the large-scale duplications expanded upon above (chromosomes 2 to 14, 2 to 12, and 18 to 20) are each syntenic to a distinct mouse chromosomal region. The corresponding mouse chromosomal regions are much more similar in sequence conservation, and even in order, to their human synteny partners than the human duplication regions are to each other. Further, the corresponding mouse chromosomal regions each bear a significant proportion of genes orthologous to the human genes on which the human duplication assignments were made. On the basis of these factors, the corresponding mouse chromosomal spans, at coarse resolution, appear to be products of the same large-scale duplications observed in humans. Although further detailed analysis must be carried out once more complete genome is assembled for mouse, the underlying large duplications appear to predate the two species’ divergence. This dates the duplications, at the latest, before divergence of the primate and rodent lineages. This date can be further refined upon examination of the synteny between human chromosomes and those of chicken, pufferfish (Fugu rubripes), or zebrafish (95). The only substantial syntenic stretches mapped in these species corresponding to both pairs of human duplications are restricted to the Hox cluster regions. When the synteny of these regions (or others) to human chromosomes is extended with further mapping, the ages of the nearly chromosome-length duplications seen in humans are likely to be dated to the root of vertebrate divergence.

The MUMmer-based results demonstrate large block duplications that range in size from a few genes to segments covering most of a chromosome. The extent of segmental duplications raises the question of whether an ancient whole-genome duplication event is the underlying explanation for the numerous duplicated regions (96). The duplications have undergone many deletions and subsequent rearrangements; these events make it difficult to distinguish between a whole-genome duplication and multiple smaller events. Further analysis, focused especially on comparing the estimated ages of all the block duplications, derived partially from interspecies genome comparisons, will be necessary to determine which of these two hypotheses is more likely. Comparisons of genomes of different vertebrates, and even crossopterygian genome comparisons, will allow for the deconvolution of duplications to eventually reveal the stagewise history of our genome, and with it a history of the emergence of many of the key functions that distinguish us from other living things.

6 A Genome-Wide Examination of Sequence Variations

Summary. Computational methods were used to identify single-nucleotide polymorphisms (SNPs) by comparison of the Celera sequence to other SNP resources. The SNP rate between two chromosomes was ~1 per 1200 to 1500 bp. SNPs are distributed nonrandomly throughout the genome. Only a very small proportion of all SNPs (~1%) potentially impact protein function based on the functional analysis of SNPs that affect the predicted coding regions. This results in an estimate that only thousands, not millions, of genetic variations may contribute to the structural diversity of human proteins.

Having a complete genome sequence enables researchers to achieve a dramatic acceleration in the rate of gene discovery, but only through analysis of sequence variation in DNA can we discover the genetic basis for variation in health among human beings. Whole-genome shotgun sequencing is a particularly effective method for detecting sequence variation in tandem with whole-genome assembly. In addition, we compared the distribution and attributes of SNPs ascertained by three other methods: (i) alignment of the Celera consensus sequence to the PFP assembly, (ii) overlap of high-quality reads of genomic sequence (referred to as “Kwok”; 1,120,195 SNPs (97), and (iii) reduced representation shotgun sequencing (referred to as “TSC”; 632,640 SNPs) (98). These data were consistent in showing an overall nucleotide diversity of ~8 × 10⁻⁴, marked heterogeneity across the genome in SNP density, and an overwhelming preponderance of noncoding variation that produces no change in expressed proteins.

6.1 SNPs found by aligning the Celera consensus to the PFP assembly

Ideally, methods of SNP discovery make full use of sequence depth and quality at every site, and quantitatively control the rate of false-positive and false-negative calls with an explicit sampling model (99). Comparison of consensus sequences in the absence of these details necessitated a more ad hoc approach (quality scores could not readily be obtained for the PFP assembly). First, all sequence differences between the two consensus sequences were identified; these were then filtered to reduce the contribution of sequencing errors and misassembly. As a measure of the effectiveness of the filtering step, we monitored the ratio of transition and transversion substitutions, because a 2:1 ratio has been well documented as typical in mammalian evolution (100) and in human SNPs.
(101, 102). The filtering steps consisted of removing variants where the quality score in the Celera consensus was less than 30 and where the density of variants was greater than 5 in 400 bp. These filters resulted in shifting the transition-to-transversion ratio from 1.57:1 to 1.89:1. When applied to 2.3 Gbp of alignments between the Celera and PFP consensus sequences, these filters resulted in identification of 2,104,820 putative SNPs from a total of 2,778,474 substitution differences. Overlaps between this set of SNPs and those found by other methods are described below.

6.2 Comparisons to public SNP databases

Additional SNPs, including 2,536,021 from dbSNP (www.ncbi.nlm.nih.gov/SNP) and 13,150 from HGMD (Human Gene Mutation Database, from the University of Wales, UK), were mapped on the Celera consensus sequence by a sequence similarity search with the program PowerBlast (103). The two largest data sets in dbSNP are the KwoK and TSC sets, with 47% and 25% of the dbSNP records. Low-quality alignments with partial coverage of the dbSNP sequence and alignments that had less than 98% sequence identity between the Celera sequence and the dbSNP flanking sequence were eliminated. dbSNP sequences mapping to multiple locations on the Celera genome were discarded. A total of 2,336,935 dbSNP variants were mapped to 1,223,038 unique locations on the Celera sequence, implying considerable redundancy in dbSNP. SNPs in the TSC set mapped to 585,811 unique genomic locations, and SNPs in the KwoK set mapped to 438,032 unique locations. The combined unique SNPs counts used in this analysis, including Celera-PFP, TSC, and KwoK, is 2,737,668. Table 15 shows that a substantial fraction of SNPs identified by one of these methods was also found by another method. The very high overlap (36.2%) between the KwoK and Celera-PFP SNPs may be due in part to the use by KwoK of sequences that went into the PFP assembly. The unusually low overlap (16.4%) between the KwoK and TSC sets is due to their being the smallest two sets. In addition, 24.5% of the Celera-PFP SNPs overlap with SNPs derived from the Celera genome sequences (46). SNP validation in population samples is an expensive and laborious process, so confirmation on multiple data sets may provide an efficient initial validation “in silico” (by computational analysis).

One means of assessing whether the three sets of SNPs provide the same picture of human variation is to tally the frequencies of the six possible base changes in each set of SNPs (Table 16). Previous measures of nucleotide diversity were mostly derived from small-scale analysis on candidate genes (101), and our analysis with all three data sets validates the previous observations at the whole-genome scale. There is remarkable homogeneity between the SNPs found in the KwoK set, the TSC set, and in our whole-genome shotgun (46) in this substitution pattern. Compared with the rest of the data sets, Celera-PFP deviates slightly from the 2:1 transition-to-transversion ratio observed in the other SNP sets. This result is not unexpected, because some fraction of the computationally identified SNPs in the Celera-PFP comparison may in fact be sequence errors. A 2:1 transition:transversion ratio for the bona fide SNPs would be obtained if one assumed that 15% of the sequence differences in the Celera-PFP set were a result of (presumably random) sequence errors.

6.3 Estimation of nucleotide diversity from ascertained SNPs

The number of SNPs identified varied widely across chromosomes. In order to normalize these values to the chromosome size and sequence coverage, we used π, the standard statistic for nucleotide diversity (104).

Nucleotide diversity is a measure of per-site heterozygosity, quantifying the probability that a pair of chromosomes drawn from the population will differ at a nucleotide site. In order to calculate nucleotide diversity for each chromosome, we need to know the number of nucleotide sites that were surveyed for variation, and in methods like reduced representation sequencing, we need to know the sequence quality and the depth of coverage at each site. These data are not readily available, so we could not estimate nucleotide diversity from the TSC effort. Estimation of nucleotide diversity from high-quality sequence overlaps should be possible, but again, more information is needed on the details of all the alignments.

Estimation of nucleotide diversity from a shotgun assembly entails calculating for each column of the multialignment, the probability that two or more distinct alleles are present, and the probability of detecting a SNP if in fact the alleles have different sequence (i.e., the probability of correct sequence calls). The greater the depth of coverage and the higher the sequence quality, the higher is the chance of successfully detecting a SNP (105). Even after correcting for variation in coverage, the nucleotide diversity appeared to vary across autosomes. The significance of this heterogeneity was tested by analysis of variance, with estimates of π for 100-kbp windows to estimate variability within chromosomes (for the Celera-PFP comparison, F = 29.73, P < 0.0001).

Average diversity for the autosomes estimated from the Celera-PFP comparison was 8.94 × 10^-4. Nucleotide diversity on the X chromosome was 6.54 × 10^-4. The X is expected to be less variable than autosomes, because for every four copies of autosomes in the population, there are only three X chromosomes, and this smaller effective population size means that random drift will more rapidly remove variation from the X (106).

Having ascertained nucleotide variation genome-wide, it appears that previous estimates of nucleotide diversity in humans based on samples of genes were reasonably accurate (101, 102, 106, 107). Genome-wide, our estimate of nucleotide diversity was 8.98 × 10^-4 for the Celera-PFP alignment, and a published estimate averaged over 10 densely resequenced human genes was 8.00 × 10^-4 (108).

6.4 Variation in nucleotide diversity across the human genome

Such an apparently high degree of variability among chromosomes in SNP density raises the question of whether there is heterogeneity at a finer scale within chromo-

---

Table 15. Overlap of SNPs from genome-wide SNP databases. Table entries are SNP counts for each pair of data sets. Numbers in parentheses are the fraction of overlap, calculated as the count of overlapping SNPs divided by the number of SNPs in the smaller of the two databases compared. Total SNP counts for the databases are: Celera-PFP, 2,104,820; TSC, 585,811; and KwoK, 438,032. Only unique SNPs in the TSC and KwoK data sets were included.

<table>
<thead>
<tr>
<th></th>
<th>TSC</th>
<th>KwoK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celera-PFP</td>
<td>188,694</td>
<td>158,532 (0.322)</td>
</tr>
<tr>
<td></td>
<td>72,024 (0.164)</td>
<td></td>
</tr>
</tbody>
</table>

---

Table 16. Summary of nucleotide changes in different SNP data sets.

<table>
<thead>
<tr>
<th>SNP data set</th>
<th>A/G (%)</th>
<th>C/T (%)</th>
<th>A/C (%)</th>
<th>A/T (%)</th>
<th>C/G (%)</th>
<th>T/G (%)</th>
<th>Transition: transversion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celera-PFP</td>
<td>30.7</td>
<td>30.7</td>
<td>10.3</td>
<td>8.6</td>
<td>9.2</td>
<td>10.3</td>
<td>1.59:1</td>
</tr>
<tr>
<td>KwoK*</td>
<td>33.7</td>
<td>33.8</td>
<td>8.5</td>
<td>7.0</td>
<td>8.6</td>
<td>8.4</td>
<td>2.07:1</td>
</tr>
<tr>
<td>TSC†</td>
<td>33.3</td>
<td>33.4</td>
<td>8.8</td>
<td>7.3</td>
<td>8.6</td>
<td>8.6</td>
<td>1.99:1</td>
</tr>
</tbody>
</table>

*November 2000 release of the NCBI database dbSNP (www.ncbi.nlm.nih.gov/SNP) with the methods defined as Overlap SnpDetectionWithPolyBayes. The submitter of the data is Pui-Yan KwoK from Washington University. †November 2000 release of NCBI dbSNP (www.ncbi.nlm.nih.gov/SNP) with the methods defined as TSC-Sanger, TSC-WICGR, and TSC-WUGSC. The submitter of the data is Lincoln Stein from Cold Spring Harbor Laboratory.
Fig. 13. Segmental duplications between chromosomes in the human genome. The 24 panels show the 1077 duplicated blocks of genes, containing 10,310 pairs of genes in total. Each line represents a pair of homologous genes belonging to a block; all blocks contain at least three genes on each of the chromosomes where they appear. Each panel shows all the duplications between a single chromosome and other chromosomes with shared blocks. The chromosome at the center of each panel is shown as a thick red line for emphasis. Other chromosomes are displayed from top to bottom within each panel ordered by chromosome number. The inset (bottom, center right) shows a close-up of one duplication between chromosomes 18 and 20, expanded to display the gene names of 12 of the 64 gene pairs shown.
some, and whether this heterogeneity is greater than expected by chance. If SNPs occur by random and independent mutations, then it would seem that there ought to be a Poisson distribution of numbers of SNPs in fragments of arbitrary constant size. The observed dispersion in the distribution of SNPs in 100-kbp fragments was far greater than predicted from a Poisson distribution (Fig. 14). However, this simplistic model ignores the different recombination rates and population histories that exist in different regions of the genome. Population genetics theory holds that we can account for this variation with a mathematical formulation called the neutral coalescent (109). Applying well-tested algorithms for simulating the neutral coalescent with recombination (110), and using an effective population size of 10,000 and a per-base recombination rate equal to the mutation rate (111), we generated a distribution of numbers of SNPs by this model as well (112). The observed distribution of SNPs has a much larger variance than either the Poisson model or the coalescent model, and the difference is highly significant. This implies that there is significant variability across the genome in SNP density, an observation that begs an explanation.

Several attributes of the DNA sequence may affect the local density of SNPs, including the rate at which DNA polymerase makes errors and the efficacy of mismatch repair. One key factor that is likely to be associated with SNP density is the G+C content, in part because methylated cytosines in CpG dinucleotides tend to undergo deamination to form thymine, accounting for a nearly 10-fold increase in the mutation rate of CpGs over other dinucleotides. We tallied the GC content and nucleotide diversities in 100-kbp windows across the entire genome and found that the correlation between them was positive ($r = 0.21$) and highly significant ($P < 0.0001$), but G+C content accounted for only a small part of the variation.

6.5 SNPs by genomic class

To test homogeneity of SNP densities across functional classes, we partitioned sites into intergenic (defined as $>5$ kbp from any predicted transcription unit), 5’-UTR, exonic (missense and silent), intronic, and 3’-UTR for 10,239 known genes, derived from the NCBI RefSeq database and all human genes predicted from the Celera Otto annotation. In coding regions, SNPs were categorized as either silent, for those that do not change amino acid sequence, or missense, for those that change the protein product. The ratio of missense to silent coding SNPs in Celera-PFP, TSC, and Kwok sets ($1.12, 0.91, \text{and } 0.78$, respectively) shows a markedly reduced frequency of missense variants compared with the neutral expectation, consistent with the elimination by natural selection of a fraction of the deleterious amino acid changes (112). These ratios are comparable to the missense-to-silent ratios of 0.88 and 1.17 found by Cargill et al. (101) and by Halushka et al. (102). Similar results were observed in SNPs derived from Celera shotgun sequences (46).

It is striking how small is the fraction of SNPs that lead to potentially dysfunctional alterations in proteins. In the 10,239 RefSeq genes, missense SNPs were only about 0.12, 0.14, and 0.17% of the total SNP counts in Celera-PFP, TSC, and Kwok SNPs, respectively. Nonconservative protein changes constitute an even smaller fraction of missense SNPs (47, 41, and 40% in Celera-PFP, Kwok, and TSC). Intergenic regions have been virtually unstudied (113), and we note that 75% of the SNPs we identified were intergenic (Table 17). The SNP rate was highest in introns and lowest in exons. The SNP rate was lower in intergenic regions than in introns, providing one of the first discriminators between these two classes of DNA. These SNP rates were confirmed in the Celera SNPs, which also exhibited a lower rate in exons than in introns and in extragenic regions than in introns (46). Many of these intergenic SNPs will provide valuable information in the form of markers for linkage and association studies, and some fraction is likely to have a regulatory function as well.

7 An Overview of the Predicted Protein-Coding Genes in the Human Genome

Summary. This section provides an initial computational analysis of the predicted protein set with the aim of cataloging prominent differences and similarities when the human genome is compared with other fully sequenced eukaryotic genomes. Over 40% of the predicted protein set in humans cannot be ascribed a molecular function by methods that assign proteins to known families. A protein domain–based analysis provides a detailed catalog of the prominent differences in the human genome when compared with the fly and worm genomes. Prominent among these are domain expansions in proteins involved in developmental regulation and in cellular processes such as neuronal function, hemo-stasis, acquired immune response, and cytoskeletal complexity. The final enumeration of protein families and details of protein structure will rely on additional experimental work and comprehensive manual curation.

A preliminary analysis of the predicted human protein-coding genes was conducted. Two methods were used to analyze and classify the molecular functions of 26,588 predicted proteins that represent 26,383 gene predictions with at least two lines of evidence as described above. The first method was based on an analysis at the level of protein families, with both the publicly available Pfam database (114, 115) and Celera’s Panther Classification (CPC) (Fig. 15) (116). The second method was based on an analysis at the level of protein domains, with both the Pfam and SMART databases (115, 117).

The results presented here are preliminary and are subject to several limitations.

![Fig. 14. SNP density in each 100-kbp interval as determined with Celera-PFP SNPs. The color codes are as follows: black, Celera-PFP SNP density; blue, coalescent model; and red, Poisson distribution. The figure shows that the distribution of SNPs along the genome is nonrandom and is not entirely accounted for by a coalescent model of regional history.](http://science.sciencemag.org/)
Both the gene predictions and functional assignments have been made by using
computational tools, although the statistical models in Panther, Pfam, and SMART have
been built, annotated, and reviewed by expert biologists. In the set of computationally
predicted genes, we expect both false-positive predictions (some of these may in fact be
inactive pseudogenes) and false-negative predictions (some human genes will not be computa-
tionally predicted). We also expect errors in delimiting the boundaries of exons and genes.
Similarly, in the automatic functional assignments, we also expect both false-positive and
false-negative predictions. The functional assignment protocol focuses on protein families
that tend to be found across several organisms, or on families of known human genes. There-
fore, we do not assign a function to many genes that are not in large families, even if the func-
tion is known. Unless otherwise specified, all enumeration of the genes in any given family or
functional category was taken from the set of 26,588 predicted proteins, which were assigned
functions by using statistical score cutoffs defined for models in Panther, Pfam, and
SMART.

For this initial examination of the predicted human protein set, three broad ques-
tions were asked: (i) What are the likely molecular functions of the predicted gene
products, and how are these proteins categorized with current classification meth-
ods? (ii) What are the core functions that appear to be common across the animals?
(iii) How does the human protein complement differ from that of other sequenced
eukaryotes?

7.1 Molecular functions of predicted human proteins

Figure 15 shows an overview of the putative molecular functions of the predicted
26,588 human proteins that have at least two lines of supporting evidence. About
41% (12,809) of the gene products could not be classified from this initial analysis
and are termed proteins with unknown functions. Because our automatic classifi-
cation methods treat only relatively large protein families, there are a number of
“unclassified” sequences that do, in fact, have a known or predicted function. For the
60% of the protein set that have automatic functional predictions, the specific protein
functions have been placed into broad classes. We focus here on molecular func-
tion (rather than higher order cellular processes) in order to classify as many proteins
as possible. These functional predictions are based on similarity to sequences of
known function.

In our analysis of the 12,731 additional low-confidence predicted genes (those with only
one piece of supporting evidence), only 636 (5%) of these additional putative genes were
assigned molecular functions by the automated methods. One-third of these 636 predicted
genes represented endogenous retroviral proteins, further suggesting that the majority of
these unknown-function genes are not real genes. Given that most of these additional
12,095 genes appear to be unique among the genomes sequenced to date, many may simply
represent false-positive gene predictions.

The most common molecular functions are the transcription factors and those involved
in nucleic acid metabolism (nucleic acid enzyme). Other functions that are highly represented in
the human genome are the receptors, kinases, and hydrolases. Not surprisingly, most of the
hydrolases are proteases. There are also many proteins that are members of proto-oncogene
families, as well as families of “select regulatory molecules”: (i) proteins involved in specific
steps of signal transduction such as heterotrimeric GTP-binding proteins (G proteins) and
cell cycle regulators, and (ii) proteins that modulate the activity of kinases, G proteins, and
phosphatases.

Table 17. Distribution of SNPs in classes of genomic regions.

<table>
<thead>
<tr>
<th>Genomic region class</th>
<th>Size of region examined (Mb)</th>
<th>Celera-PFP SNP density (SNP/Mb)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intergenic</td>
<td>2185</td>
<td>707</td>
</tr>
<tr>
<td>Gene (intron + exon)</td>
<td>646</td>
<td>917</td>
</tr>
<tr>
<td>Intron</td>
<td>615</td>
<td>921</td>
</tr>
<tr>
<td>First intron</td>
<td>164</td>
<td>808</td>
</tr>
<tr>
<td>Exon</td>
<td>31</td>
<td>529</td>
</tr>
<tr>
<td>First exon</td>
<td>10</td>
<td>592</td>
</tr>
</tbody>
</table>

Fig. 15. Distribution of the molecular functions of 26,383 human genes. Each slice lists the numbers and percentages (in parentheses) of human gene functions assigned to a given category of molecular function. The outer circle shows the assignment to molecular function categories in the Gene Ontology (GO) (179), and the inner circle shows the assignment to Celera’s Panther molecular function categories (116).
7.2 Evolutionary conservation of core processes

Because of the various “model organism” genome-sequencing projects that have already been completed, reasonable comparative information is available for beginning the analysis of the evolution of the human genome. The genomes of *S. cerevisiae* (“bakers’ yeast”) (118) and two diverse invertebrates, *C. elegans* (a nematode worm) (119) and *D. melanogaster* (fly) (26), as well as the first plant genome, *A. thaliana*, recently completed (92), provide a diverse background for genome comparisons.

We enumerated the “strict orthologs” conserved between human and fly, and between human and worm (Fig. 16) to address the question, what are the core functions that appear to be common across the animals? The concept of orthology is important because if two genes are orthologous, they can be traced by descent to the common ancestor of the two organisms (an “evolutionarily conserved protein set”), and therefore are likely to perform similar conserved functions in the different organisms. It is critical in this analysis to separate orthologs (a gene that appears in two organisms by descent from a common ancestor) from paralogs (a gene that appears in two organisms by descent from a common ancestor) or paralogs (a gene that appears in more than one copy in a given organism by a duplication event) because paralogs may subsequently diverge in function. Following the yeast-worm ortholog comparison in (120), we identified two different cases for each pairwise comparison (human-fly and human-worm). The first case was a pair of genes, one from each organism, for which there was no other close homolog in either organism. These are straightforwardly identified as orthologous, because there are no additional members of the families that complicate separating orthologs from paralogs. The second case is a family of genes with more than one member in either or both of the organisms being compared. Chervitz et al. (120) deal with this case by analyzing a phylogenetic tree that described the relationships between all of the sequences in both organisms, and then looked for pairs of genes that were nearest neighbors in the tree. If the nearest-neighbor pairs were from different organisms, those genes were presumed to be orthologs. We note that these nearest neighbors can often be confidently identified from pairwise sequence comparison without having to examine a phylogenetic tree (see legend to Fig. 16). If the nearest neighbors are not from different organisms, there has been a paralogous expansion in one or both organisms after the speciation event (and/or a gene loss by one organism). When this one-to-one correspondence is lost, defining an ortholog becomes ambiguous. For our initial computational overview of the predicted human protein set, we could not answer this question for every predicted protein. Therefore, we consider only “strict orthologs,” i.e., the proteins with unambiguous one-to-one relationships (Fig. 16). By these criteria, there are 2758 strict human-fly orthologs, 2031 human-worm (1523 in common between these sets). We define the evolutionarily conserved set as those 1523 human proteins that have strict orthologs in both *D. melanogaster* and *C. elegans*.

The distribution of the functions of the conserved protein set is shown in Fig. 16. Comparison with Fig. 15 shows that, not surprisingly, the set of conserved proteins is not distributed among molecular functions in the same way as the whole human protein set. Compared with the whole human set (Fig. 15), there are several categories that are overrepresented in the conserved set by a factor of 2 or more. The first category is nucleic acid enzymes, primarily the transcriptional machinery (notably DNA/RNA methyltransferases, DNA/RNA polymerases, helicases, DNA ligases, DNA- and RNA-processing factors, nucleases, and ribosomal proteins). The basic transcriptional and translational machinery is well known to have been conserved over evolution, from bacteria through to the most complex eukaryotes. Many ribonucleoproteins involved in RNA splicing also appear to be conserved among the animals. Other enzyme types are also overrepresented (transferases, oxidoreductases, ligases, lyases, and isomerases). Many of these en-

---

**Fig. 16.** Functions of putative orthologs across vertebrate and invertebrate genomes. Each slice lists the number and percentages (in parentheses) of “strict orthologs” between the human, fly, and worm genomes involved in a given category of molecular function. “Strict orthologs” are defined here as bi-directional BLAST best hits (180) such that each orthologous pair (i) has a BLASTP P-value of $\leq 10^{-10}$ (120), and (ii) has a more significant BLASTP score than any paralogs in either organism, i.e., there has likely been no duplication subsequent to speciation that might make the orthology ambiguous. This measure is quite strict and is a lower bound on the number of orthologs. By these criteria, there are 2758 strict human-fly orthologs, and 2031 human-worm orthologs (1523 in common between these sets).
zymes are involved in intermediary metabolism. The only exception is the hydrolase category, which is not significantly overrepresented in the shared protein set. Proteases form the largest part of this category, and several large protease families have expanded in each of these three organisms after their divergence. The category of select regulatory molecules is also overrepresented in the conserved set. The major conserved families are small guanosine triphosphatases (GTPases) (especially the Ras-related superfamily, including ADP ribosylation factor) and cell cycle regulators (particularly the cullin family, cyclin C family, and several cell division protein kinases). The last two significantly overrepresented categories are protein transport and trafficking, and chaperones. The most conserved groups in these categories are proteins involved in coated vesicle-mediated transport, and chaperones involved in protein folding and heat-shock response (particularly the DNAJ family, and heat-shock protein 60 (HSP60), HSP70, and HSP90 families). These observations provide only a conservative estimate of the protein families in the context of specific cellular processes that were likely derived from the last common ancestor of the human, fly, and worm. As stated before, this analysis does not provide a complete estimate of conservation across the three animal genomes, as paralogous duplication makes the determination of true orthologs difficult within the members of conserved protein families.

7.3 Differences between the human genome and other sequenced eukaryotic genomes

To explore the molecular building blocks of the vertebrate taxon, we have compared the human genome with the other sequenced eukaryotic genomes at three levels: molecular functions, protein families, and protein domains.

Molecular differences can be correlated with phenotypic differences to begin to reveal the developmental and cellular processes that are unique to the vertebrates. Tables 18 and 19 display a comparison among all sequenced eukaryotic genomes, over selected protein/ domain families (defined by sequence similarity, e.g., the serine-threonine protein kinases) and superfamilies (defined by shared molecular function, which may include several sequence-related families, e.g., the cyto- kines). In these tables we have focused on (super) families that are either very large or that differ significantly in humans compared with the other sequenced eukaryote genomes. We have found that the most prominent human expansions are in proteins involved in (i) acquired immune functions; (ii) neural development, structure, and functions; (iii) inter- cellular and intracellular signaling pathways in development and homeostasis; (iv) hemo- stasis; and (v) apoptosis.

Acquired immunity. One of the most striking differences between the human genome and the Drosophila or C. elegans genome is the appearance of genes involved in acquired immunity (Tables 18 and 19). This is expected, because the acquired immune response is a defense system that only occurs in vertebrates. We observe 22 class I and 22 class II major histocompatibility complex (MHC) antigen genes and 114 other immu- noglobulin genes in the human genome. In addition, there are 59 genes in the cognate immunoglobulin receptor family. At the domain level, this is exemplified by an expansion and recruitment of the ancient immunoglobulin fold to constitute molecules such as MHC, and of the integrin fold to form several of the cell adhesion molecules that mediate interactions between immune effector cells and the extracellular matrix. Vertebrate-spe- cific proteins include the paracrine immune regulators family of secreted 4-alpha helical bundle proteins, namely the cytokines and chemokines. Some of the cytoplasmic signal transduction components associated with cyto- kine receptor signal transduction are also features that are poorly represented in the fly and worm. These include protein domains found in the signal transducer and activator of transcription (STATs), the suppressors of cyto- kine signaling (SOCS), and protein inhibitors of activated STATs (PIAS). In contrast, many of the animal-specific protein domains that play a role in innate immune response, such as the Toll receptors, do not appear to be significantly expanded in the human genome.

Neural development, structure, and function. In the human genome, as compared with the worm and fly genomes, there is a marked increase in the number of members of protein families that are involved in neural development. Examples include neu- rotrophic factors such as ependymin, nerve growth factor, and signaling molecules such as semaphorins, as well as the number of proteins involved directly in neural structure and function such as myelin proteins, voltage-gated ion channels, and syn- aptic proteins such as synaptotagmin. These observations correlate well with the known phenotypic differences between the nervous systems of these taxa, notably (i) the increase in the number and connectivity of neurons; (ii) the increase in number of distinct neural cell types (as many as a thousand or more in human compared with a few hundred in fly and worm) (121); (iii) the increased length of individual axons; and (iv) the significant increase in glial cell number, especially the appearance of my- elinating glial cells, which are electrically inert supporting cells differentiated from the same stem cells as neurons. A number of prominent protein expansions are in- volved in the processes of neural develop- ment. Of the extracellular domains that mediate cell adhesion, the connexin domain-containing proteins (122) exist only in hu- mans. These proteins, which are not present in the Drosophila or C. elegans genomes, appear to provide the constitutive subunits of intercellular channels and the structural basis for electrical coupling. Pathway finding by axons and neuronal network forma- tion is mediated through a subset of ephrins and their cognate receptor tyrosine kinases that act as positional labels to establish topographical projections (123). The prob- able biological role for the semaphorins (22 in human compared with 6 in the fly and 2 in the worm) and their receptors (neuropils and plexins) is that of axonal guidance molecules (124). Signaling molecules such as neurotrophic factors and some cytokines have been shown to regulate neuronal cell survival, proliferation, and axon guidance (125). Notch receptors and ligands play important roles in glial cell fate determina- tion and gliogenesis (126).

Other human expanded gene families play key roles directly in neural structure and function. One example is synaptotagmin (expanded more than twofold in humans relative to the invertebrates), originally found to reg- ulate synaptic transmission by serving as a Ca2+ sensor (or receptor) during synaptic vesicle fusion and release (127). Of interest is the increased co-occurrence in humans of PDZ and the SH3 domains in neuronal- specific adaptor molecules; examples include proteins that likely modulate channel activity at synaptic junctions (128). We also noted expansions in several ion-channel families (Table 19), including the EAG subfamily (related to cyclic nucleotide gated channels), the voltage-gated calcium/sodium channel family, the inward-rectifier potassium channel family, and the voltage-gated potassium channel, alpha subunit family. Voltage-gated sodium and potassium channels are involved in the generation of action potentials in neu- rons. Together with voltage-gated calcium channels, they also play a key role in cou- pling action potentials to neurotransmitter re- lease, in the development of neurites, and in short-term memory. The recent observation of a calcium-regulated association between sodium channels and synaptotagmin may have consequences for the establishment and regulation of neuronal excitability (129).

Myelin basic protein and myelin-assos- ciated glycoprotein are major classes of protein components in both the central and peripheral nervous system of vertebrates. Myelin P0 is a major component of peripheral myelin, and myelin proteolipid and myelin oligodendro- cyte glycoprotein are found in the central nervous system. Mutations in any of these
Table 18. Domain-based comparative analysis of proteins in *H. sapiens* (H), *D. melanogaster* (F), *C. elegans* (W), *S. cerevisiae* (Y), and *A. thaliana* (A). The predicted protein set of each of the above eukaryotic organisms was analyzed with Pfam version 5.5 using E value cutoffs of 0.001. The number of proteins containing the specified Pfam domains as well as the total number of domains (in parentheses) are shown in each column. Domains were categorized into cellular processes for presentation. Some domains (i.e., SH2) are listed in more than one cellular process. Results of the Pfam analysis may differ from results obtained based on human curation of protein families, owing to the limitations of large-scale automatic classifications. Representative examples of domains with reduced counts owing to the stringent E value cutoff used for this analysis are marked with a double asterisk (**). Examples include short divergent and predominantly alpha-helical domains, and certain classes of cysteine-rich zinc finger proteins.

<table>
<thead>
<tr>
<th>Accession number</th>
<th>Domain name</th>
<th>Domain description</th>
<th>H</th>
<th>F</th>
<th>W</th>
<th>Y</th>
<th>A</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF02039</td>
<td>Adrenomedullin</td>
<td>Adrenomedullin</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00122</td>
<td>ANP</td>
<td>Atrial natriuretic peptide</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00028</td>
<td>Cadherin</td>
<td>Cadherin domain</td>
<td>100 (550)</td>
<td>14 (157)</td>
<td>16 (66)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00214</td>
<td>Calc_CGRP_IAPP</td>
<td>Calcitonin/CGRP/IAPP family</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01110</td>
<td>CNTF</td>
<td>Ciliary neurotrophic factor</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01093</td>
<td>Clusterin</td>
<td>Clusterin</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00029</td>
<td>Connexin</td>
<td>Connexin</td>
<td>14 (16)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00976</td>
<td>ACTH_domain</td>
<td>Corticotropin ACTH domain</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00473</td>
<td>CRF</td>
<td>Corticotropin-releasing factor family</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00007</td>
<td>Cys_knot</td>
<td>Cysteine-knot domain</td>
<td>10 (11)</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00778</td>
<td>DIX</td>
<td>DIX domain</td>
<td>5</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00322</td>
<td>Endothelin</td>
<td>Endothelin family</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00812</td>
<td>Ephrin</td>
<td>Ephrin</td>
<td>7 (8)</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01404</td>
<td>EPH_lbd</td>
<td>Ephrin receptor ligand binding domain</td>
<td>12</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00167</td>
<td>FGF</td>
<td>Fibroblast growth factor</td>
<td>23</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01534</td>
<td>Frizzled</td>
<td>Frizzled/Smoothened family membrane region</td>
<td>9</td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00236</td>
<td>Hormone6</td>
<td>Glycoprotein hormones</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01153</td>
<td>Glypican</td>
<td>Glypican</td>
<td>14</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01271</td>
<td>Grainin</td>
<td>Grainin (chromogranin or secretogranin)</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02058</td>
<td>Guanylin</td>
<td>Guanylin precursor</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00049</td>
<td>Insulin</td>
<td>Insulin/IGF/Relaxin family</td>
<td>7</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00219</td>
<td>IGFBP</td>
<td>Insulin-like growth factor binding proteins</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02024</td>
<td>Leptin</td>
<td>Leptin</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00193</td>
<td>Link</td>
<td>Link (hyaluron binding)</td>
<td>13 (23)</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00243</td>
<td>NCF</td>
<td>Nerve growth factor family</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02158</td>
<td>Neuregulin</td>
<td>Neuregulin family</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00184</td>
<td>Hormone5</td>
<td>Neurohypophysial hormones</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02070</td>
<td>NMU</td>
<td>Neuremedin U</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00066</td>
<td>Notch</td>
<td>Notch (DSL) domain</td>
<td>3 (5)</td>
<td>2 (4)</td>
<td>2 (6)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00865</td>
<td>Osteopontin</td>
<td>Osteopontin</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00159</td>
<td>Hormone3</td>
<td>Pancreatic hormone peptides</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01279</td>
<td>Parathryoid</td>
<td>Parathyroid hormone family</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00123</td>
<td>Hormone2</td>
<td>Peptide hormone</td>
<td>5 (9)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00341</td>
<td>PDGF</td>
<td>Platelet-derived growth factor (PDGF)</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01403</td>
<td>Sema</td>
<td>Sema domain</td>
<td>27 (29)</td>
<td>8 (10)</td>
<td>3 (4)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01033</td>
<td>Somatomedin_B</td>
<td>Somatomedin B domain</td>
<td>5 (8)</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00103</td>
<td>Hormone</td>
<td>Somatotropin</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02208</td>
<td>Sorb</td>
<td>Sorbin homologous domain</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02404</td>
<td>SCF</td>
<td>Stem cell factor</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01034</td>
<td>Syndecan</td>
<td>Syndecan domain</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00020</td>
<td>TNFR_c6</td>
<td>TNFR/NFGF cysteine-rich region</td>
<td>17 (31)</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00019</td>
<td>TGF-β</td>
<td>Transforming growth factor β-like domain</td>
<td>27 (28)</td>
<td>6</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01099</td>
<td>Uteroglobin</td>
<td>Uteroglobin family</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01160</td>
<td>Opioids_neuropep</td>
<td>Vertebrate endogenous opioids neuropeptide</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00110</td>
<td>Wnt</td>
<td>Wnt family of developmental signaling proteins</td>
<td>18</td>
<td>7 (10)</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Hemostasis**

<p>| PF01821          | ANATO        | Anaphylatoxin-like domain | 6 (14) | 0 | 0 | 0 | 0 |
| PF00386          | C1q          | C1q domain              | 24 | 0 | 0 | 0 | 0 |
| PF00200          | Disintegrin  | Disintegrin             | 18 | 2 | 3 | 0 | 0 |
| PF00754          | FS_F8_type_C | FS/8 type C domain    | 15 (20) | 5 (6) | 2 | 0 | 0 |
| PF01410          | GOPII        | Fibribril collagen C-terminal domain | 0 | 0 | 0 | 0 | 0 |
| PF00039          | Fn1          | Fibronectin type I domain | 5 (18) | 0 | 0 | 0 | 0 |
| PF00400          | Fn2          | Fibronectin type II domain | 11 (16) | 0 | 0 | 0 | 0 |
| PF00051          | Kringle      | Kringle domain         | 15 (24) | 2 | 2 | 0 | 0 |
| PF01823          | MACPF        | MAC/Perforin domain    | 6 | 0 | 0 | 0 | 0 |
| PF00354          | Pentaxin     | Pentaxin family        | 9 | 0 | 0 | 0 | 0 |
| PF00277          | SAA_proteins | Serum amyloid A protein | 4 | 0 | 0 | 0 | 0 |
| PF00084          | Sushi        | Sushi domain (SCR repeat) | 53 (191) | 11 (42) | 8 (45) | 0 | 0 |
| PF02210          | TSPN         | Thrombospondin N-terminal-like domains | 14 | 1 | 0 | 0 | 0 |
| PF01108          | Tissue_fac   | Tissue factor          | 1 | 0 | 0 | 0 | 0 |
| PF00868          | Transglutamin_N | Transglutaminase family | 6 | 1 | 0 | 0 | 0 |
| PF00927          | Transglutamin_C | Transglutaminase family | 8 | 1 | 0 | 0 | 0 |</p>
<table>
<thead>
<tr>
<th>Accession number</th>
<th>Domain name</th>
<th>Domain description</th>
<th>H</th>
<th>F</th>
<th>W</th>
<th>Y</th>
<th>A</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF00594</td>
<td>Gla</td>
<td>Vitamin K-dependent carboxylation/gamma-carboxylamin (GLA) domain</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00711</td>
<td>Defensin_beta</td>
<td>Beta defensin</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00748</td>
<td>Calpain_inhib</td>
<td>Calpain inhibitor repeat</td>
<td>3 (9)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00666</td>
<td>Cathelicidins</td>
<td>Cathelicidins</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00129</td>
<td>MHC_I</td>
<td>Class I histocompatibility antigen, domains alpha 1 and 2</td>
<td>18 (20)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00993</td>
<td>MHC_II_alpha**</td>
<td>Class II histocompatibility antigen, alpha domain</td>
<td>5 (6)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00969</td>
<td>MHC_II_beta**</td>
<td>Class II histocompatibility antigen, beta domain</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00879</td>
<td>Defensin_propep</td>
<td>Defensin propeptide</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01109</td>
<td>GM_CSF</td>
<td>Granulocyte-macrophage colony-stimulating factor</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00047</td>
<td>Ig</td>
<td>Immunoglobulin domain</td>
<td>381 (930)</td>
<td>125 (291)</td>
<td>67 (323)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00143</td>
<td>Interferon</td>
<td>Interferon alpha/beta domain</td>
<td>7 (9)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00714</td>
<td>IFN-gamma</td>
<td>Interferon gamma</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00726</td>
<td>IL10</td>
<td>Interleukin-10</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02372</td>
<td>IL15</td>
<td>Interleukin-15</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00715</td>
<td>IL2</td>
<td>Interleukin-2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00727</td>
<td>IL4</td>
<td>Interleukin-4</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02025</td>
<td>IL5</td>
<td>Interleukin-5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01415</td>
<td>IL7</td>
<td>Interleukin-7/9 family</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00340</td>
<td>IL1</td>
<td>Interleukin-1</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02394</td>
<td>IL1_propep</td>
<td>Interleukin-1 propeptide</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02059</td>
<td>IL3</td>
<td>Interleukin-3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00489</td>
<td>IL6</td>
<td>Interleukin-6/G-CSF/MGF family</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01291</td>
<td>ILF_OSM</td>
<td>Leukemia inhibitory factor (ILF)/oncostatin (OSM) family</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00323</td>
<td>Defensins</td>
<td>Mammalian defensin</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01091</td>
<td>PTN_MK</td>
<td>PTN/MK heparin-binding protein</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00277</td>
<td>SAA_proteins</td>
<td>Serum amyloid A protein</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00048</td>
<td>ILB</td>
<td>Small cytokines (intercrine/chemokine), interleukin-B like</td>
<td>32</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01582</td>
<td>TIR</td>
<td>TIR domain</td>
<td>18</td>
<td>8</td>
<td>2</td>
<td>0</td>
<td>131 (143)</td>
</tr>
<tr>
<td>PF00229</td>
<td>TNF</td>
<td>TNF (tumor necrosis factor) family</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00088</td>
<td>Trefoil</td>
<td>Trefoil (P-type) domain</td>
<td>5 (6)</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00779</td>
<td>BTK</td>
<td>BTK motif</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00168</td>
<td>C2</td>
<td>C2 domain</td>
<td>73 (101)</td>
<td>32 (44)</td>
<td>24 (35)</td>
<td>6 (9)</td>
<td>66 (90)</td>
</tr>
<tr>
<td>PF00609</td>
<td>DAGKa</td>
<td>Diacylglycerol kinase accessory domain (presumed)</td>
<td>9</td>
<td>4</td>
<td>7</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>PF00781</td>
<td>DAGKc</td>
<td>Diacylglycerol kinase catalytic domain (presumed)</td>
<td>10</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>11 (12)</td>
</tr>
<tr>
<td>PF00610</td>
<td>DEP</td>
<td>Domain found in Dishevelled, Egl-10, and Pleckstrin (DEP)</td>
<td>12 (13)</td>
<td>4</td>
<td>10</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>PF01363</td>
<td>FYVE</td>
<td>FYVE zinc finger</td>
<td>28 (30)</td>
<td>14</td>
<td>15</td>
<td>5</td>
<td>15</td>
</tr>
<tr>
<td>PF00996</td>
<td>GDI</td>
<td>GDP dissociation inhibitor</td>
<td>6</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>PF00503</td>
<td>G-alpha</td>
<td>G-protein alpha subunit</td>
<td>27 (30)</td>
<td>10</td>
<td>20</td>
<td>23</td>
<td>2</td>
</tr>
<tr>
<td>PF00631</td>
<td>G-gamma</td>
<td>G-protein gamma like domains</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PF00616</td>
<td>RasGAP</td>
<td>GTPase-activator protein for Ras-like GTPase</td>
<td>11</td>
<td>5</td>
<td>8</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>PF00618</td>
<td>RasGEFN</td>
<td>Guanine nucleotide exchange factor for Ras-like GTPases; N-terminal motif</td>
<td>9</td>
<td>2</td>
<td>3</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>PF00625</td>
<td>Guanylate_kin</td>
<td>Guanylate kinase</td>
<td>12</td>
<td>8</td>
<td>7</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>PF02189</td>
<td>ITAM</td>
<td>Immunoreceptor tyrosine-based activation motif</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00169</td>
<td>PH</td>
<td>PH domain</td>
<td>193 (212)</td>
<td>72 (78)</td>
<td>65 (68)</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td>PF00130</td>
<td>DAG_PE-bind</td>
<td>Phorbol esters/diacylglycerol binding domain (C1 domain)</td>
<td>45 (56)</td>
<td>25 (31)</td>
<td>26 (40)</td>
<td>1 (2)</td>
<td>4</td>
</tr>
<tr>
<td>PF00388</td>
<td>PI-PLC-X</td>
<td>Phosphatidylinositol-specific phospholipase C, X domain</td>
<td>12</td>
<td>3</td>
<td>7</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>PF00387</td>
<td>PI-PLC-Y</td>
<td>Phosphatidylinositol-specific phospholipase C, Y domain</td>
<td>11</td>
<td>2</td>
<td>7</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>PF00640</td>
<td>PID</td>
<td>Phosphotyrosine interaction domain (PTB/PID)</td>
<td>24 (27)</td>
<td>13</td>
<td>11 (12)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02192</td>
<td>PI3K_P85B</td>
<td>PI3-kinase family, p85-binding domain</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00794</td>
<td>PI3K_rbd</td>
<td>PI3-kinase family, ras-binding domain</td>
<td>6</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01412</td>
<td>ArfGAP</td>
<td>Putative GTP-ase activating protein for Arf</td>
<td>16</td>
<td>9</td>
<td>8</td>
<td>6</td>
<td>15</td>
</tr>
<tr>
<td>PF02196</td>
<td>RBD</td>
<td>Raf-like Ras-binding domain</td>
<td>6 (7)</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02145</td>
<td>Rap_GAP</td>
<td>Rap/ras-GAP</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00788</td>
<td>RA</td>
<td>Ras association (RalGDS/AF-6) domain</td>
<td>18 (19)</td>
<td>7 (9)</td>
<td>6</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PF00071</td>
<td>Ras</td>
<td>Ras family</td>
<td>126</td>
<td>56 (57)</td>
<td>51</td>
<td>23</td>
<td>78</td>
</tr>
<tr>
<td>PF00617</td>
<td>RasGEFN</td>
<td>RasGEFN domain</td>
<td>21</td>
<td>8</td>
<td>7</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>PF00615</td>
<td>RGS</td>
<td>Regulator of G protein signaling domain</td>
<td>27</td>
<td>6 (7)</td>
<td>12 (13)</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PF02197</td>
<td>Rila</td>
<td>Regulatory subunit of type II PKA R-subunit</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Accession number</td>
<td>Domain name</td>
<td>Domain description</td>
<td>H</td>
<td>F</td>
<td>W</td>
<td>Y</td>
<td>A</td>
</tr>
<tr>
<td>------------------</td>
<td>------------</td>
<td>--------------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>PF00620</td>
<td>RhoGAP</td>
<td>RhoGAP domain</td>
<td>59</td>
<td>19</td>
<td>20</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>PF00621</td>
<td>RhoGEF</td>
<td>RhoGEF domain</td>
<td>46</td>
<td>23</td>
<td>18</td>
<td>19</td>
<td>3</td>
</tr>
<tr>
<td>PF00536</td>
<td>SAM</td>
<td>SAM domain (Sterile alpha motif)</td>
<td>29 (31)</td>
<td>15</td>
<td>8</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>PF01369</td>
<td>Sec7</td>
<td>Sec7 domain</td>
<td>13</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>PF00017</td>
<td>SH2</td>
<td>Src homology 2 (SH2) domain</td>
<td>87 (95)</td>
<td>33 (39)</td>
<td>44 (48)</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>PF00018</td>
<td>SH3</td>
<td>Src homology 3 (SH3) domain</td>
<td>143 (182)</td>
<td>55 (75)</td>
<td>46 (61)</td>
<td>23 (27)</td>
<td>4</td>
</tr>
<tr>
<td>PF01017</td>
<td>STAT</td>
<td>STAT protein</td>
<td>7</td>
<td>1</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00790</td>
<td>VHS</td>
<td>VHS domain</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>PF00568</td>
<td>WH1</td>
<td>WH1 domain</td>
<td>7</td>
<td>2</td>
<td>2 (3)</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PF00452</td>
<td>Bcl-Z</td>
<td>Bcl-Z</td>
<td>9</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF02180</td>
<td>BH4</td>
<td>Bcl-2 homology region 4</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00619</td>
<td>CARD</td>
<td>Caspase recruitment domain</td>
<td>16</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00531</td>
<td>Death</td>
<td>Death domain</td>
<td>16</td>
<td>5</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01335</td>
<td>DED</td>
<td>Death effector domain</td>
<td>4 (5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00791</td>
<td>ICE_p20</td>
<td>ICE-like protease (caspase) p20 domain</td>
<td>11</td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00653</td>
<td>Bir</td>
<td>Inhibitor of Apoptosis domain</td>
<td>8 (14)</td>
<td>5 (9)</td>
<td>2 (3)</td>
<td>1 (2)</td>
<td>0</td>
</tr>
<tr>
<td>PF01391</td>
<td>Collagen</td>
<td>Collagen triple helix repeat (20 copies)</td>
<td>65 (279)</td>
<td>10 (46)</td>
<td>174 (384)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01413</td>
<td>C4</td>
<td>C-terminal tandem repeated domain in type 4</td>
<td>6 (11)</td>
<td>2 (4)</td>
<td>3 (6)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00431</td>
<td>CUB</td>
<td>CUB domain</td>
<td>47 (69)</td>
<td>9 (47)</td>
<td>43 (67)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00008</td>
<td>EGF</td>
<td>EGF-like domain</td>
<td>108 (420)</td>
<td>45 (186)</td>
<td>54 (157)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PF00147</td>
<td>Fibrinogen_C</td>
<td>Fibrinogen beta and gamma chains, C-terminal globular domain</td>
<td>26</td>
<td>10 (11)</td>
<td>6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00041</td>
<td>Fn3</td>
<td>Fibronectin type III domain</td>
<td>106 (545)</td>
<td>42 (168)</td>
<td>34 (156)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PF00757</td>
<td>Furin-like</td>
<td>Furin-like cysteine rich region</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00357</td>
<td>Integrin_A</td>
<td>Integrin alpha cytoplasmic region</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00362</td>
<td>Integrin_B</td>
<td>Integrins, beta chain</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00052</td>
<td>Laminin_B</td>
<td>Laminin B (Domain IV)</td>
<td>8 (12)</td>
<td>4 (7)</td>
<td>6 (10)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00053</td>
<td>Laminin_EGF</td>
<td>Laminin EGF-like (Domains III and V)</td>
<td>24 (126)</td>
<td>9 (62)</td>
<td>11 (65)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00054</td>
<td>Laminin_G</td>
<td>Laminin G domain</td>
<td>30 (57)</td>
<td>18 (42)</td>
<td>14 (26)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00055</td>
<td>Laminin_Nterm</td>
<td>Laminin N-terminal (Domain VI)</td>
<td>10</td>
<td>4</td>
<td>6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00059</td>
<td>Lectin_c</td>
<td>Lectin C-type domain</td>
<td>47 (76)</td>
<td>23 (24)</td>
<td>91 (132)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01463</td>
<td>LRRCT</td>
<td>Leucine rich repeat C-terminal domain</td>
<td>69 (81)</td>
<td>23 (30)</td>
<td>7 (9)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF01462</td>
<td>LRRNT</td>
<td>Leucine rich repeat N-terminal domain</td>
<td>40 (44)</td>
<td>7 (13)</td>
<td>3 (6)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00057</td>
<td>Ldl_recept_a</td>
<td>Low-density lipoprotein receptor domain class A</td>
<td>35 (127)</td>
<td>33 (152)</td>
<td>27 (113)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00058</td>
<td>Ldl_recept_b</td>
<td>Low-density lipoprotein receptor repeat B</td>
<td>15 (96)</td>
<td>9 (56)</td>
<td>7 (22)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00530</td>
<td>SRCR</td>
<td>Scavenger receptor cysteine-rich domain</td>
<td>11 (46)</td>
<td>4 (8)</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00004</td>
<td>Sushi</td>
<td>Sushi domain (SCR repeat)</td>
<td>53 (191)</td>
<td>11 (42)</td>
<td>8 (45)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00009</td>
<td>Tsp_1</td>
<td>Thrombospondin type 1 domain</td>
<td>41 (66)</td>
<td>11 (23)</td>
<td>18 (47)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00092</td>
<td>Vwa</td>
<td>von Willebrand factor type A domain</td>
<td>34 (58)</td>
<td>0</td>
<td>17 (19)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PF00093</td>
<td>Vwc</td>
<td>von Willebrand factor type C domain</td>
<td>19 (28)</td>
<td>6 (11)</td>
<td>2 (5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00094</td>
<td>Vwd</td>
<td>von Willebrand factor type D domain</td>
<td>15 (35)</td>
<td>3 (7)</td>
<td>9</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PF00244</td>
<td>14-3-3</td>
<td>14-3-3 proteins</td>
<td>20</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>PF00023</td>
<td>Ank</td>
<td>Ank repeat</td>
<td>145 (404)</td>
<td>72 (269)</td>
<td>75 (223)</td>
<td>12 (20)</td>
<td>66 (111)</td>
</tr>
<tr>
<td>PF00534</td>
<td>Armadillo_seg</td>
<td>Armadillo/beta-catenin-like repeats</td>
<td>22 (56)</td>
<td>11 (38)</td>
<td>3 (11)</td>
<td>2 (10)</td>
<td>25 (67)</td>
</tr>
<tr>
<td>PF00168</td>
<td>C2</td>
<td>C2 domain</td>
<td>73 (101)</td>
<td>32 (44)</td>
<td>24 (35)</td>
<td>6 (9)</td>
<td>66 (90)</td>
</tr>
<tr>
<td>PF00027</td>
<td>cNMP_binding</td>
<td>Cyclic nucleotide-binding domain</td>
<td>26 (31)</td>
<td>21 (33)</td>
<td>15 (20)</td>
<td>2 (3)</td>
<td>22</td>
</tr>
<tr>
<td>PF01556</td>
<td>DnaJ_C</td>
<td>DnaJ C terminal region</td>
<td>12</td>
<td>9</td>
<td>5</td>
<td>3</td>
<td>19</td>
</tr>
<tr>
<td>PF00226</td>
<td>DnaJ</td>
<td>DnaJ domain</td>
<td>44</td>
<td>34</td>
<td>33</td>
<td>20</td>
<td>93</td>
</tr>
<tr>
<td>PF00036</td>
<td>EFhand***</td>
<td>EF hand</td>
<td>83 (151)</td>
<td>64 (117)</td>
<td>41 (86)</td>
<td>4 (11)</td>
<td>120 (328)</td>
</tr>
<tr>
<td>PF00611</td>
<td>FCH</td>
<td>Fes/CIP4 homology domain</td>
<td>9</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>PF01846</td>
<td>FF</td>
<td>FF domain</td>
<td>4 (11)</td>
<td>4 (10)</td>
<td>3 (16)</td>
<td>2 (5)</td>
<td>4 (8)</td>
</tr>
<tr>
<td>PF00498</td>
<td>FHA</td>
<td>FHA domain</td>
<td>13</td>
<td>15</td>
<td>7</td>
<td>13 (14)</td>
<td>17</td>
</tr>
</tbody>
</table>
myelin proteins result in severe demyelination, which is a pathological condition in which the myelin is lost and the nerve conduction is severely impaired (130). Humans have at least 10 genes belonging to four different families involved in myelin production (five myelin P0, three myelin proteolipid, myelin basic protein, and myelin-oligodendrocyte glycoprotein, or MOG), and possibly more remotely related members of the MOG family. Flies have only a single myelin proteolipid, and worms have none at all.

Table 18 (Continued)

<table>
<thead>
<tr>
<th>Accession number</th>
<th>Domain name</th>
<th>Domain description</th>
<th>H</th>
<th>F</th>
<th>W</th>
<th>Y</th>
<th>A</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF00254 FKBP</td>
<td>FKBP-type peptidyl-prolyl cis-trans isomerases</td>
<td>15 (20)</td>
<td>7 (8)</td>
<td>7 (13)</td>
<td>4</td>
<td>24 (29)</td>
<td></td>
</tr>
<tr>
<td>PF01590 GAF</td>
<td>GAF domain</td>
<td>7 (8)</td>
<td>2 (4)</td>
<td>1</td>
<td>0</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>PF01344 Kelch</td>
<td>Kelch motif</td>
<td>54 (157)</td>
<td>12 (48)</td>
<td>13 (41)</td>
<td>3</td>
<td>102 (178)</td>
<td></td>
</tr>
<tr>
<td>PF00560 LRR**</td>
<td>Leucine Rich Repeat</td>
<td>25 (30)</td>
<td>24 (30)</td>
<td>7 (11)</td>
<td>1</td>
<td>15 (16)</td>
<td></td>
</tr>
<tr>
<td>PF00917 MATH</td>
<td>MATH domain</td>
<td>11 (5)</td>
<td>58 (161)</td>
<td>1</td>
<td>61 (74)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PF00989 PAS</td>
<td>PAS domain</td>
<td>18 (19)</td>
<td>9 (10)</td>
<td>6</td>
<td>1</td>
<td>13 (18)</td>
<td></td>
</tr>
<tr>
<td>PF00395 PDZ</td>
<td>PDZ domain (Also known as DHR or GLGF)</td>
<td>96 (154)</td>
<td>60 (87)</td>
<td>46 (66)</td>
<td>2</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>PF00169 PH</td>
<td>PH domain</td>
<td>193 (212)</td>
<td>72 (78)</td>
<td>65 (68)</td>
<td>24</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>PF01535 PPR**</td>
<td>PPR repeat</td>
<td>5</td>
<td>3 (4)</td>
<td>0</td>
<td>1</td>
<td>474 (2485)</td>
<td></td>
</tr>
<tr>
<td>PF00536 SAM</td>
<td>SAM domain (Sterile alpha motif)</td>
<td>29 (31)</td>
<td>15</td>
<td>8</td>
<td>3</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>PF01369 Sec7</td>
<td>Sec7 domain</td>
<td>13</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>PF00017 SH2</td>
<td>Src homology 2 (SH2) domain</td>
<td>87 (95)</td>
<td>33 (39)</td>
<td>44 (48)</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>PF00018 SH3</td>
<td>Src homology 3 (SH3) domain</td>
<td>143 (182)</td>
<td>55 (75)</td>
<td>46 (61)</td>
<td>23</td>
<td>27 (4)</td>
<td></td>
</tr>
<tr>
<td>PF01740 STAS</td>
<td>STAS domain</td>
<td>1</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>PF00151 TPR**</td>
<td>TPR domain</td>
<td>72 (131)</td>
<td>39 (101)</td>
<td>28 (54)</td>
<td>16</td>
<td>31 (65)</td>
<td></td>
</tr>
<tr>
<td>PF00400 WD40**</td>
<td>WD40 domain</td>
<td>136 (305)</td>
<td>98 (226)</td>
<td>72 (153)</td>
<td>56</td>
<td>121 (167)</td>
<td></td>
</tr>
<tr>
<td>PF00397 WW</td>
<td>WW domain</td>
<td>32 (53)</td>
<td>24 (39)</td>
<td>16 (24)</td>
<td>5 (8)</td>
<td>11 (15)</td>
<td></td>
</tr>
<tr>
<td>PF00569 ZZ</td>
<td>ZZ-Zinc finger present in dystrophin, CBP/p300</td>
<td>10 (11)</td>
<td>13</td>
<td>10</td>
<td>2</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

**Nuclear interaction domains**

| PF01754 ZF-A20 | A20-like zinc finger | 2 (8) | 2 | 2 | 0 | 8 |
| PF01388 ARID   | ARID DNA binding domain | 11 | 6 | 4 | 2 | 7 |
| PF01426 BAH    | BAH domain | 8 (10) | 7 (8) | 4 (5) | 5 | 21 (25) |
| PF00643 ZF-B-box** | B-box zinc finger | 32 (35) | 1 | 2 | 0 | 0 |
| PF00533 BRCT   | BRCA1 C Terminus (BRCT) domain | 17 (28) | 10 (18) | 23 (35) | 10 (16) | 12 (16) |
| PF00439 Bromodomain | Bromodomain | 37 (48) | 16 (22) | 18 (26) | 10 (15) | 28 |
| PF00651 BTB    | BTB/POZ domain | 97 (98) | 62 (64) | 86 (91) | 1 (2) | 30 (31) |
| PF00145 DNA_methylase | C-5 cytosine-specific DNA methylase | 3 (4) | 1 | 0 | 0 | 13 (15) |
| PF00385 Chromo | Chromo (CHRromatin Organization MIdifier) | 24 (27) | 14 (15) | 17 (18) | 1 (2) | 12 |
| PF00125 Histone | Core histone H2A/H2B/H3/H4 | 75 (81) | 5 | 71 (73) | 8 | 48 |
| PF00134 Cyclin | Cyclin | 19 | 10 | 10 | 11 | 35 |
| PF00270 DEAD   | DEAD/DEAH box helicase | 63 (66) | 42 (50) | 55 (57) | 50 (52) | 84 (87) |
| PF01529 ZF-DHHC | DHHC zinc finger domain | 15 | 20 | 16 | 7 | 22 |
| PF00646 F-box** | F-box domain | 16 | 15 | 309 (324) | 9 | 165 (167) |
| PF00250 Fork_head | Fork head domain | 35 (36) | 20 (21) | 15 | 4 | 0 |
| PF00320 GATA   | GATA zinc finger | 11 (17) | 5 (6) | 8 (10) | 9 | 26 |
| PF01585 G-patch | G-patch domain | 18 | 16 | 13 | 4 | 14 (15) |
| PF00010 HLH**  | Helix-loop-helix DNA-binding domain | 60 (61) | 44 | 24 | 4 | 39 |
| PF00850 Hist_deacetyl | Histone deacetylase family | 12 | 5 (6) | 8 (10) | 5 | 10 |
| PF00046 Homeobox | Homeobox domain | 160 (178) | 100 (103) | 82 (84) | 6 | 66 |
| PF01833 TIG    | IPT/TIG domain | 29 (53) | 11 (13) | 5 (7) | 2 | 1 |
| PF02373 JmjC   | JmjC domain | 10 | 4 | 6 | 4 | 7 |
| PF02375 JmjN   | JmjN domain | 7 | 4 | 2 | 3 | 7 |
| PF00013 KH-domain | KH domain | 28 (67) | 14 (32) | 17 (46) | 4 (14) | 27 (61) |
| PF01352 KRAB   | KRAB box | 204 (243) | 0 | 0 | 0 | 0 |
| PF00104 Hormone_rec | Ligand-binding domain of nuclear hormone receptor | 47 | 17 | 142 (147) | 0 | 0 |
| PF00412 LIM    | LIM domain containing proteins | 62 (129) | 33 (83) | 33 (79) | 4 (7) | 10 (16) |
| PF00917 MATH   | MATH domain | 11 | 5 | 88 (161) | 1 | 61 (74) |
| PF00249 Myb_DNA-binding | Myb-like DNA-binding domain | 32 (43) | 18 (24) | 17 (24) | 15 (20) | 243 (401) |
| PF02344 Myc-LZ | Myc leucine zipper domain | 1 | 0 | 0 | 0 | 0 |
| PF01753 ZF-MYND | MYND finger | 14 | 14 | 9 | 1 | 7 |
| PF00628 PHD    | PHD-finger | 68 (86) | 40 (53) | 32 (44) | 14 (15) | 96 (105) |
| PF00157 Pou    | Pou domain—N-terminal to homeobox domain | 15 | 5 | 4 | 0 | 0 |
| PF002257 RFX_DNA_binding | RFX DNA-binding domain | 7 | 2 | 1 | 1 | 0 |
| PF00076 Rrm    | RNA recognition motif (a.k.a. RRM, RBD, or RNP domain) | 224 (324) | 127 (199) | 94 (145) | 43 (73) | 232 (369) |
| PF002037 SAP   | SAP domain | 15 | 8 | 5 | 5 | 6 (7) |
| PF00622 SPRY   | SPRY domain | 44 (51) | 10 (12) | 5 (7) | 3 | 6 |
| PF01852 START  | START domain | 10 | 2 | 6 | 0 | 23 |
| PF00907 T-box  | T-box | 17 (19) | 8 | 22 | 0 | 0 |
(Tables 18 and 19). They include secreted hormones and growth factors, receptors, intracellular signaling molecules, and transcription factors.

Developmental signaling molecules that are enriched in the human genome include growth factors such as wnt, transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), nerve growth factor, platelet derived growth factor (PDGF), and ephrins. These growth factors affect tissue differentiation and a wide range of cellular processes involving actin-cytoskeletal and nuclear regulation. The corresponding receptors of these developmental ligands are also expanded in humans. For example, our analysis suggests at least 8 human ephrin genes (2 in the fly, 4 in the worm) and 12 ephrin receptors (2 in the fly, 1 in the worm). In the wnt signaling pathway, we find 18 wnt family genes (6 in the fly, 5 in the worm) and 12 frizzled receptors (6 in the fly, 5 in the worm). The Groucho family of transcriptional corepressors downstream in the wnt pathway are even more markedly expanded, with 13 predicted members in humans (2 in the fly, 1 in the worm).

Extracellular adhesion molecules involved in signaling are expanded in the human genome (Tables 18 and 19). The interactions of several of these adhesion domains with extracellular matrix proteoglycans play a critical role in host defense, morphogenesis, and tissue repair (131). Consistent with the well-defined role of heparan sulfate proteoglycans in modulating these interactions (132), we observe an expansion of the heparin sulfate sulfotransferases in the human genome relative to worm and fly. These sulfotransferases modulate tissue differentiation (133). A similar expansion in humans is noted in structural proteins that constitute the actin-cytoskeletal architecture. Compared with the fly and worm, we observe an explosive expansion of the nebulin (35 domains per protein on average), aggrecan (12 domains per protein on average), and plectin (5 domains per protein on average) repeats in humans. These repeats are present in proteins involved in modulating the actin-cytoskeleton with predominant expression in neuronal, muscle, and vascular tissues.

Comparison across the five sequenced eukaryotic organisms revealed several expanded protein families and domains involved in cytoplasmic signal transduction (Table 18). In particular, signal transduction pathways playing roles in developmental regulation and acquired immunity were substantially enriched. There is a factor of 2 or greater expansion in humans in the Ras superfamily GTPases and the GTPase activator and GTP exchange factors associated with them. Although there are about the same number of tyrosine kinases in the human and C. elegans genomes, in humans there is an increase in the SH2, PTB, and ITAM domains involved in phosphotyrosine signal transduction. Further, there is a twofold expansion of phosphodiesterases in the human genome compared with either the worm or fly genomes.

The downstream effectors of the intracellular signaling molecules include the transcription factors that transduce developmental fates. Significant expansions are noted in the ligand-binding nuclear hormone receptor class of transcription factors compared with the fly genome, although not to the extent observed in the worm (Tables 18 and 19). Perhaps the most striking expansion in humans is in the C2H2 zinc finger transcription factors. Pfam detects a total of 4500 C2H2 zinc finger domains in 564 human proteins, compared with 771 in 234 fly proteins. This means that there has been a dramatic expansion not only in the number of C2H2 transcription factors, but also in the number of these DNA-binding motifs per transcription factor (8 on average in humans, 3.3 on average in the fly, and 2.3 on average in the worm). Furthermore, many of these transcription factors contain either the KRAB or SCAN domain of the Kruppel family genes (6 in the fly, 5 in the worm). The transcription factor family involved in metabolic regulation.

Hemostasis. Hemostasis is regulated primarily by plasma proteases of the coagulation pathway and by the interactions that occur between the vascular endothelium and platelets. Consistent with known anatomical and physiological differences between vertebrates and invertebrates, extracellular adhesion domains that constitute proteins integral to hemostasis are expanded in the human relative to the fly and worm (Tables 18 and 19). We note the evolution of domains such as FIMAC, FN1, FN2, and C1q that mediate surface interactions between hematopoietic cells and the vascular matrix. In addition, there has been extensive recruitment of more-ancient animal-specific domains such as VWA, VWC, VWD, kringle, and FN3 into multidomain proteins that are involved in hemostatic regulation. Although we do not find a large expansion in the total number of serine proteases, this enzymatic domain has been specifically recruited into several of these multidomain proteins for proteolytic regulation in the vascular compartment. These are represented in plasma proteins that belong to the kinin and complement pathways. There is a
significant expansion in two families of matrix metalloproteases: ADAM (a disintegrin and metalloprotease) and MMPs (matrix metalloproteases) (Table 19). Proteolysis of extracellular matrix (ECM) proteins is critical for tissue development and for tissue degradation in diseases such as cancer, arthritis, Alzheimer’s disease, and a variety of inflammatory conditions (135, 136). ADAMs are a family of integral membrane proteins with a pivotal role in fibrinolysis and modulating interactions between hemapoietic components and the vascular matrix components. These proteins have been shown to cleave matrix proteins, and even signaling molecules; ADAM-17 converts tumor necrosis factor–α, and ADAM-10 has been implicated in the Notch signaling pathway (135). We have identified 19 members of the matrix metalloprotease family, and a total of 51 members of the ADAM and ADAM-TS families.

**Apoptosis.** Evolutionary conservation of some of the apoptotic pathway components across eukarya is consistent with its central role in developmental regulation and as a response to pathogens and stress signals. The signal transduction pathways involved in programmed cell death, or apoptosis, are mediated by interactions between well-characterized domains that include extracellular domains, adaptor (protein-protein interaction) domains, and those found in effector and regulatory enzymes (137). We enumerated the protein counts of central adaptor and effector enzyme domains that are found only in the apoptotic pathways to provide an estimate of divergence across eukarya and relative expansion in the human genome when compared with the fly and worm (Table 18). Adaptor domains found in proteins restricted only to apoptotic regulation such as the DED domains are vertebrate-specific, whereas others like BIR, CARD, and Bcl2 are represented in the fly and worm (although the number of Bcl2 family members in humans is significantly expanded). Although plants and yeast lack the caspases, caspase-like molecules, namely the para- and meta-caspases, have been reported in these organisms (138). Compared with other animal genomes, the human genome shows an expansion in the adaptor and effector domain-containing proteins involved in apoptosis, as well as in the proteases involved in the cascade such as the caspase and calpain families.

**Expansions of other protein families.**

**Metabolic enzymes.** There are fewer cytochrome P450 genes in humans than in either the fly or worm. Lipoxygenases (six in humans), on the other hand, appear to be specific to the vertebrates and plants, whereas the lipoxygenase-activating proteins (four in humans) may be vertebrate-specific. Lipoxygenases are involved in arachidonic acid metabolism, and they and their activators have been implicated in diverse human pathology ranging from allergic responses to cancers. One of the most surprising human expansions, however, is in the number of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes (46 in humans, 3 in the fly, and 4 in the worm). There is, however, evidence for many retrotransposed GAPDH pseudogenes (139), which may account for this apparent expansion. However, it is interesting that GAPDH, long known as a conserved enzyme involved in basic metabolism found across all phyla from bacteria to humans, has recently been shown to have other functions. It has a second cat-

<table>
<thead>
<tr>
<th>Panther family/subfamily*</th>
<th>H</th>
<th>F</th>
<th>W</th>
<th>Y</th>
<th>A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neural structure, function, development</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ependymin</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ion channels</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetylcholine receptor</td>
<td>17</td>
<td>12</td>
<td>56</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Amiloride-sensitive/degenerin</td>
<td>11</td>
<td>24</td>
<td>27</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CNG/EAG</td>
<td>22</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>30</td>
</tr>
<tr>
<td>IRK</td>
<td>16</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>ITP/ryanodine</td>
<td>10</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neurotransmitter-gated</td>
<td>61</td>
<td>51</td>
<td>59</td>
<td>0</td>
<td>19</td>
</tr>
<tr>
<td>P2X purinoceptor</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TASK</td>
<td>12</td>
<td>12</td>
<td>48</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Transient receptor</td>
<td>15</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Voltage-gated Ca&lt;sup&gt;2+&lt;/sup&gt; alpha</td>
<td>22</td>
<td>4</td>
<td>8</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Voltage-gated Ca&lt;sup&gt;2+&lt;/sup&gt; alpha-2</td>
<td>10</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Voltage-gated Ca&lt;sup&gt;2+&lt;/sup&gt; beta</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Voltage-gated Ca&lt;sup&gt;2+&lt;/sup&gt; gamma</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Voltage-gated K&lt;sup&gt;+&lt;/sup&gt; alpha</td>
<td>33</td>
<td>5</td>
<td>11</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Voltage-gated K&lt;sup&gt;+&lt;/sup&gt;QT</td>
<td>6</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Voltage-gated Na&lt;sup&gt;+&lt;/sup&gt;</td>
<td>11</td>
<td>4</td>
<td>4</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Myelin basic protein</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Myelin PO</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Myelin proteolipid</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Myelin-oligodendrocyte glycoprotein</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neuruplin</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Plexin</td>
<td>9</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Semaphorin</td>
<td>22</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Synaptotagmin</td>
<td>10</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Immune response</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Defensin</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cytokine†</td>
<td>86</td>
<td>14</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CSF</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>GMCSF</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Interocrine alpha</td>
<td>15</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Interocrine beta</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Interferon</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Interleukin</td>
<td>26</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leukemia inhibitory factor</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>MCSF</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Peptidoglycan recognition protein</td>
<td>2</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pre-B cell enhancing factor</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Small inducible cytokine A</td>
<td>14</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>SI cytokine</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TNF</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cytokine receptor‡</td>
<td>62</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Bradykinin/C-C chemokine receptor</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fl cytokine receptor</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Interferon receptor</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Interleukin receptor</td>
<td>32</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leukocyte tyrosine kinase receptor</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>M-CSF receptor</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TNF receptor</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Immunoglobulin receptor†</td>
<td>59</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>T-cell receptor alpha chain</td>
<td>16</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>T-cell receptor beta chain</td>
<td>15</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>T-cell receptor gamma chain</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>T-cell receptor delta chain</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Immunoglobulin Fc receptor</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Killer cell receptor</td>
<td>16</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Polymeric-immunoglobulin receptor</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
alytic activity, as a uracil DNA glycosylase (140) and functions as a cell cycle regulator (141) and has even been implicated in apoptosis (142).

Translation. Another striking set of human expansions has occurred in certain families involved in the translational machinery. We identified 28 different ribosomal subunits that each have at least 10 copies in the genome; on average, for all ribosomal proteins there is about an 8- to 10-fold expansion in the number of genes relative to either the worm or fly. Retrotransposed pseudogenes may account for many of these expansions [see the discussion above and (143)]. Recent evidence suggests that a number of ribosomal proteins have secondary functions independent of their involvement in protein biosynthesis; for example, L13a and the related L7 subunits (36 copies in humans) have been shown to induce apoptosis (144).

There is also a four- to fivefold expansion in the elongation factor 1-alpha family (eEF1α; 56 human genes). Many of these expansions likely represent intronless paralogs that have presumably arisen from retrotransposition, and again there is evidence that many of these may be pseudogenes (145). However, a second form (eEF1A2) of this factor has been identified with tissue-specific expression in skeletal muscle and a complementary expression pattern to the ubiquitously expressed eEF1A (146).

Ribonucleoproteins. Alternative splicing results in multiple transcripts from a single gene, and can therefore generate additional diversity in an organism’s protein complement. We have identified 269 genes for ribonucleoproteins. This represents over 2.5 times the number of ribonucleoprotein genes in the worm, two times that of the fly, and about the same as the 265 identified in the Arabidopsis genome. Whether the diversity of ribonucleoprotein genes in humans contributes to gene regulation at either the splicing or translational level is unknown.

Posttranslational modifications. In this set of processes, the most prominent expansion is the transglutaminases, calcium-dependent enzymes that catalyze the cross-linking of proteins in cellular processes such as hemostasis and apoptosis (147). The vitamin K-dependent gamma carboxylase gene product acts on the GLA domain (missing in the fly and worm) found in coagulation factors, osteocalcin, and matrix GLA protein (148). Tyrosylprotein sulfotransferases participate in the posttranslational modification of proteins involved in inflammation and hemostasis, including coagulation factors and chemokine receptors (149). Although there is no significant numerical increase in the counts for domains involved in nuclear protein modification, there are a number of domain arrangements in the predicted human proteins that are not found in the other currently sequenced genomes. These include the tandem association of two histone deacetylase domains in HD6 with a ubiquitin finger domain, a feature lacking in the fly genome. An additional example is the co-occurrence of important nuclear regulatory enzyme PARP (poly-ADP ribosyl transferase) domain fused to protein-interaction domains—BRCT and VWA in humans.

**Concluding remarks.** There are several possible explanations for the differences in phenotypic complexity observed in humans when compared to the fly and worm. Some of these relate to the prominent differences in the immune system, hemostasis, neuronal, vascular, and cytoskeletal complexity. The finding that the human genome contains fewer genes than previously predicted might be compensated for by combinatorial diversity generated at the levels of protein architecture, transcriptional and translational control, post-translational modification of proteins, or posttranscriptional regulation. Extensive domain shuffling to increase or alter combinatorial diversity can provide an exponential...
increase in the ability to mediate protein-protein interactions without dramatically increasing the absolute size of the protein complement (150). Evolution of apparently new (from the perspective of sequence analysis) protein domains and increasing regulatory complexity by domain accretion both quantitatively and qualitatively (recruitment of novel domains with preexisting ones) are two features that we observe in humans. Perhaps the best illustration of this trend is the C2H2 zinc finger-containing transcription factors, where we see expansion in the number of domains per protein, together with vertebrate-specific domains such as KRAB and SCAN. Recent reports on the prominent use of internal ribosomal entry sites in the human genome to regulate translation of specific classes of proteins suggests that this is an area that needs further research to identify the full extent of this process in the human genome (151). At the posttranslational level, although we provide examples of expansions of some protein families involved in these modifications, further experimental evidence is required to evaluate whether this is correlated with increased complexity in protein processing. Posttranscriptional processing and the extent of isoform generation in the human remain to be cataloged in their entirety. Given the conserved nature of the spliceosomal machinery, further analysis will be required to dissect regulation at this level.

8 Conclusions

8.1 The whole-genome sequencing approach versus BAC by BAC

Experience in applying the whole-genome shotgun sequencing approach to a diverse group of organisms with a wide range of genome sizes and repeat content allows us to assess its strengths and weaknesses. With the success of the method for a large number of microbial genomes, Drosophila, and now the human, there can be no doubt concerning the utility of this method. The large number of microbial genomes that have been sequenced by this method (15, 80, 152) demonstrate that megabase-sized genomes can be sequenced efficiently without any input other that the de novo mate-paired sequences. With more complex genomes like those of Drosophila or human, map information, in the form of well-ordered markers, has been critical for long-range ordering of scaffolds. For joining scaffolds into chromosomes, the quality of the map (in terms of the order of the markers) is more important than the number of markers per se. Although this mapping could have been performed concurrently with sequencing, the prior existence of mapping data was beneficial. During the sequencing of the A. thaliana genome, sequencing of individual BAC clones permitted extension of the sequence.

Table 19 (Continued)

<table>
<thead>
<tr>
<th>Transcription factors/chromatin organization</th>
<th>Panther family/subfamily*</th>
<th>H</th>
<th>F</th>
<th>W</th>
<th>Y</th>
<th>A</th>
</tr>
</thead>
<tbody>
<tr>
<td>C2H2 zinc finger–containing†</td>
<td>607 232 79 28 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COE</td>
<td>7 1 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CREB</td>
<td>7 1 2 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETS-related</td>
<td>25 8 10 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forkhead-related</td>
<td>34 19 15 4 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOS</td>
<td>8 2 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Groucho</td>
<td>13 2 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histone H1</td>
<td>5 0 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histone H2A</td>
<td>24 1 17 3 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histone H2B</td>
<td>21 1 17 2 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histone H3</td>
<td>28 2 24 2 16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histone H4</td>
<td>9 1 16 1 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homeotic†</td>
<td>168 104 74 4 78</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABO-8</td>
<td>5 0 4 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bithoraxoid</td>
<td>1 8 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iroquois class</td>
<td>7 3 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distal-less</td>
<td>5 2 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engrailed</td>
<td>2 2 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIM-containing</td>
<td>17 8 3 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEIS/KNOX class</td>
<td>9 4 4 2 26</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NK-3/NK-2 class</td>
<td>9 4 5 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paired box</td>
<td>38 28 23 0 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNAI</td>
<td>5 3 4 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leucine zipper</td>
<td>6 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuclear hormone receptor†</td>
<td>59 25 183 1 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pou-related</td>
<td>15 5 4 1 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Runt-related</td>
<td>13 4 2 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECM adhesion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cadherin</td>
<td>113 17 16 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Claudin</td>
<td>20 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complement receptor-related</td>
<td>22 8 6 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connexin</td>
<td>14 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelatin</td>
<td>12 5 22 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glycican</td>
<td>13 2 1 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICAM</td>
<td>6 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrin alpha</td>
<td>24 7 4 0 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrin beta</td>
<td>9 2 2 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL receptor family</td>
<td>26 19 20 0 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proteoglycans</td>
<td>22 9 7 0 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apoptosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bcl-2</td>
<td>12 1 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calpain</td>
<td>22 4 11 1 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calpain inhibitor</td>
<td>4 0 0 0 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caspase</td>
<td>13 7 3 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemostasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADAM/ADAMTS</td>
<td>51 9 12 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibronectin</td>
<td>3 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Globin</td>
<td>10 2 3 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matrix metalloprotease</td>
<td>19 2 7 0 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum amyloid A</td>
<td>4 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum amyloid P (subfamily of Pentaxin)</td>
<td>2 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum paraoxonase/arylesterase</td>
<td>4 0 3 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum albumin</td>
<td>4 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transglutaminase</td>
<td>10 1 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other enzymes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytochrome p450</td>
<td>60 89 83 3 256</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>46 3 4 3 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparan sulfotransferase</td>
<td>11 4 2 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splicing and translation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EF-1-alpha</td>
<td>56 13 10 6 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ribonuclease proteins†</td>
<td>269 135 104 60 265</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ribosomal proteins†</td>
<td>812 111 80 117 256</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The table lists Panther families or subfamilies relevant to the text that either (i) are not specifically represented by Pfam (Table 18) or (ii) differ in counts from the corresponding Pfam models. †This class represents a number of different families in the same Panther molecular function subcategory. ††This count includes only rhodopsin-class, secretin-class, and metabotropic glutamate-class GPCRs.
sequence well into centromeric regions and allowed high-quality resolution of complex repeat regions. Likewise, in Drosophila, the BAC physical map was most useful in regions near the highly repetitive centromeres and telomeres. WGA has been found to deliver excellent-quality reconstructions of the unique regions of the genome. As the genome size, and more importantly the repetitive content, increases, the WGA approach delivers less of the repetitive sequence.

The cost and overall efficiency of clone-by-clone approaches makes them difficult to justify as a stand-alone strategy for future large-scale genome-sequencing projects. Specific applications of BAC-based or other clone mapping and sequencing strategies to resolve ambiguities in sequence assembly that cannot be efficiently resolved with computational approaches alone are clearly worth exploring. Hybrid approaches to whole-genome sequencing will only work if there is sufficient coverage in both the whole-genome shotgun phase and the BAC clone sequencing phase. Our experience with human genome assembly suggests that this will require at least 5x coverage of both whole-genome and BAC shotgun sequence data.

8.2 The low gene number in humans

We have sequenced and assembled ~95% of the euchromatic sequence of H. sapiens and used a new automated gene prediction method to produce a preliminary catalog of the human genes. This has provided a major surprise: we have found far fewer genes (26,000 to 38,000) than the earlier molecular predictions (50,000 to over 140,000). Whatever the reasons for this current disparity, only detailed annotation, comparative genomics (particularly using the Mus musculus genome), and careful molecular dissection of complex phenotypes will clarify this critical issue of the basic “parts list” of our genome. Certainly, the analysis is still incomplete and considerable refinement will occur in the years to come as the precise structure of each transcription unit is evaluated. A good place to start is to determine why the gene estimates derived from EST data are so discordant with our predictions. It is likely that the following contribute to an inflated gene number derived from ESTs: the variable lengths of 3’- and 5’-untranslated leaders and trailers; the little-understood vagaries of RNA processing that often leave intronic regions in an unspliced condition; the finding that nearly 40% of human genes are alternatively spliced (153); and finally, the unsolved technical problems in EST library construction where contamination from heterogeneous nuclear RNA and genomic DNA are not uncommon. Of course, it is possible that there are genes that remain unpredicted owing to the absence of EST or protein data to support them, although our use of mouse genome data for predicting genes should limit this number. As was true at the beginning of genome sequencing, ultimately it will be necessary to measure mRNA in specific cell types to demonstrate the presence of a gene.

J. B. S. Haldane speculated in 1937 that a population of organisms might have to pay a price for the number of genes it can possibly carry. He theorized that when the number of genes becomes too large, each zygote carries so many new deleterious mutations that the population simply cannot maintain itself. On the basis of this premise, and on the basis of available mutation rates and x-ray–induced mutations at specific loci, Muller, in 1967 (154), calculated that the mammalian genome would contain a maximum of not much more than 30,000 genes (155). An estimate of 30,000 gene loci for humans was also arrived at by Crow and Kimura (156). Muller’s estimate for D. melanogaster was 10,000 genes, compared to 13,000 derived by annotation of the fly genome (26, 27). These arguments for the theoretical maximum gene number were based on simplified ideas of genetic load—that all genes have a certain low rate of mutation to a deleterious state. However, it is clear that many mouse, fly, worm, and yeast knockout mutations lead to almost no discernible phenotypic perturbations.

The modest number of human genes means that we must look elsewhere for the mechanisms that generate the complexities inherent in human development and the sophisticated signaling systems that maintain homeostasis. There are a large number of ways in which the functions of individual genes and gene products are regulated. The degree of “openness” of chromatin structure and hence transcriptional activity is regulated by protein complexes that involve histone and DNA enzymatic modifications. We enumerate many of the proteins that are likely involved in nuclear regulation in Table 19. The location, timing, and quantity of transcription are intimately linked to nuclear signal transduction events as well as by the tissue-specific expression of many of these proteins. Equally important are regulatory DNA elements that include insulators, repeats, and endogenous viruses (157); methylation of CpG islands in imprinting (158); and promoter-enhancer and intronic regions that modulate transcription. The splicosomal machinery consists of multisubunit proteins (Table 19) as well as structural and catalytic RNA elements (159) that regulate transcript structure through alternative start and termination sites and splicing. Hence, there is a need to study different classes of RNA molecules (160) such as small nucleolar RNAs, antisense riboregulator RNA, RNA involved in X-dosage compensation, and other structural RNAs to appreciate their precise role in regulating gene expression. The phenomenon of RNA editing in which coding changes occur directly at the level of mRNA is of clinical and biological relevance (161). Finally, examples of translational control include internal ribosomal entry sites that are found in proteins involved in cell cycle regulation and apoptosis (162). At the protein level, minor alterations in the nature of protein–protein interactions, protein modifications, and localization can have dramatic effects on cellular physiology (163). This dynamic system therefore has many ways to modulate activity, which suggests that definition of complex systems by analysis of single genes is unlikely to be entirely successful.

In situ studies have shown that the human genome is asymmetrically populated with G+C content, CpG islands, and genes (68). However, the genes are not distributed quite as unequally as had been predicted (Table 9) (69). The most G+C-rich fraction of the genome, H3 isochores, constitute more of the genome than previously thought (about 9%), and are the most gene-dense fraction, but contain only 25% of the genes, rather than the predicted ~40%. The low G+C L isochores make up 65% of the genome, and 48% of the genes. This inhomogeneity, the net result of millions of years of mammalian gene duplication, has been described as the “desertiﬁcation” of the vertebrate genome (71). Why are there clustered regions of high and low gene density, and are these accidents of history or driven by selection and evolution? If these deserts are dispensable, it ought to be possible to ﬁnd mammalian genomes that are far smaller in size than the human genome. Indeed, many species of bats have genome sizes that are much smaller than that of humans; for example, Miniopterus, a species of Italian bat, has a genome size that is only 50% that of humans (164). Similarly, Munni bicus, a species of Asian barking deer, has a genome size that is ~70% that of humans.

8.3 Human DNA sequence variation and its distribution across the genome

This is the first eukaryotic genome in which a nearly uniform ascertainment of polymorphism has been completed. Although we have identiﬁed and mapped more than 3 million SNPs, this by no means implies that the task of ﬁnding and cataloging SNPs is complete. These represent only a fraction of the SNPs present in the human population as a whole. Nevertheless, this ﬁrst glimpse at genome-wide variation has revealed strong inhomogeneities in the distribution of SNPs across the genome. Polymorphism in DNA carries with it a snapshot of the past operation of population genetic forces, including mutation, migration, selection, and genetic drift. The availability of a dense array of SNPs will allow questions related to each of these factors to be addressed on a genome-wide basis. SNP studies can establish the range of haplo-
types present in subjects of different ethnographic origins, providing insights into population history and migration patterns. Although such studies have suggested that modern human lineages derive from Africa, many important questions regarding human origins remain unanswered, and more analyses using detailed SNP maps will be needed to settle these controversies. In addition to providing evidence for population expansions, migration, and admixture, SNPs can serve as markers for the extent of evolutionary constraint acting on particular genes. The correlation between patterns of intraspecies and interspecies genetic variation may prove to be especially informative to identify sites of reduced genetic diversity that may mark loci where sequence variations are not tolerated.

The remarkable heterogeneity in SNP density implies that there are a variety of forces acting on polymorphism—sparse regions may have lower SNP density because the mutation rate is lower, because most of those regions have a lower fraction of mutations that are tolerated, or because recent strong selection in favor of a newly arisen allele “swept” the linked variation out of the population (165). The effect of random genetic drift also varies widely across the genome. The nonrecombining portion of the Y chromosome faces the strongest pressure from random drift because there are roughly one-quarter as many Y chromosomes in the population as there are autosomal chromosomes, and the level of polymorphism on the Y is correspondingly less. Similarly, the X chromosome has a smaller effective population size than the autosomes, and its nucleotide diversity is also reduced. But even across a single autosome, the effective population size can vary because the density of deleterious mutations may vary. Regions of high density of deleterious mutations will see a greater rate of elimination by selection, and the effective population size will be smaller (166). As a result, the density of even completely neutral SNPs will be lower in such regions. There is a large literature on the association between SNP density and local recombination rates in Drosophila, and it remains an important task to assess the strength of this association in the human genome, because of its impact on the design of local SNP densities for disease-association studies. It also remains an important task to validate SNPs on a genomic scale in order to assess the degree of heterogeneity among geographic and ethnic populations.

8.4 Genome complexity

We will soon be in a position to move away from the cataloging of individual components of the system, and beyond the simplistic notions of “this binds to that, which then docks on this, and then the complex moves there…” (167) to the exciting area of network perturbations, nonlinear responses and thresholds, and their pivotal role in human diseases.

The enumeration of other “parts lists” reveals that in organisms with complex nervous systems, neither gene number, neuron number, nor number of cell types correlates in any meaningful manner with even simplistic measures of structural or behavioral complexity. Nor would they be expected to; this is the realm of nonlinearities and epigenesis (168). The 520 million neurons of the common octopus exceed the neuronal number in the brain of a mouse by an order of magnitude. It is apparent from a comparison of genomic data on the mouse and human, and from comparative mammalian neuroanatomy (169), that the morphological and behavioral diversity found in mammals is underpinned by a similar gene repertoire and similar neuroanatomies. For example, when one compares a pygmy marmoset (which is only 4 inches tall and weighs about 6 ounces) to a chimpanzee, the brain volume of this minute primate is found to be only about 1.5 cm³, two orders of magnitude less than that of a chimpanzee and three orders less than that of humans. Yet the neuroanatomies of all three brains are strikingly similar, and the behavioral characteristics of the pygmy marmoset are little different from those of chimpanzees. Between humans and chimpanzees, the gene number, gene structures and functions, chromosomal and genomic organizations, and cell types and neuroanatomies are almost indistinguishable, yet the developmental modifications that predisposed human lineages to cortical expansion and development of the larynx, giving rise to language, culminated in a massive singularity that by even the simplest of criteria made humans more complex in a behavioral sense.

Simple examination of the number of neurons, cell types, or genes of the genome size does not alone account for the differences in complexity that we observe. Rather, it is the interactions within and among these sets that result in such great variation. In addition, it is possible that there are “special cases” of regulatory gene networks that have a disproportionate effect on the overall system. We have presented several examples of “regulatory genes” that are significantly increased in the human genome compared with the fly and worm. These include extracellular ligands and their cognate receptors (e.g., wnt, frizzled, TGF-β, ephrins, and connexins), as well as nuclear regulators (e.g., the KRAB and homeodomain transcription factor families), where a few proteins control broad developmental processes. The answers to these “complexities” perhaps lie in these expanded gene families and differences in the regulatory control of ancient genes, proteins, pathways, and cells.

8.5 Beyond single components

While few would disagree with the intuitive conclusion that Einstein’s brain was more complex than that of Drosophila, closer comparisons such as whether the set of predicted human proteins is more complex than the protein set of Drosophila, and if so, to what degree, are not straightforward, since protein, protein domain, or protein-protein interaction measures do not capture context-dependent interactions that underpin the dynamics underlying phenotype.

Currently, there are more than 30 different mathematical descriptions of complexity (170). However, we have yet to understand the mathematical dependency relating the number of genes with organism complexity. One pragmatic approach to the analysis of biological systems, which are composed of nonidentical elements (proteins, protein complexes, interacting cell types, and interacting neuronal populations), is through graph theory (171). The elements of the system can be represented by the vertices of complex topographies, with the edges representing the interactions between them. Examination of large networks reveals that they can self-organize, but more important, they can be particularly robust. This robustness is not due to redundancy, but is a property of homogeneously wired networks. The error tolerance of such networks comes with a price; they are vulnerable to the selection or removal of a few nodes that contribute disproportionately to network stability. Gene knockouts provide an illustration. Some knockouts may have minor effects, whereas others have catastrophic effects on the system. In the case of vimentin, a supposedly critical component of the cytoplasmic intermediate filament network of mammals, the knockout of the gene in mice reveals them to be reproductively normal, with no obvious phenotypic effects (172), and yet the usually conspicuous vimentin network is completely absent. On the other hand, ~30% of knockouts in Drosophila and mice correspond to critical nodes whose reduction in gene product, or total elimination, causes the network to crash most of the time, although even in some of these cases, phenotypic normalcy ensues, given the appropriate genetic background. Thus, there are no “good” genes or “bad” genes, but only networks that exist at various levels and at different connectivities, and at different states of sensitivity to perturbation. Sophisticated mathematical analysis needs to be constantly evaluated against hard biological data sets that specifically address network dynamics. Nowhere is this more critical than in attempts to come to grips with “complexity,” particularly because deconvoluting and correcting complex networks that have undergone perturbation, and have resulted in human diseases, is the greatest significant challenge now facing us.

It has been predicted for the last 15 years that complete sequencing of the human ge-
Nome would open up new strategies for human biological research and would have a major impact on medicine, and through medicine and public health, on society. Effects on biomedical research are already being felt. This assembly of the human genome sequence is but a first, hesitant step on a long and exciting journey toward understanding the role of the genome in human biology. It has been possible only because of innovations in instrumentation and software that have allowed automation of almost every step of the process from DNA preparation to annotation. The next steps are clear: We must define the complexity that ensues when this relatively modest set of about 30,000 genes is expressed. The sequence provides the framework upon which all the genetics, biochemistry, physiology, and ultimately phenotype depend. It provides the boundaries for scientific inquiry. The sequence is only the first level of understanding of the genome. All genes and their control elements must be identified; their functions, in concert as well as in isolation, defined; their sequence variation worldwide described; and the relationship between genome variation and specific phenotypic characteristics determined. Now we know what we have to explain.

Another paramount challenge awaits: public discussion of this information and its potential for improvement of personal health. Many diverse sources of data have shown that any two individuals are more than 99.9% identical in sequence, which means that all any two individuals are more than 99.9% identical in sequence, which means that all

References and Notes


37. Trace processing generates quality values for base calls by means of Paracel’s TraceTuner, trims sequence reads according to quality values, trims vector and adapter sequence from high-quality reads, and screens sequences for contaminants. Similar in design and algorithm to the phred program (174), TraceTuner reports quality values that reflect the local error rate for each base being called. Quality was evaluated in 50-bp windows, each read being trimmed to include only those consecutive 50-bp segments with a minimum mean accuracy of 97%. End windows (both ends of the trace of 1, 5, 10, 25, and 50 bases were trimmed to a minimum mean accuracy of 98%. Every read was further checked for vector and contaminant matches of 50 bp or more, and if found, the read was removed from consideration. Finally, any match to the vector or adapter sequence in the initial part of a read was removed.


40. All bactigs over 3 kbp were examined for coverage by at least one interval of a bactig. We then deemed an assembly error where there were no mate pairs spanning the interval and at least two reads that should have their mate on the other side of the interval but did not. In other words, there was no mate pair evidence supporting a join in the breakpoint interval and at least two mate pairs contradicting the join. By this criterion, we detected and broke apart bactigs at 13,037 locations, or equivalently, we found 2.13% of the bactigs to be inconsistent with the sequence coming from a single domain. By this criterion, 74,717 of the 101,000 bactigs were broken into two parts, or 73.8% of the bactigs.

41. We considered a BAC entry to be chimeric if, by the Lander-Waterman statistic (175), the odds were 0.99 or more that the assembly we produced was inconsistent with the sequence coming from a single domain. By this criterion, 714.7% of 2.24% of BAC entries were deemed chimeric.


45. M. A. Mail et al., Genome Res. 7, 1072 (1997).

46. J. Zhang et al., in preparation.

47. Shredded bactigs were located on long CSA scaffolds (>500 kbp) and the distribution of these fragments on the scaffolds was analyzed. If the spread of these fragments was greater than four times the maximum score of a given BAC, the assembly was considered chimeric. In addition, if >20% of bactigs of a given BAC were found on different scaffolds that were not adjacent in map position, then the BAC was also considered chimeric. The total chimeric BACs divided by the number of BACs used for CSA gave the minimum estimate of chimerism rate.


55b. See http://genome.ucsc.edu/.


73. R. D. Smith et al., Hum. Genom. 9, 2117 (2000).


89. Lek first compares all proteins in the proteome to each other and then to the reference proteome. For an expectation of zero, a user-specified threshold constitutes an edge. Lek then uses this graph to compute a similarity between each protein pair i j in the context of the graph as a whole by simply dividing the number of BLAST hits shared in common between the two proteins by the total number of protein hits by i and j. This simple metric has several interesting properties. First, because the similarity metric takes into account both the similarity and the differences between the two sequenc- es at the level of BLAST hits, the metric respects the multidomain nature of protein space. Two multidom- main proteins, for instance, each containing domains A and B, will have a greater pairwise similarity to each other than either one will have to a protein containing only A or B domains, so long as A-B- containing proteins are less frequent in the proteome than are single-domain proteins con- taining A or B domains. A second interesting prop- erty of this similarity metric is that it can be used to produce a similarity matrix for the proteome as a whole without having to first produce a multiple alignment for each protein family, an error-prone and very time-consuming process. Finally, the met- ric does not require that either sequence have sig-
share at least one significant BLAST hit in common. This is an especially interesting property of the model on which the rapid recovery of protein families from the proteome for which no multiple alignment is possible, thus providing a computational basis for the extension of protein homology searches beyond those of current HMM- and profile-based search methods. Once the whole-proteome similarity matrix has been calculated, Lek first partitions the proteome into single-linkage clusters (a posteriori basis of one or more shared BLAST hits) between two sequences. Next, these single-linkage clusters are further partitioned into subclusters, each member of which shares a user-specified pair-wise identity with its members and other members of the clus-
ter, as described above. For the purposes of this publication, we have focused on the analysis of single-linkage clusters and what we have termed “complete clusters,” e.g., those subclusters for which every member has a similarity metric of 1 to every other member of the subcluster. We believe that the single-linkage and complete clusters are of special interest, in part, because they allow us to estimate and to compare sizes of core protein sets in a rigorous manner. The rationale for this is as follows: if one imagines for a moment a perfect clustering of the genome into real clusters, then it will be clustered by single linkage together with all single-domain proteins containing domains A or B. Likewise, for a predicted protein set containing a single multi-
domain protein, the number of real clusters must always be less than or equal to the number of complete clusters, because it is impossible to place a unique multidomain protein into a complete cluster. Thus, the single-linkage and complete clusters plus singletons should comprise a lower and upper bound of sizes of core protein sets, respectively, allowing us to compare the relative size and com-
plexity of different organisms’ predicted protein set.

93. The probability that a contiguous set of proteins is the result of a real duplication can be esti-
mated approximately as follows. Given that protein A and B occur on one chromosome, and that A’ and B’ (paralogs of A and B) also exist in the genome, the probability of observing both A and B occurring immediately after A’ is 1/N, where N is the number of proteins in the set (for this analysis, N = 26,588). Allowing for B’ to occur as any of the next J-1 proteins [leaving a gap between A’ and B’ increases the probability to J−1−1/N], allowing B’ A’ or A’ B’ gives a probability of 2 J−1/−1/N. Considering three genes ABC, the probability of observing A B’ C’ elsewhere in the genome, given that the paralogs exist, is 1/N2. Three pro-
teins can occur across a spread of five positions in six ways; more generally, we compute the number of ways that K proteins can spread across J possible arrangements of K – 2 proteins in the J – 2 positions between the first and last protein. Allowing for a spread to vary from K positions (no gaps) to j gives

L = \sum_{k=2}^{J-1} \binom{X}{k} \binom{X-k}{2}

arrangements. Thus, the probability of chance occurrence is L \binom{n}{k}^{-1}. Allowing for both sets of genes (e.g., ABC and A B’ C’ ) to be spread across J positions instead of K, the preceding expression can be extended. The duplicated segment might be rearranged by the operations of reversal or translocation; allowing for M such rearrangements gives us a probability P = L \binom{n}{k}^{-M}. For example, the probability of observing a duplicated set of three genes in two different locations, where the three genes occur across a spread of five positions in both locations, is N^2/36!; the expected number of such matched sets in the predicted protein set is approxi-
mately (N3/36!)^2 = 36N/6, a value < 1. Therefore, any such duplicated genes is unlikely to result from random rearrangements of the genome. If any of the genes occur in more than two copies, the probability that the apparent duplication has oc-
curred by chance is even lower. The algorithm for select-
ing candidate duplications only generates matched protein sets with P \leq 1, 94. B. J. Trask et al., Hum. Mol. Genet. 7, 13 (1998);
96. W. B. Barbazuk et al., Genome Res. 10, 1351 (2000);
102. W. J. Li, Molecular Evolution (Sinater, Sunderland, MA, 1997).
107. From the observed coverage of the sequences at each site for each individual, we calculated the probability that a SNP would be detected at the site if it were present. For each level of coverage, there is a binomial sampling of the two homologs for each individual, and the probability of detection is given by (1/n)^k. If even homologs are present, then the probability of detection is < 1 because a fraction of sites failed the quality criteria. Integrating over coverage levels, the binomial sampling, and the quality distribution, we derived an expected number of sites in the genome that were ascer-
tained for polymorphism for each individual. The nucleotide diversity was then the observed number of variable sites divided by the expected number of sites ascertained.
114. M. Kaurna, The Neutral Theory of Molecular Evolu-
118. F. Nakamura, R. C. Kalb, S. M. Strittmattter, J. Neuro-
122. M. Geppert, T. C. Sudhof, Annu. Rev. Neurosci. 21, 44 (1998); J. T. Littleton, H. J. Bellen, Trends Neu-

Downloaded through http://science.sciencemag.org/ on January 25, 2018
functional genomics web site

- links to breaking news in genomics and biotech, from Science, ScienceNOW, and other sources.
- pointers to classic papers, reviews, and new research, organized by categories relevant to the post-genomics world.
- Science's genome special issues.
- collections of Web resources in genomics and post-genomics, including special pages on model organisms, educational resources, and genome maps.
- a special node of news, information, and links on the biotech business.

www.sciencegenomics.org
ERRATUM
post date 8 June 2001

CORRECTIONS AND CLARIFICATIONS

REPORTS: "The sequence of the human genome" by J. C. Venter et al. (16 Feb. 2001, p. 1304). In Table 10, the last column under the heading "Gene prediction" should have read "Total (Otto + de novo/2×)."

This section of the table with the corrected column heading is shown here. The asterisk indicates that the chromosomal assignment is unknown.

In the References and Notes section, the authors for reference 176 should have read "A. Krogh et al.;" the journal name in reference 177 should have been "Proc. Intell. Syst. Mol. Biol.;" and in note 181, the acknowledgement list should have included after G. Edwards the names L. Foster, D. Bhandari, P. Davies, T. Safford, and J. Schira.
The Sequence of the Human Genome


DOI: 10.1126/science.1058040